Ai-guided synthetic biology development platform, systems, and methods

Abstract

An AI-guided synthetic biology development platform, systems, and methods substantially as shown and described.

Description

AI-GUIDED SYNTHETIC BIOLOGY DEVELOPMENT PLATFORM, SYSTEMS, AND METHODSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of each of the following U.S. Applications.

[0002] U.S. Provisional Application No. Serial No. 63 / 655,575; filed June 3, 2024.

[0003] U.S. Provisional Application No. Serial No. 63 / 803,471; filed May 9, 2025.

[0004] Each of the aforementioned earlier-filed applications is hereby incorporated by reference in its entirety.BACKGROUND

[0005] Most synthetic biology work today is lab-driven, and hence capital intensive, painstaking, expensive, and uncertain. However, the rapid development of Al models in general, as well as in pharma and specific segments within the life sciences, is poised to spur rapid innovation in AI- driven synthetic biology. Competition will emerge as Al, LLMs, and supporting technologies accelerate. These advancements could reduce barriers to entry, contributing to the emergence of a rapidly evolving research and development landscape and marketplace.SUMMARY

[0006] Embodiments include an Al-guided synthetic biology development platform, systems, and methods substantially as shown and described.

[0007] Embodiments include a method for providing Al-guided synthetic biology development platform, systems, and methods substantially as shown and described.

[0008] In embodiments, a computer-implemented method for data integration in an Al-guided analytic platform for development of biologic synthesis processes may comprise: receiving, by a platform, biologic data from a plurality of databases, wherein the biologic data use different data formats and / or semantics; converting the received biologic data into at least one standardized data format to create an integrated dataset; processing the integrated dataset through at least one data normalization process to minimize batch-specific systemic variation; storing the normalized biologic data in a structured format that describes biologic components and their relationships to other components; applying at least one machine learning method to the normalized biologic data to generate at least one predictive model for synthetic biology design; and outputting at least one specification for biologic system design based on the at least one predictive model.

[0009] In embodiments, the data normalization processes used by the platform may include applying a Bayesian statistical model that incorporates prior knowledge about strain behavior, modeling different sources of variation including biological effects and technical factors, estimating strain performance while accounting for batch effects and other sources of systematic variability, batch effect correction, wherein a batch effect correction addresses systematic variations across at least one of a plurality of experimental runs, equipment, or operators, multimodal data integration, or some other type of data normalization process.

[0010] In embodiments, multi-modal data integration may include data relating to at least one of an enzyme level, a metabolite concentration, or a gene expression level.

[0011] In embodiments, data normalization processes used by the platform may include standardized nomenclature across different data sources, quality control normalization, including flagging an anomalous data point, and / or flagging a well or sample that failed during an experiment.

[0012] In embodiments, data normalization processes used by the platform may include experiment normalization, such as experiment nonnalization to account for a variation across a plurality of experimental runs using a similar strain or condition. Experiment normalization used by the platform may implement a statistical method to minimize impact of a technical variation, and / or may use a control sample and spike-in standard for validation.

[0013] In embodiments, data normalization processes used by the platform may include crossplatform data harmonization, including but not limited to data harmonization that standardizes data from a plurality of experimental platforms and setups.

[0014] In embodiments, data normalization processes used by the platform may include time series data normalization, wherein the time series data normalization includes normalizing data relating to time-varying growth conditions, wherein the time series data normalization includes nonnalizing data relating to variations in a feed profile or fermentation parameter.

[0015] In embodiments, data normalization processes used by the platform may include knowledge graph-based normalization, including but not limited to knowledge graph-based nonnalization that represents biological entities and relationships in standardized format, knowledge graph-based normalization that associates infonnation across a plurality of experiments or organisms, and / or knowledge graph-based normalization integrates a plurality of biological data types.

[0016] In embodiments, a predictive model used by the platform may include, but is not limited to, a long-short tenn memory' model, a transformer model, a convolutional neural network model, a perceptron model, or a multi-modal deep learning architecture.

[0017] In embodiments, the platform may include a computer-implemented method for data quality assurance in an Al-guided analytic platform for development of biologic synthesis processes, comprising: collecting raw experimental data associated with a strain performance measurement; implementing a data normalization and quality control procedure to process the raw experimental data; validating a genotype of a strain through a data intake process; generating an analytical measure associated with quality control for the experimental data; identifying an outlier in an experimental dataset; maintaining metadata about an experimental condition or processing step; and storing processed and validated data in a knowledge graph structure that tracks data provenance from a raw experimental measurement to a processed value.

[0018] In embodiments, the platform may collect raw experimental data measuring key metabolites across a population of engineered strains, detecting and flagging anomalous data points through automated quality control, and / or identifying wells or samples that exhibit contamination or produce readouts outside expected ranges based on historical data.

[0019] In embodiments, the platform may include strain performance measurement that is an expression level, that is a metabolite concentration, that is growth rate measurement, and / or that is enzyme activity level.

[0020] In embodiments, the platform may include a system for ensuring data quality in an AI- guided analytic platform for development of a biologic synthesis process, comprising: one or more processors; memory storing instructions that, when executed by the one or more processors, cause the platfonn to implement a multi-objective optimization system for performing multi-objective optimizations of the biologic synthesis process, wherein the multi-objective optimization system comprises: a data intake and staging pipeline configured to: collect raw data from a plurality' of experimental sources; convert the raw data into at least one standardized format; apply a quality7assurance step to identify and correct error and inconsistency in the data; apply a normalization technique to remove a batch effect or technical variation; validate that the normalization technique preserve a specified biologic signal; and a knowledge management system configured to: maintain a log and audit trail for a platform data processing activity7; track data lineage from a raw measurement to a processed value; and enable verification of a data processing step to confirm scientific validity.

[0021] In embodiments, the platform may include a method for hit identification in an Al-guided analytic platform for development of biologic synthesis processes, comprising: collecting raw experimental data on strain perfonnance; normalizing the experimental data using a probabilistic approach to generate normalized strain performance data; representing strains as probability distributions over possible performance levels, wherein the probability distributions capture both a point estimate of the strain performance and uncertainty around the estimate; defining a hit based on the probability distributions by determining the strains having a specified probability of outperforming a parent strain by a predetermined margin; and identifying a promising strain for further investigation based on the defined hit.

[0022] In embodiments, defining a hit may comprise setting a threshold for minimum performance improvement over the parent strain, calculating a probability7that each strain exceeds a threshold, and / or ranking strains based on their full performance distribution rather than point estimates.

[0023] In embodiments, the platform may include a method for hit identification in an Al-guided analytic platform for development of biologic synthesis processes, comprising: one or more processors; memory storing instructions that, when executed by the one or more processors, cause the platform to implement a multi-objective optimization system for performing multi-objective optimizations of the biologic synthesis processes, wherein the multi-objective optimization system comprises: performing data qualify assurance on experimental strain performance data; applying a Bayesian data normalization process to the experimental strain performance data; generating probability distributions representing strain performance and associated uncertainty7for a plurality of strains; identifying hits by comparing the probability distributions to defined at least one performance threshold, wherein the hits comprise strains exhibiting improved performanceregarding a performance criterion relative to a reference strain; and outputting the identified hits for further optimization and investigation.

[0024] In embodiments, data quality assurance may include collecting metadata about experimental conditions, tracking data provenance from raw measurements through processing steps, and / or identifying and correcting errors or inconsistencies in the data.

[0025] In embodiments, the platform may include a system for integrating synthetic biology data in an Al-guided analytic platform for development of a biologic synthesis process, comprising: one or more processors; memory storing instructions that, when executed by the one or more processors, cause the platform to implement a multi-objective optimization system for performing multi-objective optimizations of biologic synthesis processes, wherein the multi-objective optimization system comprises: a data intake and staging pipeline configured to: collect biologic data from a plurality of data sources; integrate the collected biologic data into a computationally appropriate form; normalize the integrated biologic data using batch effect correction; validate quality and consistency of the normalized biologic data; store the validated biologic data in a structured format describing relationships between biologic entities; and a machine learning model configured to analyze the stored validated biologic data to generate at least one prediction for synthetic biology system design.

[0026] In embodiments, a structured data format may be a bipartite graph database structure, wherein the bipartite graph database structure organizes data into at least one molecule node and at least one process node, wherein the at least one molecule node represents at least one of a molecules, atomic elements, ions, compounds, nucleic acids, proteins, or macromolecules, wherein the at least one process node represents at least one of chemical reactions, protein folding, transport, regulatory' interactions, or active site binding, and wherein connections between nodes indicate roles that create the relationships between a molecule and a process.

[0027] In embodiments, a structured data format may be a non-relational database format, a knowledge graph structure, or some other format type.

[0028] In embodiments, the platform may include a computer-implemented method for normalizing synthetic biology data in an Al-guided analytic platform for development of biologic synthesis processes, comprising: receiving experimental data associated with synthetic biology development from a plurality of sources; performing a data quality assurance on the received experimental data to identify at least one anomalous data point; applying a Bayesian statistical normalization model to the experimental data to: model a batch-specific systemic variation; account for a technical factor contributing to a batch effect; separate a biologic signal from the technical factor; and generate normalized synthetic biology data; and outputting the normalized synthetic biology data for use in a machine learning application.

[0029] In embodiments, data quality assurance may comprise detecting a well or sample that failed to grow property, identifying samples exhibiting contamination, flagging a readout that falls outside an expected range based on historical data for a similar strain, and / or identifying a potential measurement error or mislabel in the experimental data.

[0030] In embodiments, modeling the batch-specific systemic variation may comprise constructing a plate notation model representing at least one strain effect, constructing a plate notation model representing at least one experimental effect, constructing a plate notation model representing at least one plate-to-plate variation, constructing a plate notation model representing at least one plate lot effect, and / or constructing a plate notation model representing at least one position effect of a sample on a plate. A plate notation model may provide a formal representation of at least one factor contributing to observed data.

[0031] In embodiments, the platform may include a system for normalizing synthetic biology experimental data in an Al-guided analytic platform for development of a biologic synthesis process, comprising: one or more processors; memory’ storing instructions that, when executed by the one or more processors, cause the platform to implement a multi-obj ective optimization system for performing multi-objective optimizations of the biologic synthesis process, wherein the multiobjective optimization system comprises: intake raw experimental data from a plurality of synthetic biology experiments; apply a quality control process to identify an anomalous experimental data point: construct a hierarchical Bayesian model representing: a strain performance measurement; an experimental variability factor; and a batch effect; fit the hierarchical Bayesian model to the experimental data to infer underlying strain performance while accounting for at least one confounding factor; generate at least one uncertainty estimate for a normalized perfonnance value; and output normalized experimental data with associated uncertainty estimates.

[0032] In embodiments, control processes used by the platform may include analyzing repeated measurements of strains across multiple plates, identifying a strain exhibiting inconsistent behavior when measured multiple times, detecting a systematic variation between a plurality of experimental runs of genetically identical strains, and / or flagging data points where strain performance variance exceeds an expected threshold.

[0033] In embodiments, constructing a hierarchical Bayesian model may comprise incorporating prior data relating to expected strain behavior, modeling multiple sources of experimental variability, representing relationships between a small-scale and a large-scale experiment, and / or generating at least one probability distribution that captures uncertainty in strain performance measurements.

[0034] In embodiments, the platform may include a computer-implemented method for handling batch effects in an Al-guided analytic platform for development of a biologic synthesis process, comprising: receiving biologic experimental data from a plurality of experiments; detecting a systematic variation between the experiments that is not related to a biologic factor of interest; applying a data normalization technique to minimize batch-specific systemic variation while preserving underlying biologic signals; generating probability distributions representing experimental outcomes to provide a summary of uncertainty; using a machine learning model to identify' and correct batch effects directly from the data without requiring explicit modeling of all possible sources of variation; and outputting normalized biologic data with reduced batch effects for use in strain engineering.

[0035] In embodiments, the platform may include a method for managing batch effects in synthetic biology experiments in an Al-guided analytic platform for development of a biologic synthesis process, comprising: one or more processors; memory storing instructions that, when executed by the one or more processors, cause the platform to implement a multi-objective optimization system for perfomiing multi-objective optimizations of biologic synthesis processes, wherein the multi-obj ective optimization system comprises : collect raw experimental data on strain performance across a plurality of experiments; implement a data normalization and quality control process to address variability' between experiments of genetically identical strains; represent hits and non-hits as probability' distributions; allow definition of at least one threshold for hit identification; apply an iterative splitting process to account for variation between constructs with identical genetic makeup; and output batch-effect corrected data suitable for machine learning model training and strain optimization.

[0036] In embodiments, the platform may include a computer-implemented method for iterative splitting in synthetic biology development in an Al-guided analytic platform for development of biologic synthesis processes, comprising: receiving data associated with sequences having identical genetic makeup but exhibiting different behaviors; initially labeling constructs with identical sequences as distinct entities; fitting a probabilistic model to observations of the constructs, wherein model accounts for experimental conditions and measurement techniques that influence construct behavior; processing the data through a data quality assurance pipeline to identify and validate variations between genetically identical constructs; and generating nomialized data across different experimental sources based on a probabilistic batch correction model.

[0037] In embodiments, the platform may identify' an observation that is unlikely to have been generated by a current probabilistic batch correction model; splitting the identified observation into separate entries with independent parameters; and refitting the probabilistic batch correction model after each splitting iteration, wherein fitting the probabilistic batch correction model comprises starting with a prior parameter that assumes constructs with identical sequences have identical activity7, wherein fitting the probabilistic batch correction model comprises requiring empirical evidence to override a prior parameter, wherein fitting the probabilistic batch correction model comprises adjusting at least one model parameter based on an observed variation between identical sequences.

[0038] In embodiments, the platform may include a system for iterative data processing in synthetic biology development in an Al-guided analytic platform for development of biologic synthesis processes, comprising: one or more processors; memory storing instructions that, when executed by the one or more processors, cause the system to: receive biologic sequencing data containing systemic variation across multiple batches; implement an iterative splitting process that: identifies constructs with identical genetic sequences exhibiting different behaviors; labels the identified constructs as separate entities; applies a probabilistic model to account for experimental condition variations; flags observations that deviate from predicted model behavior to identify' potential measurement errors or data inconsistencies; and generate normalized datasets thataccount for validated variations between genetically identical constructs while maintaining data quality assurance.

[0039] In embodiments, implementing the iterative splitting process may further comprise: maintaining sufficient anchor points between datasets to enable data combination across experimental sites; identifying when anchor points exhibit significantly different behaviors; and adjusting at least one model parameter to account for a validated difference while preserving ability to combine datasets.

[0040] In embodiments, the platform may estimate a scaffold parameter based on a validated construct variation; use the estimated scaffold parameter to calculate a more accurate expression estimate for a strain; and update the probabilistic model based on a refined expression estimate.

[0041] In embodiments, the platform may flag observations that deviate from predicted model behavior comprises: identifying a vertical outlier in a model fit visualization; calculating a probability assignment for each observation; and selecting an observation with a low probability assignment as a candidate for splitting.

[0042] In embodiments, the platform may include a computer-implemented method for training artificial intelligence models with specialized biologic data in an Al-guided analytic platform for development of a biologic synthesis process, comprising: collecting multimodal biologic data including at least one of a gene expression level. mRNA, metabolic reaction fluxes, or intracellular metabolite concentrations from biologic systems; processing the collected biologic data through data normalization and quality assurance steps to create model-ready data; and generating at least one output predicting an effect of genetic modification on a metabolite level or a reaction flux.

[0043] In embodiments, normalized biologic data may be converted from a first structured format to a second format suitable for model training.

[0044] In embodiments, one or more artificial intelligence models may be trained using the model-ready data to predict a cellular phenotype based on a genetic perturbation, wherein training the one or more artificial intelligence models comprises: using a knowledge graph to represent biological entities as nodes; representing relationships between entities as edges; and capturing biological relationships in a format appropriate for use by machine learning algorithms.

[0045] In embodiments, collecting multimodal biological data may comprise: obtaining RNA sequencing data for genome-wide gene expression levels; measuring metabolic reaction fluxes; and collecting metabolite concentration data using mass spectrometry, wherein the mass spectrometry is liquid chromatography-mass spectrometry, wherein the mass spectrometry is gas chromatography-mass spectrometry.

[0046] In embodiments, processing the collected multimodal biological data may comprise: identifying and correcting batch-specific systemic variation; standardizing nomenclature across different data sources; and correcting for missing data to ensure consistency across experimental setups.

[0047] In embodiments, the platfonn may include a system for specialized biologic data processing and model training in an Al-guided analytic platform for development of a biologic synthesis process, comprising: one or more processors; memory’ storing instructions that, whenexecuted by the one or more processors, cause the platform to implement a multi-objective optimization system for performing multi-objective optimizations of biologic synthesis processes, wherein the multi-objective optimization system comprises: a data collection system configured to collect time-resolved metabolomics data from living cells; a data processing pipeline configured to: integrate multiple types of high-dimensional biologic data; normalize and correct batch effects in the biologic data; and transfomi the biologic data into a format suitable for machine learning.

[0048] In embodiments, the platform may use a data collection system that is a rapid sampling system, wherein the rapid sampling system comprises: automated sampling mechanisms for collecting standardized samples; near-instantaneous quenching of cellular metabolism; and integration with liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry for metabolite analysis.

[0049] In embodiments, one or more artificial intelligence models may7be trained using processed data to predict a cellular phenotype.

[0050] In embodiments, the data processing pipeline may be further configured to: track data lineage from a raw experimental measurement to a processed value; maintain detailed metadata about experimental conditions; and validate a normalization method using a control sample.

[0051] In embodiments, the platform may integrate multiple types of high-dimensional biological data that comprises: combining gene expression data from RNA sequencing; incorporating flux data from an isotope-labeled experiment; and merging a metabolite concentration measurement from mass spectrometry.

[0052] In embodiments, the platform may include a system for training specialized biologic models in an Al-guided analytic platform for development of biologic synthesis processes, comprising instructions that when executed cause a processor to: collect multimodal biologic data; process the collected multimodal biologic data through quality7assurance steps to identify and correct errors or inconsistencies; employ multi-modal deep learning architectures with a separate encoding branch for different data modalities; combine encoded representations through fusion layers; and generate a prediction about cellular phenotypes based on the processed multimodal biologic data.

[0053] In embodiments, the multimodal biologic data may derive from at least one integrated sensor and / or automated sampling system.

[0054] In embodiments, the multi-modal deep learning architectures may comprise: the separate encoding branches for gene expression data; dedicated pathways for metabolite profile processing; and specialized branches for reaction flux analysis.

[0055] In embodiments, processing the collected multimodal biologic data may comprise: applying batch effect correction across experimental runs; normalizing data across different organisms and conditions; and ensuring data consistency for machine learning applications.

[0056] In embodiments, generating predictions may comprise: evaluating effects of genetic modifications on metabolic pathways; predicting changes in metabolite concentrations: and estimating reaction flux distributions in response to genetic perturbations.

[0057] In embodiments, the multi-modal deep learning architecture used by the platform may be a combination of a plurality of multi-modal deep learning architectures.

[0058] In some example embodiments, a method of generating a biologic product of a biologic synthesis process includes selecting a first biologic parent having a first feature; selecting a second biologic parent having a second feature; and selecting the biologic product based on an evaluation of a set of combinations of the first biologic parent and the second biologic parent.

[0059] In some example embodiments, a method of generating a biologic product of a biologic synthesis process includes selecting at least two objectives of the biologic product; selecting a biologic parent of the biologic product; and determining the biologic product based on an evaluation of the at least two objectives for a set of variants of the biologic parent.

[0060] In some example embodiments, an Al-guided analytic platform for development of biologic synthesis processes includes a multi-objective optimization system for performing multiobjective optimizations of the biologic synthesis processes; at least one multi -objective evaluation artificial intelligence model configured to evaluate a biologic product according to each of at least two objectives; and at least one variant evaluation module configured to generate a set of variants of a biologic parent and evaluate each variant of the set of variants of the biologic parent using the at least one multi-objective evaluation artificial intelligence model.

[0061] In some example embodiments, an Al-guided analytic platform for development of biologic synthesis processes includes one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the platform to implement a multiobjective optimization system for performing multi-objective optimizations of the biologic synthesis processes, the system including at least one biologic synthesis simulation system that is configured to evaluate multiple objectives of the biologic synthesis processes based on simulation of the biologic synthesis processes.

[0062] In some example embodiments, a method of optimizing a biologic synthesis process includes identifying at least one bottleneck in the biologic synthesis process; evaluating a set of variants of the biologic synthesis process; and selecting an adjusted biologic synthesis process, wherein the adjusted biologic synthesis process includes at least one variant of the set of variants that reduces the at least one bottleneck of the biologic synthesis process.

[0063] In some example embodiments, a method of optimizing a biologic synthesis process includes identifying at least one bottleneck in the biologic synthesis process; determining, by at least one simulation of the biologic synthesis process, at least one cause of the at least one bottleneck; and selecting an adjusted biologic synthesis process, wherein the adjusted biologic synthesis process alters the biologic synthesis process to at least reduce the at least one cause of the at least one bottleneck of the biologic synthesis process.

[0064] In some example embodiments, an Al-guided analytic platform for development of biologic synthesis processes includes one or more processors and memory storing instructions that, when executed by the one or more processors, cause the Al-guided analytic platform to perform steps including, identifying at least one bottleneck in a biologic synthesis process; evaluating a set of variants of the biologic synthesis process; and selecting an adjusted biologic synthesis process,wherein the adjusted biologic synthesis process includes at least one variant of the set of variants that reduces the at least one bottleneck of the biologic synthesis process.

[0065] In some example embodiments, an Al-guided analytic platform for development of biologic synthesis processes includes one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the Al-guided analytic platfonn to implement a system that evaluates the biologic synthesis processes, wherein the system includes at least one simulation system that is configured to simulate biologic synthesis processes to identify bottlenecks in the biologic synthesis processes.

[0066] In some aspects, the techniques described herein relate to a platform for generating a set of recommendations for modifications to a set of genes of a biological strain, including: a set of data integration facilities for integrating content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces a functional output, wherein the output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and at least one member of the set of Al -based learning models that is configured to generate a set of recommendations wherein the set of recommendations relates to modifications to a set of genes of the biological strain such that the set of recommendations enhance production of the functional output by the biological strain.

[0067] In some aspects, the techniques described herein relate to a platform, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory' (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

[0068] In some aspects, the techniques described herein relate to a platform, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0069] In some aspects, the techniques described herein relate to a platform, wherein the at least one proprietary7dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

[0070] In some aspects, the techniques described herein relate to a platform, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

[0071] In some aspects, the techniques described herein relate to a platform, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0072] In some aspects, the techniques described herein relate to a platform, further including a simulation engine, the simulation engine configured to: generate a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to a set of genes; execute simulations for the plurality of simulated process scenarios; and generate simulation data based on the executed simulations; wherein the set of Al-based learning models is further configured to: receive the simulation data as additional input; and generate a set of recommendations based at least in part on the simulation data.

[0073] In some aspects, the techniques described herein relate to a platform, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.

[0074] In some aspects, the techniques described herein relate to a method, including: integrating, by a set of data integration facilities, content of at least one publication data set relating to a biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces a functional output; providing the integrated content as input to a set of artificial intelligence (Al)-based learning models; and generating, by at least one member of the set of Al-based learning models, a set of recommendations wherein the set of recommendations relates to modifications to a set of genes of the biological strain such that the set of recommendations enhance production of the functional output by the biological strain.

[0075] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

[0076] In some aspects, the techniques described herein relate to a method, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0077] In some aspects, the techniques described herein relate to a method, wherein the at least one proprietary dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulator}' and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

[0078] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

[0079] In some aspects, the techniques described herein relate to a method, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0080] In some aspects, the techniques described herein relate to a method, further including: generating, by a simulation engine, a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to a set of genes; executing simulations for the plurality of simulated process scenarios; generating simulation data based on the executed simulations; receiving the simulation data as additional input to the set of Al-based learning models; and generating a set of recommendations based at least in part on the simulation data.

[0081] In some aspects, the techniques described herein relate to a method, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin. Platform for environmental / performance optimization.

[0082] In some aspects, the techniques described herein relate to a platform for generating a set of recommendations for modifications to a set of environmental parameters for a synthetic biological process in which a biological strain produces a functional output, including: a set of data integration facilities for integrating content of at least publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of the synthetic biological process in which the biological strain produces the functional output, wherein the output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and at least one member of the set of Al-based learning models that is configured to generate a set of recommendations wherein the set of recommendations relate to modifications to the set of environmental parameters of a synthetic biological process in which the biological strain produces a functional output such that the recommendations enhance production of the functional output by the biological strain.

[0083] In some aspects, the techniques described herein relate to a platform, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory' (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

[0084] In some aspects, the techniques described herein relate to a platform, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0085] In some aspects, the techniques described herein relate to a platform, wherein the at least one proprietary dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory7and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy' consumption parameters.

[0086] In some aspects, the techniques described herein relate to a platform, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity7management, pressure, or salinity.

[0087] In some aspects, the techniques described herein relate to a platform, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0088] In some aspects, the techniques described herein relate to a platform, further including a simulation engine, the simulation engine configured to: generate a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to a set of environmental parameters; execute simulations for the plurality of simulated process scenarios; and generate simulation data based on the executed simulations; wherein the set of Al-based learning models is further configured to: receive the simulation data as additional input; and generate a set of recommendations based at least in part on the simulation data.

[0089] In some aspects, the techniques described herein relate to a platform, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital tw in, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.

[0090] In some aspects, the techniques described herein relate to a method for generating a set of recommendations for modifications to a set of environmental parameters for a synthetic biological process in which a biological strain produces a functional output, including: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of the synthetic biological process in which the biological strain produces the functional output; providing the integrated content as input to a set of artificial intelligence (Al)-based learning models; and generating, by at least one member of the set of Al-based learning models, a set of recommendations wherein the set of recommendations relate to modifications to the set of environmental parameters of thesynthetic biological process such that the recommendations enhance production of the functional output by the biological strain.

[0091] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory' (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

[0092] In some aspects, the techniques described herein relate to a method, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0093] In some aspects, the techniques described herein relate to a method, wherein the at least one proprietary dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

[0094] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity management, pressure, or salinity.

[0095] In some aspects, the techniques described herein relate to a method, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0096] In some aspects, the techniques described herein relate to a method, further including: generating, by a simulation engine, a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to a set of environmental parameters; executing simulations for the plurality of simulated process scenarios; generating simulation data based on the executed simulations; receiving the simulation data as additional input to the set of Al-based learning models; and generating a set of recommendations based at least in part on the simulation data.

[0097] In some aspects, the techniques described herein relate to a method, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzy me digital twin.

[0098] In some aspects, the techniques described herein relate to a platform for generating a set of recommendations for modifications to a set of biological pathw ays associated with a process in which a biological strain produces a functional output, including: a set of data integration facilities for integrating content of at least one publication data set relating to the biological strain and atleast one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein the output of data integration facilities is configured as an input to a set of Al-based learning models and at least one member of the set of Al-based learning models that is configured to generate a set of recommendations wherein the set of recommendations relate to modifications to the set of biological pathways such that the recommendations enhance production of the functional output by the biological strain.

[0099] In some aspects, the techniques described herein relate to a platform, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

[0100] In some aspects, the techniques described herein relate to a platform, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0101] In some aspects, the techniques described herein relate to a platform, wherein the at least one proprietary dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy- consumption parameters.

[0102] In some aspects, the techniques described herein relate to a platform, wherein the set of recommendations relates to at least one of identification and overexpression of key enzymes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

[0103] In some aspects, the techniques described herein relate to a platform, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0104] In some aspects, the techniques described herein relate to a platform, further including a simulation engine, the simulation engine configured to: generate a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to a set of pathways; execute simulations for the plurality of simulated process scenarios; and generate simulation data based on the executed simulations; wherein the set of Al-based learning models is further configured to: receive the simulation data as additional input; and generate a set of recommendations based at least in part on the simulation data.

[0105] In some aspects, the techniques described herein relate to a platform, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin,a synthetic biological process digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.

[0106] In some aspects, the techniques described herein relate to a method for generating a set of recommendations for modifications to a set of biological pathways associated with a process in which a biological strain produces a functional output, including: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary' data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output; providing the integrated content as input to a set of Al-based learning models; and generating, by at least one member of the set of Al-based learning models, a set of recommendations wherein the set of recommendations relate to modifications to the set of biological pathways such that the recommendations enhance production of the functional output by the biological strain.

[0107] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, a lin-log model, a large language model, a large protein model, or a protein language model.

[0108] In some aspects, the techniques described herein relate to a method, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0109] In some aspects, the techniques described herein relate to a method, wherein the at least one proprietary' dataset includes at least one of genetic parameters, metabolic parameters, grow th and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenoty pic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

[0110] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to at least one of identification and overexpression of key enzy mes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.[OHl] In some aspects, the techniques described herein relate to a method, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0112] In some aspects, the techniques described herein relate to a method, further including: generating, by a simulation engine, a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has adifferent set of modifications to a set of pathways; executing, by the simulation engine, simulations for the plurality of simulated process scenarios; generating, by the simulation engine, simulation data based on the executed simulations; receiving, by the set of Al-based learning models, the simulation data as additional input; and generating, by the set of Al-based learning models, a set of recommendations based at least in part on the simulation data.

[0113] In some aspects, the techniques described herein relate to a method, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a synthetic biological process digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzy me digital twin. Platform for Protein / Enzymes Optimization

[0114] In some aspects, the techniques described herein relate to a platform for generating a set of recommendations for modification of a set of proteins and / or enzymes associated with a biological strain that produces a functional output, including: a set of data integration facilities for integrating content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein the output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and at least one member of the set of Al-based learning models that is configured to generate a set of recommendations wherein the set of recommendations relate to modifications to a set of proteins and / or enzymes such that the recommendations enhance production of the functional output by the biological strain.

[0115] In some aspects, the techniques described herein relate to a platform, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory7(LSTM) model, a multi-layer perceptron, a lin-log model, a large language model, a large protein model, or a protein language model.

[0116] In some aspects, the techniques described herein relate to a platform, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0117] In some aspects, the techniques described herein relate to a platform, wherein the at least one proprietary dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy7consumption parameters.

[0118] In some aspects, the techniques described herein relate to a platform, wherein the set of recommendations relates to at least one of enzy me overexpression, use of stronger promoters, site- directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification ofenzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

[0119] In some aspects, the techniques described herein relate to a platform, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0120] In some aspects, the techniques described herein relate to a platform, further including a simulation engine, the simulation engine configured to: generate a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to a set of proteins and / or enzy mes; execute simulations for the plurality of simulated process scenarios; and generate simulation data based on the executed simulations; wherein the set of Al-based learning models is further configured to: receive the simulation data as additional input; and generate a set of recommendations based at least in part on the simulation data.

[0121] In some aspects, the techniques described herein relate to a platform, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.

[0122] In some aspects, the techniques described herein relate to a method for generating a set of recommendations for modification of a set of proteins and / or enzymes associated with a biological strain that produces a functional output, including: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output; providing the integrated content as input to a set of artificial intelligence (Al)-based learning models; and generating, by at least one member of the set of Al-based learning models, a set of recommendations wherein the set of recommendations relate to modifications to a set of proteins and / or enzy mes associated with a biological strain such that the recommendations enhance production of the functional output by the biological strain.

[0123] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, a lin-log model, a large language model, a large protein model, or a protein language model.

[0124] In some aspects, the techniques described herein relate to a method, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0125] In some aspects, the techniques described herein relate to a method, wherein the at least one proprietary' dataset includes at least one of genetic parameters, metabolic parameters, growthand physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

[0126] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site- directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzy mes, allosteric modulation, or integration of modular enzyme assemblies.

[0127] In some aspects, the techniques described herein relate to a method, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0128] In some aspects, the techniques described herein relate to a method, further including: generating, by a simulation engine, a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to a set of proteins and / or enzymes; executing, by the simulation engine, simulations for the plurality of simulated process scenarios; generating, by the simulation engine, simulation data based on the executed simulations; receiving, by the set of Al-based learning models, the simulation data as additional input; and generating, by the set of Al-based learning models, a set of recommendations based at least in part on the simulation data.

[0129] In some aspects, the techniques described herein relate to a method, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.

[0130] In some aspects, the techniques described herein relate to a rapid sampling system for obtaining samples from a fermentation system, including: a sample inlet fluidly connected to the fermentation system; a pump fluidly connected to the sample inlet and configured to draw a sample from the fermentation system; a first valve fluidly connected to an outlet of the pump; a second valve fluidly connected to a liquid nitrogen chamber; a multi-well filter plate, wherein an individual well of the multi-well filter plate is configured to collect and filter a sample; a motorized base operatively connected to the multi-well filter plate configured to adjust a position of the multi-well filter plate; a control unit including one or more processors and one or more memories operatively connected to the pump, the first valve, the second valve, and the motorized base, the control unit configured to automatically initiate and perfonn a plurality of sampling operations at predetermined time intervals, wherein each sampling operation includes: controlling the operation of the pump to obtain a sample, controlling the operation of the first valve to dispense a sample into a first well of the multi-well filter plate; controlling the operation of the second valve to dispense liquid nitrogen into the first well of the multi-well filter plate; controlling the operationof the motorized base to move the multi-well filter plate to position a second well beneath the first valve and the second valve.

[0131] In some aspects, the techniques described herein relate to a rapid sampling system, further including a purge compressed air inlet fluidly connected to the first valve and operatively connected to the control unit, wherein the control unit is further configured to control operation of the first valve to dispense compressed air into the selected well before receiving the sample.

[0132] In some aspects, the techniques described herein relate to a rapid sampling system, further including a purge solvent inlet fluidly connected to the first valve and operatively connected to the control unit wherein the control unit is further configured to control operation of the first valve to dispense solvent into the selected well before obtaining the sample.

[0133] In some aspects, the techniques described herein relate to a rapid sampling system, further including a vacuum base wherein the vacuum base is operatively connected to the multi -well filter plate and operatively connected to the control unit wherein the control unit is further configured to control operation of the vacuum base to filter one or more wells of the multi-well filter plate.

[0134] In some aspects, the techniques described herein relate to a rapid sampling system, further including a carbon source inlet fluidly connected to the fermentation system and configured to dispense a carbon source into the fermentation system wherein the carbon source inlet is operatively connected to the control unit and wherein the initiation of the plurality of sampling operations is dependent on a dispensing of carbon by the carbon source inlet.

[0135] In some aspects, the techniques described herein relate to a rapid sampling system, further including a sampling loop.

[0136] In some aspects, the techniques described herein relate to a rapid sampling system, wherein the rapid sampling system is configured for a pilot scale.

[0137] In some aspects, the techniques described herein relate to a rapid sampling system, wherein the rapid sampling system is configured for industrial scale.

[0138] In some aspects, the techniques described herein relate to a rapid sampling system, wherein the first valve is an HPLC valve.

[0139] In some aspects, the techniques described herein relate to a rapid sampling system, wherein the second valve is a cryogenic valve.

[0140] In some aspects, the techniques described herein relate to a rapid sampling system, wherein the rapid sampling system is represented as a digital twin.

[0141] In some aspects, the techniques described herein relate to a rapid sampling system that is integrated with a mass and / or optical analytical system and an automated omics for generalization svstem.

[0142] In some aspects, the techniques described herein relate to a method for obtaining samples from a fermentation system, including: drawing, by a pump fluidly connected to a sample inlet, a sample from the fermentation system; dispensing, by a first valve fluidly connected to an outlet of the pump, a sample into a first well of a multi-well filter plate; dispensing, by a second valve fluidly connected to a liquid nitrogen chamber, liquid nitrogen into the first well of the multi-well filter plate; adjusting, by a motorized base operatively connected to the multi -well filter plate, a positionof the multi-well filter plate to position a second well beneath the first valve and the second valve; and automatically initiating and performing, by a control unit, a plurality of sampling operations at predetermined time intervals.

[0143] In some aspects, the techniques described herein relate to a method, further including: dispensing, by the first valve, compressed air from a purge compressed air inlet into the selected well before receiving the sample.

[0144] In some aspects, the techniques described herein relate to a method, further including: dispensing, by the first valve, solvent from a purge solvent inlet into the selected well before obtaining the sample.

[0145] In some aspects, the techniques described herein relate to a method, further including: filtering, by a vacuum base operatively connected to the multi-well filter plate, one or more wells of the multi-well filter plate.

[0146] In some aspects, the techniques described herein relate to a method, further including: dispensing, by a carbon source inlet fluidly connected to the fermentation system, a carbon source into the fermentation system, wherein initiation of the plurality of sampling operations is dependent on the dispensing of the carbon source.

[0147] In some aspects, the techniques described herein relate to a method, further including utilizing a sampling loop.

[0148] In some aspects, the techniques described herein relate to a method, wherein the method is performed at pilot scale.

[0149] In some aspects, the techniques described herein relate to a method, wherein the method is performed at an industrial scale.

[0150] In some aspects, the techniques described herein relate to a method, wherein the first valve is an HPLC valve.

[0151] In some aspects, the techniques described herein relate to a method, wherein the second valve is a cry ogenic valve.

[0152] In some aspects, the techniques described herein relate to a method, wherein the method is represented as a digital twin.

[0153] In some aspects, the techniques described herein relate to a method, wherein the method is integrated with a mass and / or optical analytical system and an automated omics for generalization system. Automated "Omics" for Generalization.

[0154] In some aspects, the techniques described herein relate to a method for converting raw data from an analytical and mass spectrometry instrument to model-ready data, the method including: receiving, by computing hardware, data from the analytical and mass spectrometry instrument wherein the data includes measurement data from a set of control samples and a set of test samples; extracting, by a computing hardware, a set of peak lists including a set of test peak lists and a set of control peak lists from the received data; compressing, by computer hardware, the extracted peak lists using a compression algorithm; identifying, by computer hardware, a set of metabolites that correspond to a set of peaks from the compressed peak lists by comparing a set of mass-to-charge ratios and a set of retention times associated with the set of peaks with the mass-to-charge ratios and retention times associated with known metabolites from a set of spectral databases; calculating, by computer hardware, a set of peak areas corresponding to the set of peaks; generating, by computer hardware, a calibration curve for each identified metabolite based on the calculated area from its corresponding peaks from the compressed set of control peak lists and its known concentration; calculating, by computer hardware, a set of concentrations for the set of identified metabolites associated with the peaks from the compressed set of test peak lists using the generated calibration curves; and generating, by computer hardware, a compilation of results.

[0155] In some aspects, the techniques described herein relate to a method, further including analyzing, by computer hardware, the identified peaks to determine a need for a deconvolution and / or window adjustment on one or more of the identified peaks, and, upon determination of said need, performing deconvolution and / or window adjustment on the one or more of the identified peaks.

[0156] In some aspects, the techniques described herein relate to a method, further including generating, by computer hardware, a quality control website wherein the uality control website presents a set of calibration curves representing the control samples and test samples for each of the metabolites of the set of metabolites.

[0157] In some aspects, the techniques described herein relate to a method, wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry (LC-MS) instrument, a gas chromatography-mass spectrometry (GC-MS) instrument, a quadruple time-of- flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, or a free induction decay (FID) instrument. In embodiments, the of analytical and mass spectrometry instrument may be a quadrupole mass spectrometry (QMS) instrument, a time-of-flight mass spectrometry (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry instrument, a sector mass spectrometry instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, and an atmospheric pressure photoionization (APPI) instrument, among many others.

[0158] In some aspects, the techniques described herein relate to a method, further including comparing, by computer hardware, a set of fragmentation patterns from the set of peaks from the compressed peak lists with a set of fragmentation patterns from the set of spectral databases.

[0159] In some aspects, the techniques described herein relate to a method, further including applying, by computer hardware, a dilution factor to the set of concentrations.

[0160] In some aspects, the techniques described herein relate to a method, further including nonnalizing, by computer hardware, the concentrations to biomass content.

[0161] In some aspects, the techniques described herein relate to a system for converting raw data from an analytical and mass spectrometry instrument to model-ready data, including: computing hardware configured to: receive data from an analytical and mass spectrometry instrument wherein the data includes measurement data from a set of control samples and a set of test samples; extract a set of peak lists including a set of test peak lists and a set of control peak lists from the received data; compress the extracted peak lists using a compression algorithm;identify a set of metabolites that correspond to a set of peaks from the compressed peak lists by comparing a set of mass-to-charge ratios and a set of retention times associated with the set of peaks with the mass-to-charge ratios and retention times associated with known metabolites from a set of spectral databases; calculate a set of peak areas corresponding to the set of peaks; generate a calibration curve for each identified metabolite based on the calculated area from its corresponding peaks from the compressed set of control peak lists and its known concentrations; calculate a set of concentrations for the set of identified metabolites associated with the peaks from the compressed set of test peak lists using the generated calibration curves; and generate a compilation of results.

[0162] In some aspects, the techniques described herein relate to a system, wherein the computing hardware is further configured to analyze the identified peaks to determine a need for a deconvolution and / or window adjustment on one or more of the identified peaks, and, upon determination of said need, perform deconvolution and / or window adjustment on the one or more of the identified peaks.

[0163] In some aspects, the techniques described herein relate to a system, wherein the computing hardware is further configured to generate a quality control website wherein the quality control website presents a set of calibration curves for control samples and test samples for each of the metabolites of the set of metabolites.

[0164] In some aspects, the techniques described herein relate to a system, wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry (LC-MS) instrument, a gas chromatography-mass spectrometry (GC-MS) instrument, a quadruple time-of- flight (QTOF) mass spectrometry' instrument, an ultraviolet-visible (UV-Vis) instrument, or a free induction decay (FID) instrument, a quadrupole mass spectrometry (QMS) instrument, a time-of- flight mass spectrometry' (TOF-MS) instrument, an ion trap mass spectrometry' instrument, an orbitrap mass spectrometry' instrument, a sector mass spectrometry instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, or an atmospheric pressure photoionization (APPI) instrument.

[0165] In some aspects, the techniques described herein relate to a system, wherein the computing hardware is further configured to compare a set of fragmentation patterns from the set of peaks from the compressed peak lists with a set of fragmentation patterns from the set of spectral databases.

[0166] In some aspects, the techniques described herein relate to a system, wherein the computing hardware is further configured to apply a dilution factor to the set of concentrations.

[0167] In some aspects, the techniques described herein relate to a system, wherein the computing hardware is further configured to normalize the concentrations to biomass content.

[0168] In some aspects, the techniques described herein relate to a system, including: a rapid sampling system configured to collect a set of samples from a fermentation system at predetermined time increments; a robotic handling system configured to obtain the set of samples from the rapid sampling system and prepare the samples for an analy tical and mass spectrometry'instrument; an analytical and mass spectrometry instrument configured to generate raw measurement data associated with the set of samples and provide the raw measurement data to an automated omics for generalization system; and an automated omics for generalization system configured to detennine a set of concentrations for a set of metabolites in the set of samples based on the raw measurement data and output the set of concentrations.

[0169] In some aspects, the techniques described herein relate to a system, wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry (LC-MS) instrument, a gas chromatography-mass spectrometry (GC-MS) instrument, a quadruple time-of- flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, or a free induction decay (FID) instrument. In embodiments, the of analytical and mass spectrometry instrument may be a quadrupole mass spectrometry (QMS) instrument, a time-of-flight mass spectrometry (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry instrument, a sector mass spectrometry instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, and an atmospheric pressure photoionization (APPI) instrument, among many others.

[0170] In some aspects, the techniques described herein relate to a system, wherein the system is further configured to provide the set of concentrations to an artificial intelligence (Al)-based learning model training system configured to train and / or retrain a set of Al-based learning models.

[0171] In some aspects, the techniques described herein relate to a system, wherein the system is further configured to provide the set of concentrations to a set of artificial intelligence (Al)-based learning models, wherein at least one member of the set of Al-based learning models is trained to identify one or more metabolite bottlenecks.

[0172] In some aspects, the techniques described herein relate to a system, wherein the set of AI- based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, a lin- log model, a large language model, a large protein model, or a protein language model.

[0173] In some aspects, the techniques described herein relate to a system, wherein the system is further configured to provide the set of concentrations to a set of artificial intelligence (Al)-based learning models, wherein at least one member of the set of Al-based learning models is trained to generate a set of recommendations for an intervention to a fermentation process in the fermentation system, wherein the set of recommendations includes at least one of a genetic modification, a process optimization, or an environmental adjustment.

[0174] In some aspects, the techniques described herein relate to a system, wherein the set of AI- based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, a lin- log model, a large language model, a large protein model, or a protein language model.

[0175] In some aspects, the techniques described herein relate to a system, wherein the system is further configured to calculate a flux of a metabolic pathway from the set of metabolite concentrations.

[0176] In some aspects, the techniques described herein relate to a system, wherein the system is further configured to provide the set of concentrations to a digital twin system, and wherein the digital twin system is configured to generate a digital twin representing a metabolic flux associated with a fermentation process in the fennentation system.

[0177] In some aspects, the techniques described herein relate to a system, wherein the system is further configured to calculate at least one of a predicted product yield measure, a fermentation productivity measure, a set of metabolite kinetic rates, or a set of pathway efficiency measures for a fermentation process in the fermentation system.

[0178] In some aspects, the techniques described herein relate to a system, wherein the system is configured to build a set of kinetic models for a fermentation process in the fermentation system.

[0179] In some aspects, the techniques described herein relate to a method for determining a set of concentrations for a set of metabolites from a fermentation system, the method including: collecting, by a rapid sampling system, a set of samples from a fermentation system at predetermined time increments; preparing, by a robotic handling system, the set of samples for an analytical and mass spectrometry instrument; generating, by’ the analytical and mass spectrometry instrument, raw measurement data associated with the set of samples: providing, by the analytical and mass spectroscopy instrument, the raw measurement data to an automated omics for generalization system; determining, by an automated omics for generalization system, a set of concentrations for a set of metabolites in the set of samples based on the raw measurement data; and outputting the set of concentrations.

[0180] In some aspects, the techniques described herein relate to a method, wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry' (LC-MS) instrument, a gas chromatography-mass spectrometry' (GC-MS) instrument, a quadruple time-of- flight (QTOF) mass spectrometry’ instrument, an ultraviolet- visible (UV-Vis) instrument, a free induction decay (FID) instrument, a quadrupole mass spectrometry’ (QMS) instrument, a time-of- flight mass spectrometry (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry instrument, a sector mass spectrometry instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, or an atmospheric pressure photoionization (APPI) instrument.

[0181] In some aspects, the techniques described herein relate to a method, further including providing the set of concentrations to an artificial intelligence (Al)-based learning model training system configured to train and / or retrain a set of Al-based learning models.

[0182] In some aspects, the techniques described herein relate to a method, further including providing the set of concentrations to a set of artificial intelligence (Al)-based learning models, wherein at least one member of the set of Al-based learning models is trained to identify one or more metabolite bottlenecks.

[0183] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, a lin-log model, a large language model, a large protein model, or a protein language model.

[0184] In some aspects, the techniques described herein relate to a method, further including providing the set of concentrations to a set of artificial intelligence (Al)-based learning models, wherein at least one member of the set of Al-based learning models is trained to generate a set of recommendations for an intervention to a fermentation process in the fermentation system, wherein the set of recommendations includes at least one of a genetic modification, a process optimization, or an environmental adjustment.

[0185] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, a lin-log model, a large language model, a large protein model, or a protein language model.

[0186] In some aspects, the techniques described herein relate to a method, further including calculating a flux of a metabolic pathway from the set of metabolite concentrations.

[0187] In some aspects, the techniques described herein relate to a method, further including: providing the set of concentrations to a digital twin system; and generating, by the digital twin system, a digital twin representing a metabolic flux associated with a fermentation process in the fermentation system.

[0188] In some aspects, the techniques described herein relate to a method, further including calculating at least one of a predicted product yield measure, a fermentation productivity measure, a set of metabolite kinetic rates, or a set of pathway efficiency measures for a fermentation process in the fermentation system.

[0189] In some aspects, the techniques described herein relate to a method, further including building a set of kinetic models for a fermentation process in the fermentation system.

[0190] In some aspects, the techniques described herein relate to a computer-implemented method for data integration in an Al-guided synthetic biology development platform, including: receiving biological data from a plurality of experimental sources and databases; converting the received biological data into at least one standardized data format through a data intake and staging pipeline; processing the standardized biological data through a data normalization facility to minimize batch-specific systemic variation; storing the normalized biological data in a structured format that describes biological components and their relationships; applying at least one machine learning method to the normalized biological data to generate a predictive model for synthetic biology design; and outputting a specification for biological system optimization based on the predictive model.

[0191] In some aspects, the techniques described herein relate to a method, wherein the data normalization facility applies a Bayesian statistical model that incorporates prior knowledge about strain behavior.

[0192] In some aspects, the techniques described herein relate to a method, wherein processing the biological data includes modeling a source of variation including a biological effect.

[0193] In some aspects, the techniques described herein relate to a method, wherein the structured format includes a bipartite graph database structure organizing data into molecule nodes and process nodes.

[0194] In some aspects, the techniques described herein relate to a method, wherein the molecule nodes represent at least one of a molecule, atomic element, ion, compound, nucleic acid, protein, or macromolecule.

[0195] In some aspects, the techniques described herein relate to a method, wherein the process nodes represent at least one of a chemical reaction, protein folding, transport, regulatory interaction, or active site binding.

[0196] In some aspects, the techniques described herein relate to a method, wherein the data intake and staging pipeline includes an automated sampling mechanism for collecting a standardized sample.

[0197] In some aspects, the techniques described herein relate to a method, further including tracking data lineage from a raw experimental measurement to a processed value.

[0198] In some aspects, the techniques described herein relate to a method, wherein processing includes batch effect correction addressing systematic variation across experimental runs, equipment, or operators.

[0199] In some aspects, the techniques described herein relate to a method, further including validating data quality using a control sample.

[0200] In some aspects, the techniques described herein relate to a method, wherein receiving biological data includes collecting time-resolved metabolomic data from living cells.

[0201] In some aspects, the techniques described herein relate to a method, further including integrating a plurality of high-dimensional biological data types including at least one of gene expression data, flux data, or metabolite concentration measurement.

[0202] In some aspects, the techniques described herein relate to a method, wherein the machine learning method includes a neural network configured for processing biological parameter data.

[0203] In some aspects, the techniques described herein relate to a method, further including implementing an edge computing architecture for local processing of sensor data.

[0204] In some aspects, the techniques described herein relate to a method, further including maintaining metadata relating to an experimental condition.

[0205] In some aspects, the techniques described herein relate to a method, further including generating a visualization output of metabolic pathway perfonnance.

[0206] In some aspects, the techniques described herein relate to a system for analytics-as-a- service in an Al-guided synthetic biology platform, including: one or more processors; memory7storing instructions that, when executed by the one or more processors, cause a platform to: identifyT1an appropriate analytic method based on assessment of a biological data characteristic; implement a data preparation procedure specific to a synthetic biology application; apply a machine learning model to analyze biological data and generate a prediction; perform a model validation procedure to ensure analytical reliability; create an audit trail documenting an analytic procedure and result; and generate technical documentation and visualization of an analytic finding.

[0207] In some aspects, the techniques described herein relate to a system, wherein identifying the appropriate analytical method includes evaluating at least one of a data type, distribution, or relationship in biological data.

[0208] In some aspects, the techniques described herein relate to a system, wherein the data preparation procedure includes automated feature engineering for a biological data ty pe.

[0209] In some aspects, the techniques described herein relate to a system, wherein the machine learning model includes a protein language model for analyzing a protein sequence.

[0210] In some aspects, the techniques described herein relate to a system, further including implementing a distributed computing capability for handling computationally intensive analysis.

[0211] In some aspects, the techniques described herein relate to a system, wherein model validation includes both in-sample and out-of-sample testing.

[0212] In some aspects, the techniques described herein relate to a system, further including monitoring model performance over time and implementing a procedure to detect model degradation.

[0213] In some aspects, the techniques described herein relate to a system, wherein technical documentation includes at least one of a methodology description, assumption, or limitation.

[0214] In some aspects, the techniques described herein relate to a system, wherein the machine learning model includes a hybrid model combining mechanistic understanding with a machine learning method.

[0215] In some aspects, the techniques described herein relate to a system, further including implementing an automated model selection procedure.

[0216] In some aspects, the techniques described herein relate to a system, wherein model validation includes sensitivity analysis to evaluate model robustness.

[0217] In some aspects, the techniques described herein relate to a system, further including implementing a caching mechanism to improve processing efficiency.

[0218] In some aspects, the techniques described herein relate to a system, further including maintaining documentation of a standardization procedure.

[0219] In some aspects, the techniques described herein relate to a system, further including implementing a resource allocation procedure to optimize computational efficiency.

[0220] In some aspects, the techniques described herein relate to a system for data quality management in an Al-guided synthetic biology platform, including: a data intake and staging pipeline configured to: collect raw data from an experimental source; convert raw data into a standardized format; apply a quality assurance step to identify and correct an error; apply a normalization technique to remove a batch effect; validate that normalization preserves a biological signal; and a knowledge management system configured to: maintain an audit trail of dataprocessing; track data lineage from a raw measurement to a processed value; enable verification of a data processing step; store validated data in a structured format describing a biological relationship; and generate a quality’ metric.

[0221] In some aspects, the techniques described herein relate to a system, wherein the quality assurance step includes detecting a well or sample that failed to grow properly.

[0222] In some aspects, the techniques described herein relate to a system, wherein the quality assurance step includes identifying a sample exhibiting contamination.

[0223] In some aspects, the techniques described herein relate to a system, wherein the quality assurance step includes flagging a readout that falls outside an expected range.

[0224] In some aspects, the techniques described herein relate to a system, wherein the normalization technique includes Bayesian statistical normalization.

[0225] In some aspects, the techniques described herein relate to a system, wherein the structured format includes a bipartite graph database structure.

[0226] In some aspects, the techniques described herein relate to a system, further including implementing an automated validation check.

[0227] In some aspects, the techniques described herein relate to a system, wherein tracking data lineage includes maintaining detailed metadata.

[0228] In some aspects, the techniques described herein relate to a system, further including implementing error handling and retry logic.

[0229] In some aspects, the techniques described herein relate to a system, wherein the quality metric includes completeness analysis.

[0230] In some aspects, the techniques described herein relate to a system, further including implementing a cross-reference validation technique.

[0231] In some aspects, the techniques described herein relate to a system, wherein the normalization technique includes batch effect correction.

[0232] In some aspects, the techniques described herein relate to a system, further including implementing an automated classification process.

[0233] In some aspects, the techniques described herein relate to a system, further including implementing a data enrichment capability'.

[0234] In some aspects, the techniques described herein relate to a method for multi-modal data integration in an Al-guided synthetic biology platform, including: collecting time-resolved metabolomics data from a living cell through an automated sampling mechanism; integrating multiple types of high-dimensional biological data including at least one of gene expression, metabolic flux, or protein concentration measurement; normalizing the integrated biological data using batch effect correction; validating quality and consistency of the normalized biological data; storing the validated biological data in a structured format describing relationships between biological entities; and analyzing the stored validated biological data using a machine learning model to generate a prediction for synthetic biology system design.

[0235] In some aspects, the techniques described herein relate to a method, wherein the automated sampling mechanism includes near-instantaneous quenching of cellular metabolism.

[0236] In some aspects, the techniques described herein relate to a method, wherein integrating includes combining gene expression data from RNA sequencing.

[0237] In some aspects, the techniques described herein relate to a method, wherein integrating includes incorporating flux data from an isotope-labeled experiment.

[0238] In some aspects, the techniques described herein relate to a method, wherein integrating includes merging a metabolite concentration measurement from mass spectrometry.

[0239] In some aspects, the techniques described herein relate to a method, wherein normalizing includes applying a Bayesian statistical model.

[0240] In some aspects, the techniques described herein relate to a method, wherein the structured format is a knowledge graph structure.

[0241] In some aspects, the techniques described herein relate to a method, further including tracking data lineage from a raw measurement.

[0242] In some aspects, the techniques described herein relate to a method, further including maintaining detailed metadata about an experimental condition.

[0243] In some aspects, the techniques described herein relate to a method, wherein the machine learning model includes a neural network with a multi-headed attention mechanism.

[0244] In some aspects, the techniques described herein relate to a method, further including implementing a distributed computing capability.

[0245] In some aspects, the techniques described herein relate to a method, wherein validating includes using a control sample.

[0246] In some aspects, the techniques described herein relate to a method, further including generating a visualization output.

[0247] In some aspects, the techniques described herein relate to a method, wherein analyzing includes predicting strain performance.

[0248] In some aspects, the techniques described herein relate to a method, further including implementing an edge computing architecture.

[0249] In some aspects, the techniques described herein relate to a method, wherein storing includes maintaining an audit trail.

[0250] In some aspects, the techniques described herein relate to a system for real-time data processing in an Al-guided synthetic biology platform, including: one or more processors, each configured with an Al processing core optimized for biological data types; a data collection system configured to collect a continuous data stream from laboratory equipment; a data processing pipeline configured to: perform real-time normalization; integrate a plurality of data streams in parallel; implement edge computing for local data processing; apply a machine learning model for real-time analysis; and generate an automated alert or recommendation based on processed data.

[0251] In some aspects, the techniques described herein relate to a system, wherein the Al processing core includes a GPU configured for protein structure prediction.

[0252] In some aspects, the techniques described herein relate to a system, wherein the Al processing core includes an NPU optimized for metabolic pathway analysis.

[0253] In some aspects, the techniques described herein relate to a system, wherein the data stream includes bioreactor sensor data.

[0254] In some aspects, the techniques described herein relate to a system, wherein the data stream includes mass spectrometry data.

[0255] In some aspects, the techniques described herein relate to a system, wherein real-time normalization includes batch effect correction.

[0256] In some aspects, the techniques described herein relate to a system, further including implementing a load balancing algorithm.

[0257] In some aspects, the techniques described herein relate to a system, further including implementing an automated failover mechanism.

[0258] In some aspects, the techniques described herein relate to a system, wherein the machine learning model is a hybrid model.

[0259] In some aspects, the techniques described herein relate to a system, further including implementing a distributed computing capability.

[0260] In some aspects, the techniques described herein relate to a system, wherein the alert includes a quality control notification.

[0261] In some aspects, the techniques described herein relate to a system, further including generating a real-time visualization.

[0262] In some aspects, the techniques described herein relate to a system, wherein the recommendation includes a process parameter adjustment.

[0263] In some aspects, the techniques described herein relate to a system, further including implementing an automated validation check.

[0264] In some aspects, the techniques described herein relate to a method for data management in an Al-guided synthetic biology7platform, including: implementing a knowledge graph structure to represent at least one biological entity7; integrating experimental data, literature data, and proprietary7data into the knowledge graph; maintaining data lineage and provenance tracking; applying a machine learning model to analyze graph relationships; generating a recommendation based on graph analysis; and providing an interactive visualization of the knowledge graph.

[0265] In some aspects, the techniques described herein relate to a method, wherein the biological entity7includes at least one of a gene, protein, or metabolite.

[0266] In some aspects, the techniques described herein relate to a method, wherein relationships include a regulatory interaction and metabolic pathway.

[0267] In some aspects, the techniques described herein relate to a method, wherein the experimental data includes a time-series measurement.

[0268] In some aspects, the techniques described herein relate to a method, wherein literature data includes a published research finding.

[0269] In some aspects, the techniques described herein relate to a method, wherein proprietary data includes a strain perfonnance datum.

[0270] In some aspects, the techniques described herein relate to a method, further including implementing automated data validation.

[0271] In some aspects, the techniques described herein relate to a method, wherein the machine learning model is a graph neural networks.

[0272] In some aspects, the techniques described herein relate to a method, further including maintaining an audit trails of changes.

[0273] In some aspects, the techniques described herein relate to a method, wherein visualization includes a network diagram.

[0274] In some aspects, the techniques described herein relate to a method, wherein the recommendation includes a strain optimization strategy.

[0275] In some aspects, the techniques described herein relate to a system for managing biological data in an Al-guided synthetic biology platform, including: a knowledge graph structure configured to: represent biological entities as nodes and their relationships as edges; store validated experimental data describing relationships between biological components; maintain data lineage from a raw measurement to a processed value; track a relationship between a strain, genetic design, experimental condition, and a performance datum; a machine learning system configured to: analyze the knowledge graph structure to identify a patterns or relationship; generate a prediction for synthetic biology system design; and provide a query capability for retrieving interconnected biological data.

[0276] In some aspects, the techniques described herein relate to a system, wherein biological entities include at least one of a gene, protein, metabolite, or strain.

[0277] In some aspects, the techniques described herein relate to a system, wherein relationships include at least one of a metabolic pathway, regulatory interaction, or protein-protein interaction.

[0278] In some aspects, the techniques described herein relate to a system, wherein experimental data includes time-resolved metabolomics data.

[0279] In some aspects, the techniques described herein relate to a system, wherein the knowledge graph enables retrieval of a strain that modifies a particular metabolic pathway.

[0280] In some aspects, the techniques described herein relate to a system, further including a visualization capability for exploring a graph relationship.

[0281] In some aspects, the techniques described herein relate to a system, wherein the machine learning system includes a graph neural network.

[0282] In some aspects, the techniques described herein relate to a system, further including automated validation of a data relationship.

[0283] In some aspects, the techniques described herein relate to a system, wherein data lineage includes experimental conditions metadata.

[0284] In some aspects, the techniques described herein relate to a system, further including version control for tracking graph changes.

[0285] In some aspects, the techniques described herein relate to a system, wherein a prediction includes a strain optimization recommendation.

[0286] In some aspects, the techniques described herein relate to a system, wherein the query capability includes filtering by pathway modifications.

[0287] In some aspects, the techniques described herein relate to a system, further including integration with an external biological database.

[0288] In some aspects, the techniques described herein relate to a system, wherein the knowledge graph maintains an audit trail.

[0289] In some aspects, the techniques described herein relate to a system, further including realtime updates from experimental data.

[0290] In some aspects, the techniques described herein relate to a computer-implemented method for structured biological data storage in an Al-guided synthetic biology platform, including: implementing a bipartite graph database structure organizing data into molecule nodes and process nodes; storing biological components and their relationships in the graph database structure; maintaining connections between nodes indicating roles in biological processes; integrating a plurality of high-dimensional biological data types; applying a machine learning method to analyze a graph relationship; and generating a prediction for synthetic biology optimization based on graph analysis.

[0291] In some aspects, the techniques described herein relate to a method, wherein molecule nodes represent at least one of an atomic element, ion, compound, nucleic acid, protein, or macromolecule.

[0292] In some aspects, the techniques described herein relate to a method, wherein process nodes represent at least one of a chemical reaction, protein folding, transport, regulatory interaction, or active site binding.

[0293] In some aspects, the techniques described herein relate to a method, wherein highdimensional biological data includes gene expression data from RNA sequencing.

[0294] In some aspects, the techniques described herein relate to a method, wherein highdimensional biological data includes flux data from isotope-labeled experiments.

[0295] In some aspects, the techniques described herein relate to a method, wherein highdimensional biological data includes metabolite concentration measurements.

[0296] In some aspects, the techniques described herein relate to a method, further including implementing data normalization procedures.

[0297] In some aspects, the techniques described herein relate to a method, wherein the machine learning method is a hybrid model.

[0298] In some aspects, the techniques described herein relate to a method, further including maintaining data provenance tracking.

[0299] In some aspects, the techniques described herein relate to a method, wherein the prediction includes pathway bottleneck identification.

[0300] In some aspects, the techniques described herein relate to a method, further including implementing a quality control mechanism.

[0301] In some aspects, the techniques described herein relate to a method, wherein the graph relationship includes a metabolic pathway connection.

[0302] In some aspects, the techniques described herein relate to a method, further including generating a visualization output.

[0303] In some aspects, the techniques described herein relate to a method, wherein the machine learning method includes a neural network.

[0304] In some aspects, the techniques described herein relate to a method, further including implementing an automated validation check.

[0305] In some aspects, the techniques described herein relate to a method, wherein predictions include strain performance estimates.

[0306] In some aspects, the techniques described herein relate to a system for multi-modal data storage in an Al-guided synthetic biology platform, including: one or more processors; memory storing instructions that, when executed by the one or more processors, cause the platform to: implement a specialized data structure optimized for a biological data type; store time-series experimental data in a vector database; maintain a knowledge graph for biological relationship mapping; integrate structured and unstructured biological data; apply a machine learning model to analyze a cross-structure relationship; and generate a unified data presentation for decision support.

[0307] In some aspects, the techniques described herein relate to a system, wherein the specialized data structure includes a bipartite graph database.

[0308] In some aspects, the techniques described herein relate to a system, wherein time-series data includes a bioreactor sensor measurement.

[0309] In some aspects, the techniques described herein relate to a system, wherein time-series data includes a metabolomics measurement.

[0310] In some aspects, the techniques described herein relate to a system, wherein the knowledge graph represents a strain lineage.

[0311] In some aspects, the techniques described herein relate to a system, wherein structured data includes an experimental parameter.

[0312] In some aspects, the techniques described herein relate to a system, wherein unstructured data includes scientific literature.

[0313] In some aspects, the techniques described herein relate to a system, further including implementing a data normalization procedure.

[0314] In some aspects, the techniques described herein relate to a system, wherein the machine learning model is a hybrid architecture.

[0315] In some aspects, the techniques described herein relate to a system, further including maintaining an audit trail.

[0316] In some aspects, the techniques described herein relate to a system, wherein the unified presentation includes a visualization.

[0317] In some aspects, the techniques described herein relate to a system, further including implementing an automated validation check.

[0318] In some aspects, the techniques described herein relate to a system, wherein relationships include a metabolic pathway.

[0319] In some aspects, the techniques described herein relate to a system, wherein decision support includes a strain optimization recommendation.

[0320] In some aspects, the techniques described herein relate to a system for integrated data processing in an Al-guided synthetic biology platform, including: a data storage layer configured to: maintain a knowledge graph structure representing biological entities and relationships; store time-series experimental data in at least one vector database; track data lineage; an artificial intelligence layer configured to: analyze a data relationship using a machine learning model; generate a prediction for synthetic biology optimization; maintain a model performance metric: an automated processing layer configured to: implement a standardized data collection protocol; perform a quality control check; apply a normalization procedure; and an integration layer configured to: coordinate a data flow between system components; maintain a synchronized state across layers; and provide a unified access to platform capabilities.

[0321] In some aspects, the techniques described herein relate to a system, wherein the knowledge graph structure represents at least one of a gene, protein, metabolite or their interactions.

[0322] In some aspects, the techniques described herein relate to a system, wherein the machine learning model includes at least one ofa foundation model, a mechanistic model, or a hybrid model.

[0323] In some aspects, the techniques described herein relate to a system, wherein quality control includes automated detection of anomalous data.

[0324] In some aspects, the techniques described herein relate to a system, wherein normalization procedures include a Bayesian statistical model.

[0325] In some aspects, the techniques described herein relate to a system, wherein data flow coordination includes automated staging and validation.

[0326] In some aspects, the techniques described herein relate to a system, wherein the integration layer implements standardized APIs.

[0327] In some aspects, the techniques described herein relate to a system, wherein the prediction includes a strain optimization recommendation.

[0328] In some aspects, the techniques described herein relate to a system, wherein the model metric includes performance tracking and validation.

[0329] In some aspects, the techniques described herein relate to a system, wherein data collection includes an automated sampling mechanism.

[0330] In some aspects, the techniques described herein relate to a system, wherein quality control includes control sample validation.

[0331] In some aspects, the techniques described herein relate to a system, wherein normalization preserves a biological signal.

[0332] In some aspects, the techniques described herein relate to a system, wherein coordination includes error handling.

[0333] In some aspects, the techniques described herein relate to a system, wherein synchronization includes version control.

[0334] In some aspects, the techniques described herein relate to a system, wherein access includes role-based permissions.

[0335] In some aspects, the techniques described herein relate to a system, wherein capabilities include a visualization tool.

[0336] In some aspects, the techniques described herein relate to a computer-implemented method for integrated synthetic biology data processing, including: receiving biological data through an automated collection mechanism; storing received data in a structured format optimized for a biological data type; processing stored data through a uality control and nonnalization pipeline; analyzing processed data using a machine learning model; maintaining a synchronized data state across platform components; generating a unified output for decision support; and tracking data transformation throughout the integrated process.

[0337] In some aspects, the techniques described herein relate to a method, wherein the collection mechanism includes sensor integration.

[0338] In some aspects, the techniques described herein relate to a method, wherein the structured format includes knowledge graphs.

[0339] In some aspects, the techniques described herein relate to a method, wherein quality control includes automated validation.

[0340] In some aspects, the techniques described herein relate to a method, wherein normalization includes batch effect correction.

[0341] In some aspects, the techniques described herein relate to a method, wherein the machine learning model includes a hybrid architecture.

[0342] In some aspects, the techniques described herein relate to a method, wherein synchronization includes state management.

[0343] In some aspects, the techniques described herein relate to a method, wherein the output includes a visualization capability.

[0344] In some aspects, the techniques described herein relate to a method, wherein tracking includes an audit trail.

[0345] In some aspects, the techniques described herein relate to a method, wherein processing includes error handling.

[0346] In some aspects, the techniques described herein relate to a method, wherein outputs include recommendations.

[0347] In some aspects, the techniques described herein relate to a method, wherein automated collection includes metadata capture.

[0348] In some aspects, the techniques described herein relate to a method, wherein validation includes a control sample.

[0349] In some aspects, the techniques described herein relate to a method, wherein synchronization includes a failover mechanism.

[0350] In some aspects, the techniques described herein relate to a system for coordinated synthetic biology workflow execution, including: one or more processors; memory' storing instructions that, when executed by the one or more processors, cause a platform to: implement an automated data collection and storage process; coordinate a quality' control and normalizationworkflow; manage a machine learning model execution; track workflow execution status; and generate integrated process documentation.

[0351] In some aspects, the techniques described herein relate to a system, wherein the collection process includes sensor integration.

[0352] In some aspects, the techniques described herein relate to a system, wherein quality control includes automated validation.

[0353] In some aspects, the techniques described herein relate to a system, wherein normalization includes a Bayesian model.

[0354] In some aspects, the techniques described herein relate to a system, wherein the machine learning includes model selection.

[0355] In some aspects, the techniques described herein relate to a system, wherein documentation includes a quality metric.

[0356] In some aspects, the techniques described herein relate to a system, wherein the workflow includes a validation step.

[0357] In some aspects, the techniques described herein relate to a system, wherein execution includes version control.

[0358] In some aspects, the techniques described herein relate to a system, wherein collection includes metadata capture.

[0359] In some aspects, the techniques described herein relate to a system, wherein validation includes a control sample.

[0360] In some aspects, the techniques described herein relate to a computer-implemented method for automated data handling in an Al-guided synthetic biology' platform, including: receiving experimental data from a plurality of sources through an automated data sampling mechanism; implementing an automated validation check to ensure data integrity during transfer; applying an automated data normalization procedure to the received experimental data to standardize at least one data format and remove batch effects; performing an automated quality control to identify data anomalies; storing processed data with automated lineage metadata; and generating documentation summarizing the automated data handling.

[0361] In some aspects, the techniques described herein relate to a method, wherein automated data sampling mechanism includes near-instantaneous quenching of cellular metabolism.

[0362] In some aspects, the techniques described herein relate to a method, wherein the automated validation check verifies at least one of a data type, a value range, or a pattern.

[0363] In some aspects, the techniques described herein relate to a method, wherein the automated data normalization procedure includes a Bayesian statistical model.

[0364] In some aspects, the techniques described herein relate to a method, wherein quality control includes detecting a failed sample.

[0365] In some aspects, the techniques described herein relate to a method, wherein lineage tracking maintains metadata about an experimental condition.

[0366] In some aspects, the techniques described herein relate to a method, further including automated classification of a data sensitivity level.

[0367] In some aspects, the techniques described herein relate to a method, further including automated error handling and retry logic.

[0368] In some aspects, the techniques described herein relate to a method, wherein documentation includes a quality scorecard.

[0369] In some aspects, the techniques described herein relate to a method, further including automated batch effect correction.

[0370] In some aspects, the techniques described herein relate to a method, wherein validation includes cross-reference validation.

[0371] In some aspects, the techniques described herein relate to a method, further including automated data enrichment.

[0372] In some aspects, the techniques described herein relate to a method, wherein quality control includes a statistical check.

[0373] In some aspects, the techniques described herein relate to a method, further including automated format conversion.

[0374] In some aspects, the techniques described herein relate to a method, wherein documentation includes an audit trail.

[0375] In some aspects, the techniques described herein relate to a system for automated data processing in an Al-guided synthetic biology platform, including: one or more processors; memory storing instructions that, when executed by the one or more processors, cause the platform to: implement an automated ETL process for a biological data source; perform automated data quality assessment and validation; apply an automated nonnalization and standardization procedure; maintain an automated tracking of data transformation; generate automated documentation of a processing step; and provide an automated alert relating to a processing issue.

[0376] In some aspects, the techniques described herein relate to a system, wherein the ETL process handles structured and unstructured data.

[0377] In some aspects, the techniques described herein relate to a system, wherein quality assessment includes completeness analysis.

[0378] In some aspects, the techniques described herein relate to a system, wherein normalization includes batch effect correction.

[0379] In some aspects, the techniques described herein relate to a system, wherein tracking includes data lineage documentation.

[0380] In some aspects, the techniques described herein relate to a system, further including automated error detection.

[0381] In some aspects, the techniques described herein relate to a system, wherein documentation includes a processing history.

[0382] In some aspects, the techniques described herein relate to a system, further including automated data classification.

[0383] In some aspects, the techniques described herein relate to a system, wherein validation includes a control sample check.

[0384] In some aspects, the techniques described herein relate to a system, further including automated data format harmonization.

[0385] In some aspects, the techniques described herein relate to a system, wherein the alert relates to a quality threshold violation.

[0386] In some aspects, the techniques described herein relate to a system, further including automated metadata extraction.

[0387] In some aspects, the techniques described herein relate to a system, wherein processing includes outlier detection.

[0388] In some aspects, the techniques described herein relate to a system, further including automated version control.

[0389] In some aspects, the techniques described herein relate to a system, wherein documentation includes a quality metric.

[0390] In some aspects, the techniques described herein relate to a system, further including automated data staging.

[0391] In some aspects, the techniques described herein relate to a system for automated data integration in an Al-guided synthetic biology platform, including: a data intake pipeline configured to: automatically collect data from a plurality of experimental sources; perform automated data format standardization; implement an automated data quality control check; apply an automated data normalization procedure; a data management system configured to: maintain automated tracking of data processing; generate automated documentation; implement an automated data validation procedure; and provide an automated alert regarding verification of completed processing steps.

[0392] In some aspects, the techniques described herein relate to a system, wherein experimental sources include bioreactor sensors.

[0393] In some aspects, the techniques described herein relate to a system, wherein standardization includes unit conversion.

[0394] In some aspects, the techniques described herein relate to a system, wherein quality control includes anomaly detection.

[0395] In some aspects, the techniques described herein relate to a system, wherein normalization includes Bayesian models.

[0396] In some aspects, the techniques described herein relate to a system, wherein tracking includes an audit trail.

[0397] In some aspects, the techniques described herein relate to a system, wherein documentation includes a quality scorecard.

[0398] In some aspects, the techniques described herein relate to a system, wherein validation includes a control sample check.

[0399] In some aspects, the techniques described herein relate to a system, wherein an alert includes an error notification.

[0400] In some aspects, the techniques described herein relate to a system, further including automated data classification.

[0401] In some aspects, the techniques described herein relate to a system, wherein processing includes batch correction.

[0402] In some aspects, the techniques described herein relate to a system, further including automated metadata management.

[0403] In some aspects, the techniques described herein relate to a system, wherein validation includes cross-referencing.

[0404] In some aspects, the techniques described herein relate to a system, further including automated data enrichment.

[0405] In some aspects, the techniques described herein relate to a system, wherein documentation includes a processing log.

[0406] In some aspects, the techniques described herein relate to a system further including automated version tracking.

[0407] In some aspects, the techniques described herein relate to a system for machine learningbased analysis in an Al-guided synthetic biology platform, including: one or more processors configured with an Al processing core; memory storing instructions that, when executed by the one or more processors, cause the platform to: implement a multi-modal deep learning architecture with separate encoding branches for different data modalities; process gene expression data, metabolite profile, and reaction flux data through specialized neural network branches; combine encoded representations through fusion layers; generate at least one prediction about a cellular phenotype based on the processed multimodal biological data; and output a specification for biological system optimization based on the at least one prediction.

[0408] In some aspects, the techniques described herein relate to a system, wherein the Al processing core includes GPUs, NPUs, TPUs, or FPGAs optimized for biological data processing.

[0409] In some aspects, the techniques described herein relate to a system, wherein the multimodal deep learning architecture includes transformer models.

[0410] In some aspects, the techniques described herein relate to a system, wherein specialized neural network branches include protein language models.

[0411] In some aspects, the techniques described herein relate to a system, wherein the at least one prediction includes a strain performance estimate.

[0412] In some aspects, the techniques described herein relate to a system, further including implementing a distributed computing capability.

[0413] In some aspects, the techniques described herein relate to a system, wherein fusion layers combine multiple types of biological embeddings.

[0414] In some aspects, the techniques described herein relate to a system, further including implementing automated model selection.

[0415] In some aspects, the techniques described herein relate to a system, wherein processing includes batch effect correction.

[0416] In some aspects, the techniques described herein relate to a system, further including maintaining model performance metrics.

[0417] In some aspects, the techniques descnbed herein relate to a system, wherein the at least one prediction includes pathway bottleneck identification.

[0418] In some aspects, the techniques described herein relate to a system, further including implementing model validation procedures.

[0419] In some aspects, the techniques described herein relate to a system, wherein the deep learning architecture includes hybrid models.

[0420] In some aspects, the techniques described herein relate to a system, further including implementing edge computing capabilities.

[0421] In some aspects, the techniques described herein relate to a system, wherein the at least one prediction includes metabolic flux distributions.

[0422] In some aspects, the techniques described herein relate to a system, further including generating visualization outputs.

[0423] In some aspects, the techniques described herein relate to a computer-implemented method for Al-guided synthetic biology optimization, including: receiving biological data from a plurality of experimental sources; processing the biological data through a foundation model to generate a biological entity embedding; analyzing the embedding using a mechanistic model to characterize a biological process; combining the foundation model and the mechanistic model outputs through hybrid models; generating a prediction for synthetic biology system design; and implementing automated model construction to iteratively improve predictions based on new data.

[0424] In some aspects, the techniques described herein relate to a method, wherein the foundation model includes a genetic generalization model.

[0425] In some aspects, the techniques described herein relate to a method, wherein the foundation model includes a process generalization model.

[0426] In some aspects, the techniques described herein relate to a method, wherein the mechanistic model generates outputs characterizing a biological pathway.

[0427] In some aspects, the techniques described herein relate to a method, wherein hybrid models leverage respective strengths of individual models.

[0428] In some aspects, the techniques described herein relate to a method, further including implementing active learning capabilities.

[0429] In some aspects, the techniques described herein relate to a method, wherein the prediction includes a strain design specification.

[0430] In some aspects, the techniques described herein relate to a method, further including maintaining model performance tracking.

[0431] In some aspects, the techniques described herein relate to a method, wherein processing includes data nonnalization.

[0432] In some aspects, the techniques described herein relate to a method, further including implementing a validation procedure.

[0433] In some aspects, the techniques described herein relate to a method, wherein the prediction includes a process parameter optimization.

[0434] In some aspects, the techniques described herein relate to a method, further including implementing distributed computing.

[0435] In some aspects, the techniques described herein relate to a method, wherein the embedding includes a strain representation.

[0436] In some aspects, the techniques described herein relate to a method, further including maintaining an audit trail.

[0437] In some aspects, the techniques described herein relate to a method, wherein the prediction includes scale-up performance.

[0438] In some aspects, the techniques described herein relate to a method, further including generating a visualization output.

[0439] In some aspects, the techniques described herein relate to a computer-implemented method for data normalization in an Al-guided synthetic biology platform, including: receiving experimental data associated with synthetic biology development from a plurality of sources; processing the experimental data through a Bayesian statistical normalization model configured to: model batch-specific systemic variation; account for a technical factor contributing to a batch effect; separate a biological signal from a technical factor; validate that normalization preserved a specified biological signal; store the normalized data with tracked data lineage; and provide the nonnalized data to a machine learning model for analysis.

[0440] In some aspects, the techniques described herein relate to a method, wherein modeling batch-specific systemic variation includes constructing plate notation models representing a strain effect.

[0441] In some aspects, the techniques described herein relate to a method, wherein modeling includes representing an experimental effect and plate-to-plate variations.

[0442] In some aspects, the techniques described herein relate to a method, wherein the technical factor includes plate position effects.

[0443] In some aspects, the techniques described herein relate to a method, wherein the biological signal includes a metabolite concentration.

[0444] In some aspects, the techniques described herein relate to a method, wherein the biological signal includes an enzyme activity level.

[0445] In some aspects, the techniques described herein relate to a method, wherein the biological signal includes a gene expression level.

[0446] In some aspects, the techniques described herein relate to a method, further including implementing multi-modal data integration.

[0447] In some aspects, the techniques described herein relate to a method, wherein data lineage includes experimental conditions metadata.

[0448] In some aspects, the techniques described herein relate to a method, further including implementing cross-platform data harmonization.

[0449] In some aspects, the techniques described herein relate to a method, wherein normalization includes time series data normalization.

[0450] In some aspects, the techniques described herein relate to a method, further including implementing knowledge graph-based normalization.

[0451] In some aspects, the techniques described herein relate to a method, wherein the machine learning model includes a transfomier model.

[0452] In some aspects, the techniques described herein relate to a method, wherein the machine learning model includes a neural network.

[0453] In some aspects, the techniques described herein relate to a method, further including generating a visualization output.

[0454] In some aspects, the techniques described herein relate to a method, further including maintaining an audit trail.

[0455] In some aspects, the techniques described herein relate to a system for quality control in an Al-guided synthetic biology platform, including: a data intake pipeline configured to: collect raw experimental data associated with a strain performance measurement; implement data normalization and quality control procedures; validate a strain genotype through an automated process; identify outlier data in an experimental dataset; maintain metadata about an experimental condition; a machine learning system configured to: analyze a quality control metric; generate an automated alert relating to detection of anomalous data; predict an expected measurement range based on historical data; and provide a recommendation for experimental validation.

[0456] In some aspects, the techniques described herein relate to a system, wherein the strain performance measurement includes a metabolite measurement.

[0457] In some aspects, the techniques described herein relate to a system, wherein the quality control procedure detects a failed growth sample.

[0458] In some aspects, the techniques described herein relate to a system, wherein the quality control procedure identifies contamination.

[0459] In some aspects, the techniques described herein relate to a system, wherein outlier detection uses statistical analysis.

[0460] In some aspects, the techniques described herein relate to a system, wherein metadata includes processing step information.

[0461] In some aspects, the techniques described herein relate to a system, further including implementing an automated validation check.

[0462] In some aspects, the techniques described herein relate to a system, wherein the alert includes a quality threshold violation.

[0463] In some aspects, the techniques described herein relate to a system, further including implementing an error handling procedure.

[0464] In some aspects, the techniques described herein relate to a system, wherein the quality metric includes completeness analysis.

[0465] In some aspects, the techniques described herein relate to a system, further including implementing cross-reference validation.

[0466] In some aspects, the techniques described herein relate to a system, wherein the recommendation includes control sample validation.

[0467] In some aspects, the techniques described herein relate to a system, further including implementing automated classification.

[0468] In some aspects, the techniques described herein relate to a system, wherein the quality metric includes a statistical check.

[0469] In some aspects, the techniques described herein relate to a system, further including generating a quality scorecard.

[0470] In some aspects, the techniques described herein relate to a system, further including maintaining an audit trail.

[0471] In some aspects, the techniques described herein relate to a system for integrated data quality7management in an Al-guided synthetic biology' platform, including: one or more processors; memory storing instructions that, when executed by the one or more processors, cause the platform to: implement an automated sampling mechanism for standardized data collection; apply a Bayesian normalization model to experimental data; perform an automated quality control check using a machine learning model; generate a probability distribution representing strain performance; and identify a high-performing strain based on normalized measurements.

[0472] In some aspects, the techniques described herein relate to a system, wherein the sampling mechanism includes metabolomics data collection.

[0473] In some aspects, the techniques described herein relate to a system, wherein the nonnalization model incorporates prior knowledge.

[0474] In some aspects, the techniques described herein relate to a system, wherein quality control includes anomaly detection.

[0475] In some aspects, the techniques described herein relate to a system, wherein the probability distribution includes an uncertainty' estimate.

[0476] In some aspects, the techniques described herein relate to a system, further including implementing batch effect correction.

[0477] In some aspects, the techniques described herein relate to a system, wherein the machine learning model includes a hybrid model.

[0478] In some aspects, the techniques described herein relate to a system, further including maintaining a performance metric.

[0479] In some aspects, the techniques described herein relate to a system, wherein quality control includes control sample validation.

[0480] In some aspects, the techniques described herein relate to a system, further including implementing data enrichment.

[0481] In some aspects, the techniques described herein relate to a system, wherein normalization preserves a biological signal.

[0482] In some aspects, the techniques described herein relate to a system, further including implementing automated validation.

[0483] In some aspects, the techniques described herein relate to a system, wherein quality control includes a statistical check.

[0484] In some aspects, the techniques described herein relate to a system, further including generating documentation.

[0485] In some aspects, the techniques described herein relate to a system, further including maintaining an audit trail.

[0486] In some aspects, the techniques described herein relate to a platform for generating a set of recommendations associated with the production of a functional output by a biological strain, including: a set of data integration facilities for integrating content of at least one publication data set relating to the biological strain and at least one proprietary7data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein an output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and at least one member of the set of Al-based learning models that is configured to generate a set of recommendations wherein the set of recommendations relate to at least one of a set of modifications to a set of genes of the biological strain, a set of modifications to a set of environmental parameters for a synthetic biological process in which the biological strain produces the functional output, a set of modifications to a set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, or a set of modifications to a set of proteins or enzymes associated with the biological strain; wherein that the set of recommendations enhance production of the functional output by the biological strain.

[0487] In some aspects, the techniques described herein relate to a platform, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory7(LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

[0488] In some aspects, the techniques described herein relate to a platform, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0489] In some aspects, the techniques described herein relate to a platform, wherein the at least one proprietary^ dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy7consumption parameters.

[0490] In some aspects, the techniques described herein relate to a platform, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creationof synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

[0491] In some aspects, the techniques described herein relate to a platform, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity management, pressure, or salinity.

[0492] In some aspects, the techniques described herein relate to a platform, wherein the set of recommendations relates to at least one of identification and overexpression of key enzymes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

[0493] In some aspects, the techniques described herein relate to a platform, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site- directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

[0494] In some aspects, the techniques described herein relate to a platform, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0495] In some aspects, the techniques described herein relate to a platform, wherein the set of Al-based learning models is configured to process inputs in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

[0496] In some aspects, the techniques described herein relate to a platform, wherein the set of Al-based learning models uses adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

[0497] In some aspects, the techniques described herein relate to a platform, wherein the data integration facilities use dedicated processing cores to perform data transformation or integration operations.

[0498] In some aspects, the techniques described herein relate to a method for generating a set of recommendations associated with the production of a functional output by a biological strain, including: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein an output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and generating, by at least one member of the set of AI- based learning models, a set of recommendations wherein the set of recommendations relate to at least one of a set of modifications to a set of genes of the biological strain, a set of modifications to a set of environmental parameters for a synthetic biological process in which the biological strainproduces the functional output, a set of modifications to a set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, or a set of modifications to a set of proteins or enzymes associated with the biological strain; wherein that the set of recommendations enhance production of the functional output by the biological strain.

[0499] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

[0500] In some aspects, the techniques described herein relate to a method, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0501] In some aspects, the techniques described herein relate to a method, wherein the at least one proprietary dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy- consumption parameters.

[0502] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

[0503] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity management, pressure, or salinity.

[0504] In some aspects, the techniques described herein relate to a method, w herein the set of recommendations relates to at least one of identification and overexpression of key enzymes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

[0505] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to at least one of enzy me overexpression, use of stronger promoters, site- directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification ofenzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

[0506] In some aspects, the techniques described herein relate to a method, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0507] In some aspects, the techniques described herein relate to a method, wherein processing the inputs by the set of Al-based learning models includes processing in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

[0508] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

[0509] In some aspects, the techniques described herein relate to a method, wherein integrating the content includes using dedicated processing cores to perform data transformation or integration operations.

[0510] In some aspects, the techniques described herein relate to a platform for generating a set of recommendations associated with the production of a functional output by a biological strain, including: a set of data integration facilities configured to integrate the content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein an output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; a simulation engine configured to: generate a plurality of synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to at least one of a set of genes of the biological strain, a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output, a set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, or a set of proteins or enzy mes associated with the biological strain; execute simulations for the plurality of simulated process scenarios; generate simulation data based on the executed simulations wherein the simulation data is configured as an input to the set of Al-based learning models; and at least one member of the set of Al -based learning models that is configured to generate a set of recommendations wherein the set of recommendations relate to at least one of a set of modifications to a set of genes of the biological strain, a set of modifications to a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output, a set of modifications to the set of biological pathways associated with a synthetic biological process in which the biological strain produces the functional output, or a set of modifications to the set of proteins or enzymes associated with the biological strain; wherein that the set of recommendations enhance production of the functional output by the biological strain.

[0511] In some aspects, the techniques descnbed herein relate to a platform, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory’ (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

[0512] In some aspects, the techniques described herein relate to a platform, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory’ study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0513] In some aspects, the techniques described herein relate to a platform, wherein the at least one proprietary7dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

[0514] In some aspects, the techniques descnbed herein relate to a platform, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

[0515] In some aspects, the techniques described herein relate to a platfonn, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity' management, pressure, or salinity'.

[0516] In some aspects, the techniques described herein relate to a platform, wherein the set of recommendations relates to at least one of identification and overexpression of key enzy mes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

[0517] In some aspects, the techniques descnbed herein relate to a platform, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site- directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

[0518] In some aspects, the techniques described herein relate to a platform, wherein the functional output includes at least one of fuel applications and solutions, industrial applicationsand solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0519] In some aspects, the techniques described herein relate to a platform, wherein the set of Al-based learning models is configured to process inputs in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

[0520] In some aspects, the techniques described herein relate to a platform, wherein the set of Al-based learning models uses adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

[0521] In some aspects, the techniques described herein relate to a platform, wherein the data integration facilities use dedicated processing cores to perform data transformation or integration operations.

[0522] In some aspects, the techniques described herein relate to a platform, wherein the simulation engine uses distributed computing to parallelize the execution of simulations across a plurality of computing nodes.

[0523] In some aspects, the techniques described herein relate to a platform, wherein the simulation engine uses distributed computing to execute multiple simulations by batching neural network computations or distributing ODE integrations across a plurality of processing cores.

[0524] In some aspects, the techniques described herein relate to a method for generating a set of recommendations associated with the production of a functional output by a biological strain, including: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein an output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; generating, by a simulation engine, a plurality' of synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to at least one of a set of genes of the biological strain, a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output, a set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, or a set of proteins or enzymes associated with the biological strain; executing, by the simulation engine, simulations for the plurality of simulated process scenarios; generating, by the simulation engine, simulation data based on the executed simulations wherein the simulation data is configured as an input to the set of Al-based learning models; and generating, by at least one member of the set of Al-based learning models, a set of recommendations wherein the set of recommendations relate to at least one of a set of modifications to a set of genes of the biological strain, a set of modifications to a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output, a set of modifications to the set of biological pathw ays associated with a synthetic biological process in which the biological strain produces the functional output, or a set of modifications to the set of proteins or enzy mesassociated with the biological strain; wherein that the set of recommendations enhance production of the functional output by the biological strain.

[0525] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-tenn memory' (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

[0526] In some aspects, the techniques described herein relate to a method, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

[0527] In some aspects, the techniques described herein relate to a method, wherein the at least one proprietary dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

[0528] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

[0529] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity7management, pressure, or salinity.

[0530] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to at least one of identification and overexpression of key enzy mes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

[0531] In some aspects, the techniques described herein relate to a method, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site- directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzy mes, allosteric modulation, or integration of modular enzy me assemblies.

[0532] In some aspects, the techniques described herein relate to a method, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

[0533] In some aspects, the techniques described herein relate to a method, wherein processing the inputs by the set of Al-based learning models includes processing in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

[0534] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

[0535] In some aspects, the techniques described herein relate to a method, wherein integrating the content includes using dedicated processing cores to perform data transformation or integration operations.

[0536] In some aspects, the techniques described herein relate to a method, wherein executing the simulations includes using distributed computing to parallelize the execution of simulations across a plurality of computing nodes.

[0537] In some aspects, the techniques described herein relate to a method, wherein executing the simulations includes using distributed computing to execute multiple simulations by batching neural net ork computations or distributing ODE integrations across a plurality.

[0538] In some aspects, the techniques described herein relate to a system for converting raw data from an analytical and mass spectrometry instrument to model-ready data, including: computing hardware configured to: receive data from an analytical and mass spectrometry instrument wherein the data includes measurement data from a set of control samples and a set of test samples; extract a set of peak lists including a set of test peak lists and a set of control peak lists from the received data; compress the extracted peak lists using a compression algorithm; identify a set of metabolites that correspond to a set of peaks from the compressed peak lists by comparing a set of mass-to-charge ratios and a set of retention times associated with the set of peaks with the mass-to-charge ratios and retention times associated with known metabolites from a set of spectral databases; calculate a set of peak areas corresponding to the set of peaks; generate a calibration curve for each identified metabolite based on the calculated area from its corresponding peaks from the compressed set of control peak lists and its known concentrations; calculate a set of concentrations for the set of identified metabolites associated with the peaks from the compressed set of test peak lists using the generated calibration curves; and generate a compilation of results.

[0539] In some aspects, the techniques described herein relate to a system, wherein the computing hardware is further configured to analyze the identified peaks to determine a need for a deconvolution and / or window7adjustment on one or more of the identified peaks, and, upon determination of said need, perform deconvolution and / or window adjustment on the one or more of the identified peaks.

[0540] In some aspects, the techniques described herein relate to a system, wherein the computing hardware is further configured to generate a quality control website wherein the quality control website presents a set of calibration curves for control samples and test samples for each of the metabolites of the set of metabolites.

[0541] In some aspects, the techniques described herein relate to a system, wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry (LC-MS) instrument, a gas chromatography-mass spectrometry (GC-MS) instrument, a quadruple time-of- flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, or a free induction decay (FID) instrument, a quadrupole mass spectrometry' (QMS) instrument, a time-of- flight mass spectrometry (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry instrument, a sector mass spectrometry instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, or an atmospheric pressure photoionization (APPI) instrument.

[0542] In some aspects, the techniques described herein relate to a system, wherein the computing hardware is further configured to apply a dilution factor to the set of concentrations.

[0543] In some aspects, the techniques described herein relate to a system, wherein the computing hardware is further configured to normalize the concentrations to biomass content.

[0544] In some aspects, the techniques described herein relate to a system, wherein the system is integrated with a fermentation system and a rapid sampling system.

[0545] In some aspects, the techniques described herein relate to a system, further including comparing a set of fragmentation patterns associated with the set of peaks with the fragmentation patterns for a set of known metabolites from a set of spectral databases.

[0546] In some aspects, the techniques described herein relate to a method for converting raw data from an analytical and mass spectrometry' instrument to model-ready data, including: receiving, by computing hardware, data from an analytical and mass spectrometry instrument wherein the data includes measurement data from a set of control samples and a set of test samples; extracting, by the computing hardware, a set of peak lists including a set of test peak lists and a set of control peak lists from the received data; compressing, by the computing hardware, the extracted peak lists using a compression algorithm; identifying, by the computing hardware, a set of metabolites that correspond to a set of peaks from the compressed peak lists by comparing a set of mass-to-charge ratios and a set of retention times associated with the set of peaks with the mass- to-charge ratios and retention times associated with known metabolites from a set of spectral databases; calculating, by the computing hardware, a set of peak areas corresponding to the set of peaks; generating, by the computing hardware, a calibration curve for each identified metabolite based on the calculated area from its corresponding peaks from the compressed set of control peak lists and its known concentrations; calculating, by the computing hardware, a set of concentrations for the set of identified metabolites associated with the peaks from the compressed set of test peak lists using the generated calibration curves; and generating, by the computing hardware, a compilation of results.

[0547] In some aspects, the techniques described herein relate to a method, further including analyzing the identified peaks to determine a need for a deconvolution and / or window adjustment on one or more of the identified peaks, and, upon determination of said need, performing deconvolution and / or window adjustment on the one or more of the identified peaks.

[0548] In some aspects, the techniques described herein relate to a method, further including generating a quality control website wherein the quality control website presents a set of calibration curves for control samples and test samples for each of the metabolites of the set of metabolites.

[0549] In some aspects, the techniques described herein relate to a method, wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry' (LC-MS) instrument, a gas chromatography-mass spectrometry' (GC-MS) instrument, a quadruple time-of- flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, or a free induction decay (FID) instrument, a quadrupole mass spectrometry' (QMS) instrument, a time-of- flight mass spectrometry (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry instrument, a sector mass spectrometry instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, or an atmospheric pressure photoionization (APPI) instrument.

[0550] In some aspects, the techniques described herein relate to a method, further including applying a dilution factor to the set of concentrations.

[0551] In some aspects, the techniques described herein relate to a method, further including nomralizing the concentrations to biomass content.

[0552] In some aspects, the techniques described herein relate to a method, wherein the method is integrated with a fermentation system and a rapid sampling system.

[0553] In some aspects, the techniques described herein relate to a fermentation system including: a fermentation chamber configured to contain a fermentation medium; a plurality of sensors configured to measure fermentation parameters; a control system operatively coupled to the fermentation chamber and the plurality of sensors, the control system including: at least one processor; memory' storing instructions that, when executed by the at least one processor, cause the control system to: receive sensor data from the plurality of sensors; process the sensor data using a set of Al-based learning models to determine a set of improved fermentation parameters; generate control signals based on the determined set of improved fermentation parameters; and adjust operating conditions of the fermentation chamber based on the control signals.

[0554] In some aspects, the techniques described herein relate to a fermentation system, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multilayer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

[0555] In some aspects, the techniques described herein relate to a fermentation system, wherein the fenwentation system includes or is integrated with a rapid sampling system.

[0556] In some aspects, the techniques described herein relate to a fermentation system, wherein the fermentation system includes or is integrated with a rapid sampling system, an analytical and mass spectroscopy instrument, and an automated omics for generalization system.

[0557] In some aspects, the techniques described herein relate to a fermentation system, wherein the set of Al-based learning models are configured to process inputs in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

[0558] In some aspects, the techniques described herein relate to a fermentation system, wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model's computational complexity7based on input complexity7.

[0559] In some aspects, the techniques described herein relate to a fermentation system, wherein the plurality of sensors includes at least two of: temperature sensors, pH sensors, dissolved oxygen sensors, biomass sensors, substrate concentration sensors, redox potential sensors, foam formation sensors, gas composition sensors, pressure sensors, flow rate sensors, conductivity sensors, turbidity sensors, viscosity sensors, cell viability sensors, weight sensors, acoustic sensors, optical density sensors, infrared sensors, fluorescence-based detection systems, enzymatic electrodes, biosensors, ion-selective electrodes, imaging sensors, and heat flux sensors.

[0560] In some aspects, the techniques described herein relate to a fermentation system, wherein the plurality of sensors includes at least one of a Raman sensor and a Near-Infrared (NIR) sensor.

[0561] In some aspects, the techniques described herein relate to a fermentation system, wherein the set offermentation parameters include at least one of: temperature of the fermentation medium, pH level of the fermentation medium, dissolved oxygen concentration, pressure within the fermentation chamber, agitation rate, nutrient feed rate, substrate concentration, metabolite concentration, cell density, gas flow rate, foam level, viscosity7of the fermentation medium, redox potential, carbon dioxide evolution rate, oxygen uptake rate, osmotic pressure, specific growth rate, product formation rate, yield coefficients, mass transfer coefficients, power input, mixing time, shear stress, or biomass morphology7.

[0562] In some aspects, the techniques described herein relate to a fermentation system, wherein the control signals include signals to adjust at least one of: agitation speed of an impeller within the fermentation chamber, temperature of a heating or cooling element, flow rate of a nutrient feed pump, flow rate of an acid or base addition pump for pH control, flow rate of an antifoam addition pump, gas flow rate through a sparger, pressure within the fermentation chamber, substrate feed rate, harvest rate, mixing rate, aeration rate, or recirculation rate.

[0563] In some aspects, the techniques described herein relate to a fermentation system, wherein the fermentation system is configured as a mobile laboratory unit for deployment at remote locations.

[0564] In some aspects, the techniques described herein relate to a method of controlling a fermentation process including: containing a fermentation medium in a fermentation chamber; measuring fennentation parameters using a plurality of sensors; receiving sensor data from the plurality7of sensors; processing the sensor data using a set of Al-based learning models to determine a set of improved fermentation parameters; generating control signals based on thedetermined set of improved fermentation parameters; and adjusting operating conditions of the fermentation chamber based on the control signals.

[0565] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-tenn memory (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

[0566] In some aspects, the techniques described herein relate to a method, further including sampling the fermentation medium using a rapid sampling system.

[0567] In some aspects, the techniques described herein relate to a method, further including: sampling the fermentation medium using a rapid sampling system; analyzing samples using an analytical and mass spectroscopy instrument; and processing sample data using an automated omics for generalization system.

[0568] In some aspects, the techniques described herein relate to a method, wherein processing the sensor data includes processing inputs in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

[0569] In some aspects, the techniques described herein relate to a method, wherein processing the sensor data includes using adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

[0570] In some aspects, the techniques described herein relate to a method, wherein measuring fermentation parameters includes measuring at least two of: temperature, pH, dissolved oxygen, biomass, substrate concentration, redox potential, foam formation, gas composition, pressure, flowrates, conductivity, turbidity, viscosity, cell viability-, weight, acoustic properties, optical density-, infrared measurements, fluorescence, enzymatic activity-, biosensor readings, ion concentrations, imaging data, and heat flux.

[0571] In some aspects, the techniques described herein relate to a method, wherein measuring fermentation parameters includes using at least one of a Raman sensor and a Near-Infrared (NIR) sensor.

[0572] In some aspects, the techniques described herein relate to a method, wherein the set of fermentation parameters include at least one of: temperature of the fermentation medium, pH level of the fermentation medium, dissolved oxygen concentration, pressure within the fermentation chamber, agitation rate, nutrient feed rate, substrate concentration, metabolite concentration, cell density, gas flow rate, foam level, viscosity of the fermentation medium, redox potential, carbon dioxide evolution rate, oxygen uptake rate, osmotic pressure, specific growth rate, product formation rate, yield coefficients, mass transfer coefficients, power input, mixing time, shear stress, or biomass morphology.

[0573] In some aspects, the techniques described herein relate to a method, wherein adjusting operating conditions includes adjusting at least one of: agitation speed of an impeller within the fermentation chamber, temperature of a heating or cooling element, flow rate of a nutrient feedpump, flow rate of an acid or base addition pump for pH control, flow rate of an antifoam addition pump, gas flow rate through a sparger, pressure within the fermentation chamber, substrate feed rate, harvest rate, mixing rate, aeration rate, or recirculation rate.

[0574] In some aspects, the techniques described herein relate to a method, further including: deploying the fermentation chamber, plurality set 5: Al-driven fermentation system with sensors - Al for data collection.

[0575] In some aspects, the techniques described herein relate to a fermentation system including: a fermentation chamber configured to contain a fermentation medium; a plurality of sensors configured to measure fermentation parameters; a control system operatively coupled to the fermentation chamber and the plurality of sensors, the control system including: at least one processor; memory storing instructions that, when executed by the at least one processor, cause the control system to: receive sensor data from the plurality of sensors; process the sensor data using a set of Al-based learning models to determine a set of fermentation parameters, wherein the determined fermentation parameters are configured to generate additional training data for improving the set of Al-based learning models; generate control signals based on the determined fermentation parameters; adjust operating conditions of the fermentation chamber based on the control signals; collect response data indicating effects of the adjusted operating conditions; update the set of Al-based learning models using the collected response data as additional training data.

[0576] In some aspects, the techniques described herein relate to a fermentation system, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multilayer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

[0577] In some aspects, the techniques described herein relate to a fermentation system, wherein the fermentation system includes or is integrated with a rapid sampling system.

[0578] In some aspects, the techniques described herein relate to a fermentation system, wherein the fermentation system includes or is integrated with a rapid sampling system, an analytical and mass spectroscopy instrument, and an automated omics for generalization system.

[0579] In some aspects, the techniques described herein relate to a fermentation system, wherein the set of Al-based learning models are configured to process inputs in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

[0580] In some aspects, the techniques described herein relate to a fermentation system, wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

[0581] In some aspects, the techniques described herein relate to a fermentation system, wherein the plurality of sensors includes at least two of: temperature sensors, pH sensors, dissolved oxygen sensors, biomass sensors, substrate concentration sensors, redox potential sensors, foam formation sensors, gas composition sensors, pressure sensors, flow rate sensors, conductivity sensors, turbidity sensors, viscosity sensors, cell viability sensors, weight sensors, acoustic sensors, opticaldensity sensors, infrared sensors, fluorescence-based detection systems, enzymatic electrodes, biosensors, ion-selective electrodes, imaging sensors, and heat flux sensors.

[0582] In some aspects, the techniques described herein relate to a fermentation system, wherein the plurality of sensors includes at least one of a Raman sensor and a Near-Infrared (NIR) sensor.

[0583] In some aspects, the techniques described herein relate to a fermentation system, wherein the set of fermentation parameters include at least one of: temperature of the fermentation medium, pH level of the fermentation medium, dissolved oxygen concentration, pressure within the fermentation chamber, agitation rate, nutrient feed rate, substrate concentration, metabolite concentration, cell density7, gas flow rate, foam level, viscosity7of the fermentation medium, redox potential, carbon dioxide evolution rate, oxygen uptake rate, osmotic pressure, specific grow th rate, product formation rate, yield coefficients, mass transfer coefficients, power input, mixing time, shear stress, or biomass morphology7.

[0584] In some aspects, the techniques described herein relate to a fermentation system, wherein the control signals include signals to adjust at least one of: agitation speed of an impeller within the fermentation chamber, temperature of a heating or cooling element, flow rate of a nutrient feed pump, flow7rate of an acid or base addition pump for pH control, flow7rate of an antifoam addition pump, gas flow rate through a sparger, pressure within the fermentation chamber, substrate feed rate, harvest rate, mixing rate, aeration rate, or recirculation rate.

[0585] In some aspects, the techniques described herein relate to a fermentation system, wherein the fermentation system is configured as a mobile laboratory unit for deployment at remote locations.

[0586] In some aspects, the techniques described herein relate to a method for controlling a fermentation process, including: receiving, by a control system, sensor data from a plurality of sensors configured to measure fermentation parameters of a fermentation chamber containing a fermentation medium; processing, by the control system, the sensor data using a set of Al-based learning models to determine a set of fermentation parameters, wherein the determined fermentation parameters are configured to generate additional training data for improving the set of Al-based learning models; generating, by the control system, control signals based on the determined fermentation parameters; adjusting, by the control system, operating conditions of the fermentation chamber based on the control signals; collecting, by the control system, response data indicating effects of the adjusted operating conditions; updating, by the control system, the set of Al-based learning models using the collected response data as additional training data.

[0587] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory7(LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

[0588] In some aspects, the techniques described herein relate to a method, further including integrating the fermentation process with a rapid sampling system.

[0589] In some aspects, the techniques described herein relate to a method, further including integrating the fermentation process with a rapid sampling system, an analytical and mass spectroscopy instrument, and an automated omics for generalization system.

[0590] In some aspects, the techniques described herein relate to a method, wherein processing the sensor data includes processing inputs in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

[0591] In some aspects, the techniques described herein relate to a method, wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

[0592] In some aspects, the techniques described herein relate to a method, wherein receiving the sensor data includes receiving data from at least two of: temperature sensors, pH sensors, dissolved oxygen sensors, biomass sensors, substrate concentration sensors, redox potential sensors, foam formation sensors, gas composition sensors, pressure sensors, flow rate sensors, conductivity sensors, turbidity sensors, viscosity sensors, cell viability sensors, weight sensors, acoustic sensors, optical density sensors, infrared sensors, fluorescence-based detection systems, enzymatic electrodes, biosensors, ion-selective electrodes, imaging sensors, and heat flux sensors.

[0593] In some aspects, the techniques described herein relate to a method, wherein receiving the sensor data includes receiving data from at least one of a Raman sensor and a Near-Infrared (NIR) sensor.

[0594] In some aspects, the techniques described herein relate to a method, wherein the set of fermentation parameters include at least one of: temperature of the fermentation medium, pH level of the fermentation medium, dissolved oxygen concentration, pressure within the fermentation chamber, agitation rate, nutrient feed rate, substrate concentration, metabolite concentration, cell density, gas flow rate, foam level, viscosity of the fermentation medium, redox potential, carbon dioxide evolution rate, oxygen uptake rate, osmotic pressure, specific growth rate, product formation rate, yield coefficients, mass transfer coefficients, powder input, mixing time, shear stress, or biomass morphology.

[0595] In some aspects, the techniques described herein relate to a method, wherein generating the control signals includes generating signals to adjust at least one of: agitation speed of an impeller within the fermentation chamber, temperature of a heating or cooling element, flow rate of a nutrient feed pump, flow rate of an acid or base addition pump for pH control, flow rate of an antifoam addition pump, gas flow rate through a sparger, pressure within the fermentation chamber, substrate feed rate, harvest rate, mixing rate, aeration rate, or recirculation rate.

[0596] In some aspects, the techniques described herein relate to a method for predicting performance of a strain of a biologic organism, the method comprising: receiving, by a platform, information about the strain of a biologic organism, wherein the information describes one or more genetic edits associated with the strain; generating, by the platform, a set of embeddings based on the information about the strain of the biologic organism; receiving, by the platform, a set of bioreactor process conditions; and generating, by the platform, a prediction of a performance of the strain of the biologic organism in a bioreactor based on inputting both the set of embeddingsand the bioreactor process conditions to a pre-trained genetic generalization model, wherein the pre-trained genetic generalization model is trained using training data for a plurality of strains of the biologic organism, wherein the training data comprises: information about corresponding genetic edits for the plurality of strains of the biologic organism; information about corresponding bioreactor process conditions for the plurality of strains of the biologic organism; and target data indicating corresponding performance for the plurality of strains of the biologic organism.

[0597] In some aspects, the techniques described herein relate to a method, wherein the bioreactor process conditions comprise at least one of bioreactor volume, temperature, pH, dissolved oxygen level, feed rate, or agitation speed.

[0598] In some aspects, the techniques described herein relate to a method, wherein the prediction of the performance of the strain indicates at least one of a grow th rate, a metabolite production rate, a byproduct formation rate, a protein expression level, or a titer.

[0599] In some aspects, the techniques described herein relate to a method, wherein generating the set of embeddings comprises inputting the information about the strain of the biologic organism to one or more embeddings models, wherein the one or more embedding models include at least one of a GenePT model, a Proteinfer model, a pFBA-PCA model, or a GO-PCA model.

[0600] In some aspects, the techniques described herein relate to a method, wherein the one or more embeddings models comprise two or more embeddings models, the method further comprising aggregating the respective embeddings generated by the two or more embedding models to create the set of genetic embeddings.

[0601] In some aspects, the techniques described herein relate to a method, wherein the pretrained genetic generalization model comprises a first stage that generates a strain embedding characterizing the strain of the biologic organism and a second stage that generates the prediction based on the strain embedding. In some embodiments, the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model. Additionally or alternatively, the second stage is a multi-layer perceptron.

[0602] In some aspects, the techniques described herein relate to a method, wherein the pretrained genetic generalization model is an ensemble of multiple pre-trained genetic generalization models.

[0603] In some aspects, the techniques described herein relate to a method, wherein the set of embeddings encodes the one or more genetic edits.

[0604] In some aspects, the techniques described herein relate to a method, wherein the information about the strain comprises information about a base strain of the biologic organism. In some embodiments, the one or more genetic edits are with respect to the base strain, wherein the information about the one or more genetic edits comprises information indicating one or more gene knockouts, gene overexpressions, or gene underexpressions.

[0605] In some aspects, the techniques described herein relate to a system for predicting performance of a strain of a biologic organism, the system comprising: one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the system to: receive information about the strain of a biologic organism, wherein the informationdescribes one or more generic edits associated with the strain; generate a set of embeddings based on the information about the strain of the biologic organism; receive a set of bioreactor process conditions; and generate a prediction of a performance of the strain of the biologic organism in a bioreactor based on inputting both the set of embeddings and the bioreactor process conditions to a pre-trained genetic generalization model, wherein the pre-trained genetic generalization model is trained using training data for a plurality of strains of the biologic organism, wherein the training data comprises: infomiation about corresponding genetic edits for the plurality of strains of the biologic organism; information about corresponding bioreactor process conditions for the plurality of strains of the biologic organism; and target data indicating corresponding performance for the plurality of strains of the biologic organism.

[0606] In some aspects, the techniques described herein relate to a system, wherein the bioreactor process conditions comprise at least one of bioreactor volume, temperature, pH, dissolved oxygen level, feed rate, or agitation speed.

[0607] In some aspects, the techniques described herein relate to a system, wherein the prediction of the performance of the strain indicates at least one of a growth rate, a metabolite production rate, a byproduct formation rate, a protein expression level, or a titer.

[0608] In some aspects, the techniques described herein relate to a system, wherein generating the set of embeddings comprises inputting the information about the strain of the biologic organism to two or more embeddings models, wherein the embeddings models include at least one of a GenePT model, a Proteinfer model, a pFBA-PCA model, or a GO-PCA model, and wherein the system aggregates the respective embeddings generated by the two or more embedding models to create the set of genetic embeddings.

[0609] In some aspects, the techniques described herein relate to a system, wherein the pretrained genetic generalization model comprises: a first stage that generates a strain embedding characterizing the strain of the biologic organism, wherein the first stage is one or more of a long- short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model; and a second stage that generates the prediction based on the strain embedding, wherein the second stage is a multi-layer perceptron.

[0610] In some aspects, the techniques described herein relate to a system, wherein the pretrained genetic generalization model is an ensemble of multiple pre-trained genetic generalization models.

[0611] In some aspects, the techniques described herein relate to a system, wherein the set of embeddings encodes the one or more genetic edits.

[0612] In some aspects, the techniques described herein relate to a system, wherein the information about the strain comprises information about a base strain of the biologic organism, wherein the one or more genetic edits are with respect to the base strain, and wherein the information about the one or more genetic edits comprises information indicating one or more gene knockouts, gene overexpressions, or gene underexpressions.

[0613] In some aspects, the techniques described herein relate to a method comprising: receiving, by a platform, a first training dataset comprising a plurality of sets of genetic edits correspondingto a plurality of strains of a biologic organism, wherein the first training dataset further comprises a first target, wherein the first target comprises fitness data for the plurality of strains of the biologic organism; pre-training, by the platform, a genetic generalization model using the first training dataset, wherein the pre-training comprises training embeddings for the plurality of sets of genetic edits; receiving, by the platform, a second training dataset smaller than the first training dataset, wherein the second training dataset comprises: information about genetic edits for a second plurality of strains, wherein the second plurality of strains are different from the first plurality of strains; and information about at least one second target, wherein the at least one second target is different from the first target; and fine-tuning, by the platform, the pre-trained genetic generalization model using the second training dataset to generate a second genetic generalization model that is trained to predict the at least one second target.

[0614] In some aspects, the techniques described herein relate to a method, wherein the at least one second target comprises at least one of a bioreactor growth rate, a metabolite production rate, a byproduct formation rate, or a titer.

[0615] In some aspects, the techniques described herein relate to a method, wherein the second plurality of strains are strains of a different biologic organism than the first plurality of strains.

[0616] In some aspects, the techniques described herein relate to a method, wherein the second plurality of strains are strains of the same biologic organism as the first plurality of strains.

[0617] In some aspects, the techniques described herein relate to a method, wherein the genetic generalization model comprises a first stage that generates a strain embedding and a second stage that generates a prediction based on the strain embedding, wherein the fine-tuning comprises updating parameters of the second stage to predict the second target. In some embodiments, the fine-tuning comprises replacing at least a portion of the second stage with new layers trained to predict the second target. Additionally or alternatively, the fine-tuning uses a lower learning rate for the fine-tuning as compared to the pre-training. Additionally or alternatively, the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model. Additionally or alternatively, the second stage is a multi-layer perceptron.

[0618] In some aspects, the techniques described herein relate to a method, wherein the embeddings are generated at least in part by processing gene descriptions using a large language model prior to the pre-training.

[0619] In some aspects, the techniques described herein relate to a method, wherein the embeddings are trainable parameters during the pre-training such that they are iteratively updated during the pre-training.

[0620] In some aspects, the techniques described herein relate to a method, wherein the plurality of sets of genetic edits comprise infonnation indicating that each genetic edit is at least one of a gene knockout, a gene overexpression, or a gene underexpression.

[0621] In some aspects, the techniques described herein relate to a system comprising: one or more processors; and memory storing instructions that, when executed by the processor, cause the system to: receive a first training dataset comprising a plurality7of sets of genetic editscorresponding to a plurality of strains of a biologic organism, wherein the first training dataset further comprises a first target, wherein the first target comprises fitness data for the plurality of strains of the biologic organism; pre-train a genetic generalization model using the first training dataset, wherein the pre-training comprises training embeddings for the plurality of sets of genetic edits; receive a second training dataset smaller than the first training dataset, wherein the second training dataset comprises: information about genetic edits for a second plurality of strains, wherein the second plurality of strains are different from the first plurality of strains; information about at least one second target, wherein the at least one second target is different from the first target; and fine-tune the pre-trained genetic generalization model using the second training dataset to generate a second genetic generalization model that is trained to predict the at least one second target.

[0622] In some aspects, the techniques described herein relate to a system, wherein the at least one second target comprises at least one of a bioreactor growth rate, a metabolite production rate, a byproduct formation rate, or a titer.

[0623] In some aspects, the techniques described herein relate to a system, wherein the genetic generalization model comprises a first stage that generates a strain embedding and a second stage that generates a prediction based on the strain embedding, wherein the fine-tuning comprises updating parameters of the second stage to predict the second target. In some embodiments, the fine-tuning comprises replacing at least a portion of the second stage with new layers trained to predict the second target. Additionally or alternatively, the fine-tuning uses a lower learning rate for the fine-tuning as compared to the pre- training. Additionally or alternatively, the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model, wherein the second stage is a multi-layer perceptron. Additionally or alternatively, the embeddings are generated at least in part by processing gene descriptions using a large language model prior to the pre-training; and the embeddings are trainable parameters during the pre-training such that they are iteratively updated during the pre-training.

[0624] In some aspects, the techniques described herein relate to a system, wherein the plurality of sets of genetic edits comprise information indicating that each genetic edit is at least one of a gene knockout, a gene overexpression, or a gene underexpression.

[0625] In some aspects, the techniques described herein relate to a method comprising: receiving, by a platform, information about a strain of a biologic organism, wherein the information describes one or more genetic edits associated with the strain; generating, by the platform, a set of embeddings based on the information about the strain of the biologic organism; receiving, by the platform, a set of bioreactor process conditions for a bioreactor containing the strain; generating, by the platform, at least one prediction of performance of the strain using a pre-trained genetic generalization model that processes both the set of embeddings and the set of bioreactor process conditions, wherein the pre-trained genetic generalization model is trained using training data comprising: information about genetic edits for a plurality of strains; information about corresponding bioreactor process conditions for the plurality of strains: and target data indicating corresponding performance of the plurality' of strains with respect to the corresponding bioreactor process conditions; determining, by the platform, adjusted bioreactor process conditions based onthe at least one prediction of performance; and automatically adjusting controls of the bioreactor based on the adjusted bioreactor process conditions.

[0626] In some aspects, the techniques described herein relate to a method, wherein automatically adjusting controls comprises real-time adjustment of at least one of feed rates, pH levels, temperature, or dissolved oxygen levels of the bioreactor.

[0627] In some aspects, the techniques described herein relate to a method, wherein determining the adjusted bioreactor process conditions comprises: generating multiple predictions of performance for different combinations of bioreactor process conditions; and selecting the adjusted bioreactor process conditions based on the generated multiple predictions.

[0628] In some aspects, the techniques described herein relate to a method, further comprising: continuously monitoring performance of the strain in the bioreactor; generating updated predictions based on the monitored performance; and iteratively adjusting the controls based on the updated predictions.

[0629] In some aspects, the techniques described herein relate to a method, wherein the method is performed by a laboratory automation system, the method further comprising: automatically logging the adjustments to the controls and corresponding performance results; and using the logged adjustments and performance results to update the pre-trained genetic generalization model.

[0630] In some aspects, the techniques described herein relate to a method, further comprising: predicting strain stability under the adjusted bioreactor process conditions; and implementing automated quality control measures based on the predicted strain stability.

[0631] In some aspects, the techniques described herein relate to a method, wherein generating the set of embeddings comprises using one or more of a GenePT model, a Proteinfer model, a pFBA-PCA model, or a GO-PCA model.

[0632] In some aspects, the techniques described herein relate to a method, wherein the pretrained genetic generalization model comprises: a first stage that generates a strain embedding characterizing the strain of the biologic organism; and a second stage that generates the at least one prediction based on the strain embedding. In some embodiments, the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model. Additionally or alternatively, the second stage is a multi-layer perceptron.

[0633] In some aspects, the techniques described herein relate to a method, wherein the pretrained genetic generalization model is an ensemble of multiple pre-trained genetic generalization models.

[0634] In some aspects, the techniques described herein relate to a method, wherein the set of embeddings encodes genetic edits associated with the strain of the biologic organism.

[0635] In some aspects, the techniques described herein relate to a method, wherein the information about the strain comprises information about a base strain. In some embodiments, the information about the strain comprises information indicating that the one or more genetic edits include one or more gene knockouts, gene overexpressions, or gene underexpressions with respect to the base strain.

[0636] In some aspects, the techniques described herein relate to a system comprising: one or more processors; and memory storing instructions that, when executed by the processor, cause the system to: receive information about a strain of a biologic organism, wherein the information describes one or more genetic edits associated with the strain; generate a set of embeddings based on the information about the strain of the biologic organism; receive a set of bioreactor process conditions for a bioreactor containing the strain; generate at least one prediction of performance of the strain using a pre-trained genetic generalization model that processes both the set of embeddings and the set of bioreactor process conditions, wherein the pre-trained genetic generalization model is trained using training data comprising: information about genetic edits for a plurality of strains; information about corresponding bioreactor process conditions for the plurality of strains; and target data indicating corresponding performance of the plurality of strains with respect to the corresponding bioreactor process conditions; determine adjusted bioreactor process conditions based on the at least one prediction of performance; and automatically adjust controls of the bioreactor based on the adjusted bioreactor process conditions.

[0637] In some aspects, the techniques described herein relate to a system, wherein: automatically adjusting controls comprises real-time adjustment of at least one of feed rates, pH levels, temperature, or dissolved oxygen levels of the bioreactor; and determining the adjusted bioreactor process conditions comprises: generating multiple predictions of performance for different combinations of bioreactor process conditions; and selecting the adjusted bioreactor process conditions based on the generated multiple predictions.

[0638] In some aspects, the techniques described herein relate to a system, wherein the instructions further cause the system to: continuously monitor performance of the strain in the bioreactor; generate updated predictions based on the monitored performance; and iteratively adjust the controls based on the updated predictions.

[0639] In some aspects, the techniques described herein relate to a system, wherein the instructions further cause the system to: automatically log the adjustments to the controls and corresponding performance results; use the logged adjustments and performance results to update the pre-trained genetic generalization model.

[0640] In some aspects, the techniques described herein relate to a system, wherein the pretrained genetic generalization model comprises: a first stage that generates a strain embedding characterizing the strain of the biologic organism, wherein the first stage is one or more of a long- short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model; and a second stage that generates the at least one prediction based on the strain embedding, wherein the second stage is a multi-layer perceptron.

[0641] In some aspects, the techniques described herein relate to a system, wherein: the information about the strain comprises information about a base strain; and the information about the strain comprises information indicating that the one or more genetic edits include one or more gene knockouts, gene overexpressions, or gene underexpressions with respect to the base strain.

[0642] In some aspects, the techniques described herein relate to a platform for synthetic biology development, the platform comprising: a data collection system configured to collect performancedata for a plurality of synthetic biologic products and market data comprising costs for synthetic biology development inputs; a synthetic biology development system configured to predict performance of the synthetic biologic products under different process conditions; a techno- economic analysis system configured to: generate economic viability predictions by analyzing the predicted performance and process conditions using one or more artificial intelligence models trained on historical data, wherein the historical data includes historical market data; wherein the synthetic biology development system is further configured to prioritize development of synthetic biology products based on the predicted performance and the economic viability predictions.

[0643] In some aspects, the techniques described herein relate to a platform, wherein prioritizing development comprises: generating risk-adjusted economic predictions for each synthetic biology product; ranking products based on probability of commercial success; and adjusting development resource allocation based on the rankings.

[0644] In some aspects, the techniques described herein relate to a platform, wherein the market data further comprises one or more of feedstock costs, energy costs, labor costs, capital costs, equipment costs, or product market prices.

[0645] In some aspects, the techniques described herein relate to a platform, wherein the techno- economic analysis system is further configured to: identify economic thresholds for commercial viability; monitor performance data with respect to the economic thresholds; and automatically adjust development priorities when performance data indicates a particular economic threshold will not be met.

[0646] In some aspects, the techniques described herein relate to a platform, wherein the synthetic biology development system generates economic viability' predictions for a plurality of parallel development paths for multiple synthetic biology products, wherein the synthetic biology is configured to dynamically allocate development resources between the parallel development paths based on comparing the economic viability predictions.

[0647] In some aspects, the techniques described herein relate to a platform, wherein the one or more artificial intelligence models comprise one or more of a convolutional neural network, a long- short term memory (LSTM), and a transformer neural network.

[0648] In some aspects, the techniques described herein relate to a platform, wherein the performance data comprises one or more of yield data, titer data, productivity data, stability data, or growth rate data.

[0649] In some aspects, the techniques described herein relate to a platform, wherein the process conditions comprise one or more of temperature. pH, nutrient concentrations, dissolved oxygen levels, mixing speed, gas flow rates, or nutrient feeding rates.

[0650] In some aspects, the techniques described herein relate to a platform, wherein the historical data further comprises historical production data indicating relationships between production factors and economic outcomes.

[0651] In some aspects, the techniques described herein relate to a platform, wherein the techno- economic analysis sy stem is further configured to simulate scale-up costs for different production scenarios.

[0652] In some aspects, the techniques described herein relate to a platfonn, wherein the techno- economic analysis system is further configured to predict market-dependent revenue potential.

[0653] In some aspects, the techniques described herein relate to a platform, wherein the techno- economic analysis system is further configured to calculate economic metrics, including return on investment and payback period.

[0654] In some aspects, the techniques described herein relate to a platfonn, wherein the data collection system continuously collects the perfonnance data and market data, and wherein the techno-economic analysis system continuously updates the economic viability predictions during development of the synthetic biology7products.

[0655] In some aspects, the techniques described herein relate to a method for synthetic biology development, the method comprising: collecting, by one or more processors of a synthetic biology platform, performance data for a plurality of synthetic biologic products and market data comprising costs for synthetic biology development inputs; predicting, by the one or more processors, performance of the synthetic biologic products under different process conditions; generating, by the one or more processors, economic viability predictions by analyzing the predicted performance and process conditions using one or more artificial intelligence models trained on historical data, wherein the historical data includes historical market data; and prioritizing, by the one or more processors, development of synthetic biology products based on the predicted performance and the economic viability predictions.

[0656] In some aspects, the techniques described herein relate to a method, wherein prioritizing development comprises: generating risk-adjusted economic predictions for each synthetic biology product; ranking products based on probability of commercial success; and adjusting development resource allocation based on the rankings.

[0657] In some aspects, the techniques described herein relate to a method, wherein the market data further comprises one or more of feedstock costs, energy7costs, labor costs, capital costs, equipment costs, or product market prices.

[0658] In some aspects, the techniques described herein relate to a method, further comprising: identifying economic thresholds for commercial viability7; monitoring performance data yvith respect to the economic thresholds; and automatically adjusting development priorities when performance data indicates a particular economic threshold will not be met.

[0659] In some aspects, the techniques described herein relate to a method, wherein generating economic viability predictions comprises generating economic viability predictions for a plurality of parallel development paths for multiple synthetic biology products, wherein prioritizing development comprises dynamically allocating development resources between the parallel development paths based on comparing the economic viability predictions.

[0660] In some aspects, the techniques described herein relate to a method, wherein the performance data comprises one or more of yield data, titer data, productivity data, stability data, or growth rate data, and wherein the process conditions comprise one or more of temperature, pH, nutrient concentrations, dissolved oxygen levels, mixing speed, gas flow rates, or nutrient feeding rates.

[0661] In some aspects, the techniques described herein relate to a method, wherein collecting the performance data and the market data and generating the economic viability predictions occur continuously during development of the synthetic biology products.

[0662] In some aspects, the techniques described herein relate to a platform for synthetic biology development, the platform comprising: a data collection facility configured to collect strain data for a plurality of biological strain candidates and to receive assay data from biological strain experiments, wherein the strain data comprises biological information for each strain candidate; a prototype prediction system configured to: generate initial fitness predictions for the strain candidates using one or more first artificial intelligence models trained on historical strain performance data; and identify an initial subset of the strain candidates based on the initial fitness predictions; a scale-up prediction system configured to: receive, from the data collection facility, assay data for the initial subset of the strain candidates; analyze the assay data and the strain data using one or more second artificial intelligence models; generate scale-up performance predictions for predicting strain performance under bioreactor production conditions; and select at least one strain candidate for production based on the scale-up performance predictions.

[0663] In some aspects, the techniques described herein relate to a platform, wherein the biological information comprises one or more of genetic edits, metabolic pathway data, or strain library information.

[0664] In some aspects, the techniques described herein relate to a platform, wherein the assay data comprises one or more of yield data, titer data, productivity data, stability- data, or growth rate data.

[0665] In some aspects, the techniques described herein relate to a platform, wherein the one or more first artificial intelligence models comprise one or more of a convolutional neural network, a long-short term memory (LSTM) network, or a transformer neural network.

[0666] In some aspects, the techniques described herein relate to a platform, wherein the one or more second artificial intelligence models are trained using a training data set that includes correlations between plate assay data and data collected during bioreactor production.

[0667] In some aspects, the techniques described herein relate to a platform, wherein the bioreactor production conditions comprise one or more of temperature profiles, pH setpoints, nutrient concentrations, dissolved oxygen levels, mixing speeds, gas flow rates, or nutrient feeding rates.

[0668] In some aspects, the techniques descnbed herein relate to a platform, wherein the scale- up prediction system is further configured to: continuously collect performance data during production of the selected at least one strain candidate; and update the scale-up performance predictions based on the continuously collected performance data.

[0669] In some aspects, the techniques described herein relate to a platform, wherein the data collection facility is configured to receive the assay data for the initial subset of the strain candidates after the generation of the initial fitness predictions, wherein the prototype prediction system is further configured to re-train the one or more first artificial intelligence models using the assay data.

[0670] In some aspects, the techniques descnbed herein relate to a platform, wherein the scale- up prediction system is configured to generate embeddings that identify strain-specific sensitivities to process conditions that may affect performance at production scale.

[0671] In some aspects, the techniques described herein relate to a platform, wherein the one or more second artificial intelligence models comprise at least one ensemble model configured to generate uncertainty estimates for the scale-up performance predictions.

[0672] In some aspects, the techniques described herein relate to a platform, wherein the scale- up prediction system is configured to generate a digital twin simulation of at least one production facility7, wherein the one or more second artificial intelligence models are configured to generate scale-up performance predictions based on data from the digital twin simulation.

[0673] In some aspects, the techniques described herein relate to a method for synthetic biology development, the method comprising: collecting strain data for a plurality7of biological strain candidates, wherein the strain data comprises biological information for each strain candidate; generating initial fitness predictions for the strain candidates using one or more first artificial intelligence models trained on historical strain performance data; identifying an initial subset of the strain candidates based on the initial fitness predictions; receiving assay data from plate assays of the initial subset of the strain candidates; processing the assay data and the strain data using one or more second artificial intelligence models, wherein the processing comprises generating scale- up performance predictions for predicting strain performance under bioreactor production conditions; and selecting at least one strain candidate for production based on the scale-up performance predictions.

[0674] In some aspects, the techniques described herein relate to a method, wherein the biological information comprises one or more of genetic edits, metabolic pathway data, or strain library information, and wherein the assay data comprises one or more of yield data, titer data, productivity7data, stability7data, or grow th rate data.

[0675] In some aspects, the techniques described herein relate to a method, wherein the one or more second artificial intelligence models are trained using a training data set that includes correlations between plate assay data and data collected during bioreactor production.

[0676] In some aspects, the techniques described herein relate to a method, further comprising: continuously collecting performance data during production of the selected at least one strain candidate; and updating the scale-up performance predictions based on the continuously collected performance data.

[0677] In some aspects, the techniques described herein relate to a method, further comprising generating a digital twin simulation of at least one production facility, wherein the one or more second artificial intelligence models generate the scale-up performance predictions based on data from the digital twin simulation. In some embodiments, the digital twin simulation comprises a simulation of one or more of equipment configurations, operational parameters, environmental conditions, process control settings, material flows, or quality measurements.

[0678] In some aspects, the techniques described herein relate to a method, further comprising re-training the one or more first artificial intelligence models using the assay data received from the plate assays.

[0679] In some aspects, the techniques described herein relate to a method, wherein processing the assay data comprises generating embeddings that identify strain-specific sensitivities to process conditions that may affect perfonnance at production scale.

[0680] In some aspects, the techniques described herein relate to a method, wherein the one or more second artificial intelligence models comprise at least one ensemble model, and wherein the method further comprises generating uncertainty estimates for the scale-up performance predictions using the ensemble model.BRIEF DESCRIPTION OF THE DRAWINGS

[0681] The present disclosure will become more fully understood from the detailed description and the accompanying drawings.

[0682] FIG. 1 is a schematic diagram detailing a platform and a multi-objective optimization module that operates in tandem with other elements and resources of the platform, according to some embodiments.

[0683] FIG. 2 is a schematic diagram detailing a prototype system that typically involves exploration of candidate strains of biological entities that have the potential to produce, as an output, a molecule that is desired for its commercial or other beneficial properties, according to some embodiments.

[0684] FIG. 3 is a schematic diagram that details synthetic biology sensor collection, processing, fusion, and staging for modeling and analytics, according to some embodiments.

[0685] FIG. 4 is a schematic diagram that details synthetic biology7development workflows and services, according to some embodiments.

[0686] FIG. 5 is a schematic diagram that details specialized solution components, according to some embodiments.

[0687] FIG. 6 is a schematic diagram that details market-specific customer workflows and services, according to some embodiments.

[0688] FIG. 7 is a schematic diagram that details additional example components of a prototype system for implementing prototype systems and workflows, according to some embodiments.

[0689] FIG. 8 is a schematic diagram that details example embodiments of an optimize system, according to some embodiments.

[0690] FIG. 9 is a schematic diagram that details example embodiments of a scale-up system, according to some embodiments.

[0691] FIG. 10 is a schematic diagram that details example embodiments of a technoeconomic analyses (TEA) system, according to some embodiments.

[0692] FIG. 11 is a flowchart illustrating example cell optimization methods, according to some embodiments.

[0693] FIG. 12 is a flowchart illustrating example environment and / or performance optimization methods, according to some embodiments.

[0694] FIG. 13 is a flowchart illustrating example pathway optimization methods according to some embodiments.

[0695] FIG. 14 is a flowchart illustrating example protein and / or enzyme optimization methods, according to some embodiments.

[0696] FIG. 15 is a schematic diagram that presents a platform as described herein according to some embodiments.

[0697] FIGS. 16A, 16B, 16C, 16D, 16E, and 16F are schematic diagrams that illustrate examples of genetic generalization models according to some embodiments.

[0698] FIGS. 17A and 17B are schematic diagrams that illustrate different types of genetic embeddings according to some embodiments.

[0699] FIGS. 18A, 18B, and 18C are schematic diagrams that illustrate specific genetic generalization model architectures that generate intermediate strain embeddings according to some embodiments.

[0700] FIG. 19 is a schematic diagram that illustrates examples of a method for pre-training and fine-tuning a genetic generalization model according to some embodiments.

[0701] FIG. 20 is a schematic diagram that illustrates an example method of generating a prediction using a genetic generalization model according to some embodiments.

[0702] FIG. 21 is a schematic illustrating an example rapid sampling system according to some embodiments.

[0703] FIG. 22 is a flowchart illustrating an example rapid sampling system control unit method according to some embodiments.

[0704] FIG. 23 is a flowchart illustrating an example omics for generalization method according to some embodiments.

[0705] FIG. 24 is a flowchart illustrating an example rapid sampling and omics for generalization method according to some embodiments.

[0706] FIG. 25 is a flowchart that presents an example method of generating a biologic product of a biologic synthesis process according to some example embodiments.

[0707] FIG. 26 is another flowchart that presents an example method of generating a biologic product of a biologic synthesis process according to some example embodiments.

[0708] FIG. 27 is another flowchart that presents an example method of generating a biologic product of a biologic synthesis process according to some example embodiments.

[0709] FIG. 28 is another flowchart that presents an example method of generating a biologic product of a biologic synthesis process according to some example embodiments.

[0710] FIG. 29 is an example of an embedding space including vector representations of biologic products according to some example embodiments.

[0711] FIG. 30 is an illustration of an evaluation of a set of candidate biologic products according to some example embodiments.

[0712] FIG. 31 is another illustration of an evaluation of a set of candidate biologic products according to some example embodiments.

[0713] FIG. 32 is an illustration of a selection of biologic products resulting from an evaluation according to some example embodiments.

[0714] FIG. 33 is a flowchart that presents an example method of optimizing a biologic synthesis process according to some example embodiments.

[0715] FIG. 34 is another flowchart that presents an example method of optimizing a biologic synthesis process according to some example embodiments.

[0716] FIG. 35 is an example of an embedding space including vector representations of variants of a biologic synthesis process according to some example embodiments.

[0717] FIG. 36 is an illustration of an evaluation of a set of candidate variations according to some example embodiments.

[0718] FIG. 37 is another flowchart that presents examples of methods of optimizing a biologic synthesis process according to some example embodiments.

[0719] FIG. 38 is a schematic diagram detailing experiment evaluation by an Al agent according to some example embodiments.

[0720] FIG. 39 is a schematic diagram detailing participation of an Al agent in the synthetic biology DBTL cycle during the development of a biologic process for synthesizing biologic products according to some example embodiments.

[0721] FIG. 40 is a schematic diagram detailing an example artificial neural network with multiple layers according to some example embodiments.

[0722] FIG. 41 is a schematic diagram detailing an example of training and inference of an example artificial neural network according to some example embodiments.

[0723] FIG. 42 is a schematic diagram detailing an example of a determination of attention by a machine learning model according to some example embodiments.

[0724] FIG. 43 is a schematic diagram detailing an example transformer model according to some example embodiments.

[0725] FIG. 44 is a schematic diagram detailing an example large language model, depicted as an example decoder-only architecture according to some example embodiments.

[0726] FIG. 45 is a schematic diagram detailing an example system that uses large language models and has a RAG capability according to some example embodiments.

[0727] FIG. 46 is a schematic diagram detailing an example of tool use by an example Al agent according to some example embodiments.

[0728] FIG. 47 is a schematic diagram detailing an example Al agent featuring an agent loop according to some example embodiments.

[0729] FIG. 48 is a schematic diagram detailing a development of an artificial neural network by reinforcement learning according to some example embodiments.

[0730] The figures depict various embodiments of the present invention for purposes of illustration only. One skilled in the art will readily recognize from the following discussion thatalternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles of the invention described herein.DETAILED DESCRIPTIONFIG. 1: INTRODUCTION OF PLATFORM AND MAIN ELEMENTS

[0731] Techniques described herein provide novel approaches to accelerating synthetic biology research and development through the integration of computing hardware and advanced artificial intelligence capabilities. The platform described herein provides technical solutions that address fundamental computational and engineering challenges in synthetic biology7development, including optimizing complex biological systems across multiple objectives (from strain development to commercial-scale production), hardware-constrained limitations of traditional laboratory data processing (e.g., screening) approaches, computational difficulties in modeling and predicting performance translation from laboratory to commercial scale, and technical constraints in rapidly iterating through design-build-test cycles with limited data. By leveraging Al models, data management, and specialized workflow components in various ways, the platform described herein can accelerate synthetic biology7development across a range of applications.

[0732] The platform’s architecture enables the flexible deployment of multiple Al models, including the integration of foundation models, mechanistic models, and / or hybrid models for the various tasks described herein. The platform provides technical solutions that enable efficient model training even with sparse initial datasets, enable real-time techno-economic analysis (TEA) to select for and optimize commercial viability, use specialized neural network architectures for automated identification and optimization of genetic modifications and biosynthetic pathways, deploy a plurality7of models (e.g., using distributed / parallel computing architectures) to enable prediction and improvement of scale-up performance, implement optimized data integration pipelines across heterogeneous data ty pes, provide systematic governance and risk management throughout the development process, and other technical benefits.

[0733] As described herein, the platform may leverage distributed and / or parallel processing architectures that use multiple computing nodes to reduce computation time and / or enable processing of larger datasets. The platform may also leverage specialized machine learning model architectures, distributed data management systems, hardware-optimized workflows, and the like to accelerate synthetic biology development while reducing computational and other resource consumption compared to other methods, for example by reducing the number of experimental iterations needed for a strain design workflow. The platform may further integrate with laboratory and / or commercial equipment, such as bioreactors and other equipment described herein.AI-GUIDED SYNTHETIC BIOLOGY (“ASB”) PLATFORM.

[0734] In embodiments, an AI-Guided Synthetic Biology Development Platform 100 (the ‘“ASB Platform’’), with a range of components, services, modules, entities, workflows and other elements that are configured to enable the acceleration, through the use of artificial intelligence and other supporting technologies, of research and development at all stages of synthetic biology projects, from initial prototy ping of candidate strains and other biological entities, to optimization of thebiological entities and the environments and processes by which they will produce useful outputs, and to the scaling up of production to commercially valuable levels. With the use of an appropriately configured set of advanced artificial intelligence models, the ASB Platform can enable an accelerated path to successful development of synthetic biology products and processes even when starting datasets are sparsely populated. FIG. 1 depicts an exemplary’ embodiment of entities and interactions of an ASB Platform 100. It should be understood that the ASB Platform 100 may comprise various subsets of such entities and interactions, as well as additional elements. The ASB Platform may be arranged in a wide range of architectures and topologies, such as software-as-a-service (SaaS), platform-as-a-service (PaaS) and infrastructure-as-a-service (laaS) architectures, such as comprising a set of services, such as microservices, configured to operate on cloud computing, enterprise computing, and other computing architectures.

[0735] The Al models 3100 may be implemented using specialized computing hardware to improve processing efficiency and reduce resource consumption. For example, the platform may use graphics processing units (GPUs), neural processing units (NPUs), tensor processing units (TPUs), and / or other such processing cores for Al model training and / or inference operations such as matrix computations. Additionally or alternatively, the platform may use field-programmable gate arrays (FPGAs) or other customizable hardware to provide optimized implementations of the functions described herein. These hardware optimizations may enable faster and / or more efficient processing of large biological datasets and / or complex model architectures. Specific hardware configurations and optimizations may vary’ by model, task, workflow, etc., examples of yvhich are detailed elseyvhere herein.

[0736] In embodiments, a platfonn topology may comprise a set of artificial intelligence, neural network, machine learning, or other models, or “Al Models 3100,” each of which may be configured to operate as a standalone model, or yvhich may operate in various hybrid, serial, parallel, loop and other topologies as disclosed elseyvhere herein. Model ty pes may include those depicted in FIG. 1, or any of the other types of models disclosed herein or in the documents incorporated herein by reference, including, yvithout limitation, feedback neural netyvorks, feed forward neural networks, convolutional neural netyvorks, gated recurrent neural networks, positional encoders, transformer models, foundation models, large language models, and others. Model types may be configured and trained to enable (e.g., to embed) specific capabilities, including granular modeling of mechanistic and kinetic behaviors of biological entities and flows, including genetics of strains, process environment parameters, and many others.

[0737] With reference to FIGS. 1 and 2, the Al models 3100 may include multi-objective optimization models 3110 that are configured to enable simultaneous optimization across multiple parameters (e.g., yield, cost, process efficiency, etc.). The Al models 3100 may further include foundation models 3102 that may provide various predictions for proposed biological systems and that can be fine-tuned for specific applications. For example, the foundation models 3102 may include genetic generalization models, process generalization models, and / or other types of models described in more detail elsewhere herein. The Al models 3100 may further include mechanistic models 3104, which may generate outputs characterizing biological processes and pathways.Additionally, the Al models may include hybrid models 3106 that may combine multiple types of models to leverage the respective strengths of individual models. In embodiments, automated model construction capabilities 3108 may enable rapid development and / or iteration of new models as additional data becomes available. Furthermore. Al-guided analytics, discovery tools, digital twins, and simulations 3112 provide simulation and visualization capabilities. The Al models may further include Al and technical solution models for TEA, prototy pe, optimize, and scale 3114, which may support specific workflows / operations described in detail elsewhere herein. The Al models may also be used to generate specific recommendations across multiple optimization domains. Specific functions and applications of the Al models are described in more detail below.

[0738] The ASB Platform 100 may further comprise various data sources, such as involving sensor data collection, data processing, data and sensor fusion, and data staging for synthetic biology modeling and analytics, collectively referred to as “Al-ready data 2110.” In embodiments, the Al-ready data 2110 may be stored and / or processed into specialized data structures optimized for biological data and / or machine learning processing, examples of which are described in more detail below. These and other specialized data representations may enable more efficient storage and / or better model training and inference. Various elements of Al-ready data 2110 may be used as inputs for Al Models 3100, as well as to enable higher-level solution components of the ASB Platform 100. Data collection, extraction, processing, transformation, loading, nonnalization, storage and other techniques may include any of the techniques disclosed herein or in the documents incorporated by reference herein, or as would be understood by one of ordinary skill in the art, including use of distributed data storage, data storage structures suitable for staging data for processing by Al models (e.g., graph database, vector database, and others), and the like. For example, a data intake and staging pipeline may collect and preliminarily process various ty pes of data. A data normalization process (described elsewhere herein) may normalize data to provide consistency and compatibility7across different data sources. A data integration process (described elsewhere herein) may integrate various datatypes while maintaining data segregation and security7protocols. The platform may use biological parameters and measurements derived from experimental and / or operational data for various purposes (e.g., training). The platform may also store model output tracking data to enable systematic evaluation of model performance and iterative improvement.

[0739] In embodiments, Al models also produce insights, such as the relevance of specific genetic modifications, that can enable specialized solution components 1200 are applicable and extensible across multiple end-market solutions, as shown in FIG. 5. These solution components can include specifications for appropriate process environments and parameters, strains of biological organisms, genetic modifications can be predicted to yield desired effects, hardware components (including fennenters and other biological process hardware, robotics, 3D printers, and automation systems), software, firmware and other information technology components that can be used in synthetic biology processes, systems for providing safety7, governance, compliance and similar guidance for synthetic biology processes and products, and the like. All of theseelements work together to create a flywheel for industry growth by expanding favorable economics to a growing universe of materials.

[0740] In embodiments, the ASB Platform 100 may include a set of configured solutions, each configured to enable a set of services and workflows that are specific to a distinct phase of synthetic biology research and development, referred to herein as ‘“core platform systems 200.” With reference to FIG. 4, the core platform systems 200 may be configured as a single, unified system, or each may be configured to enable a specific phase or capability that is commonly required in synthetic biology development projects. For example, a prototype system 204 may be configured to enable the exploratory' or prototy ping phase of development of a synthetic biology7system, such as involving identification of and experimentation with candidate strains and variants that may be capable of producing a desired output product. Similarly, an optimize system 208 may be configured to enable the optimization phase of development, where various elements of biological entities, process parameters (environmental controls, feedstock elements, genetic modifications, and many others), and other elements are rapidly and iteratively improved, guided by Al specifications and recommendations, to improve the productivity' and quality of the outputs of a synthetic biology7product or system. Further, a scale-up system 210 may be configured to enable the scale-up phase of synthetic biology development, where entities and processes that were developed in the laboratory during the prototyping phase and improved at small scale (e.g., in fermenters) in the optimization phase are further adjusted, based on Al recommendations and specifications and iterative improvement, to improve the yield of a synthetic biology system (such as in larger scale commercial production environments, where imperfect conditions, such as lower quality feedstocks, less controlled environmental parameters, and other factors are likely to be present).

[0741] In embodiments, the various core systems 200, including the prototype system 204, the optimize system 208, the scale-up system 210, and the TEA system 202, may be any system described herein that is capable of implementing prototy pe workflows and sendees, optimize workflows and services, scale-up workflows and sendees, or TEA workflows and services respectively. Thus, it should be understood that although the workflows and services may in some cases be described as being performed by7specific core systems, they may also be performed by the other systems described herein that are capable of implementing the workflows and services, running Al models, etc.

[0742] Various configurations of Al models 3100 (FIGS. 1 and 2), including hybrid models, may be configured in the workflows of the respective prototype system 204, optimize system 208 and / or scale-up system 210 to provide the most effective set of predictions, recommendations, specifications, instructions, orchestration, automation, and other outputs and capabilities needed to support successful R&D projects. Each system may benefit from a particular configuration of Al models 3100 that is created to suit the needs of that system, as further described elsewhere in this disclosure.

[0743] In embodiments, the ASB platform 100 may include a techno-economic analysis system, or TEA system 202, which may include a variety7of analytic models, Al models, expert models,and the like, which operate on technical and economic input data to provide outputs relevant to the commercial viability of a synthetic biology project, product, or system. This may include outputs that predict, under various scenarios, the likely unit economics for a synthetic biology organism based on predicted input costs (e.g., feedstock prices), output value (e.g.. the market price of a product produced by the organism or system), capital costs (including the cost of equipment needed to produce a product in a commercial environment, borrowing costs, and the like), operating costs, and the like. The TEA system 202 may include machine learning and Al systems that are trained to predict relevant economic variables based on input data. The TEA system 202 may include a suite of analytic tools, such as econometric tools that frame predictions based on statistical parameters of certainty or uncertainty, including regression models and many others. The TEA system 202 may include simulation capabilities, such as random walk, random forest, and similar algorithms. The TEA system 202 may include various algorithms that are helpful for processing technical subject matter, such as clustering algorithms (e.g., k-means clustering) that can be used to group entities (such as organisms, genetics, and other biological entities or factors, environmental parameters, and the like) based on similarities.

[0744] The TEA system 202, prototype system 204, optimize system 208 and / or scale-up system 210 may be configured to enable iteration and feedback among them, such as where one of them provides feedback or feed forward inputs to the other, allowing outcomes at each phase to be used for learning and inputs at other phases. As noted above, outputs may include insights that are applicable across various phases of multiple projects, with replicable or extensible outputs being candidates for inclusion as specialized solution components 1200, as shown in FIG. 5.

[0745] In embodiments, elements of one or more of the TEA system 202, prototype system 204, optimize system 208 and / or scale-up system 210, as well as optionally some set of specialized solution components 1200, may be configured as a system, platform, system-of-systems, or the like of the ASB Platform 100 to enable a market-specific workflow, service, product, or solution, referred to herein as an “end-market solution 1100.” Thus, embodiments of the ASB Platform 100 may include ones that are specifically configured to enable particular types of end-market research and development solutions and outputs, such as for pharmaceuticals, fuels, specialty chemicals, waste remediation, and many others.

[0746] In embodiments, various platform components may iteratively optimize one or more of the Al models 3100 based on feedback data. For example, the platform may collect data from hardware assets 1206 (e.g.. Al-enabled fermenters) (in real-time or otherwise) and provide the data to mechanistic models 3104 and / or hybrid models 3106 in order to iteratively and / or continuously optimize process parameters 1202. As another example, the platform may collect predictions about strain performance from various Al models and use these predictions to trigger automated adjustments to robotics and automation systems 1210 for subsequent experimental iterations. As these examples demonstrate, the platform may leverage the data generated by any of the models and / or equipment described herein to create self-improving feedback loops by feeding the data into other models, using the data to retrain models, using model predictions to adjust operational parameters including hardware parameters and / or process parameters, and / or the like, such thatany component’s outputs may be used to continuously and iteratively improve performance of other components. The platform 100 may use these and other feedback loops to reduce computation by providing targeted model updates that improve prediction accuracy. More specific examples of optimizing the platform using feedback loops are described herein.

[0747] The platform 100 may also improve Al models by comparing predictions generated by any of the TEA system 202. prototy pe system 204. optimize system 208 and / or scale-up system 210 to later data gained from experiments (e.g., assays, production runs, etc ). Based on the comparison, the platform 100 may generate a loss signal that can be used to update the Al models used to generate the predictions. Some data (e.g., data related to failed prototypes or production runs) may be weighted more heavily for updating the models.PROTOTYPE SYSTEM

[0748] Referring to FIG. 2, further details of various embodiments of the prototype system 204 are provided. The prototype system 204 typically involves exploration of candidate strains of biological entities (e g., microbes, including various strains of bacteria, yeast, algae, fungi, mammalian cells, plants, or the like) that have the potential to produce, as an output, a molecule that is desired for its commercial or other beneficial properties (e.g., medical or wellness effects, use as a fuel, use as a catalysts or additive to a process, or many others). In many cases, the volume of production is small, such that laboratory experiments have historically been the state of the art for testing and prototyping new strains for their potential commercial application. Artificial intelligence, such as using various Al models 3100, may be used to dramatically accelerate the historical laboratory-based processes of prototyping new strains and variants.

[0749] Additional example components of a prototype system 204 for implementing prototype systems and workflows are shown at FIG. 7. As shown in the figure, the prototype system 204 may include a prototype input processing component 302 that is configured to collect, normalize, and / or prepare data from multiple sources for use in prototyping workflows. In embodiments, the input processing component 302 may receive and / or process experimental data, target molecule specifications, strain library information, known pathway data, and / or other inputs. In embodiments, the input processing component 302 may leverage the platform’s data intake pipeline and normalization capabilities (described elsewhere herein) to ensure data consistency and quality. Additionally or alternatively, the input processing component 302 may maintain and update a knowledge base that captures relationships between strains, pathways, genes, observed outcomes, etc. This data may be processed, stored, and used for various use cases of the prototype systems 204 and / or other systems. For example, the data may be used for training and / or finetuning of Al models 3100 and / or for any other use cases described herein. The input processing component 302 may be implemented by the facility for synthetic biology sensor collection, processing, fusion, and staging for modeling and analytics 2100 described below, as shown in FIG. 3. As described below, this facility may use dedicated processing cores to handle data preprocessing tasks. For example, sequence alignment operations may be performed using GPUs or other Al processing cores to reduce processing time. The input processing component 302 mayimplement distributed storage and / or processing architectures that enable parallel processing of multiple data streams from different experimental sources simultaneously.

[0750] In embodiments, the prototype system 204 may include an Al analysis and prediction component 303 that leverages various Al models 3100 to generate insights and / or predictions about prototyping candidates. For example, the Al analysis and prediction component 303 may use foundation models 3102, such as genetic generalization models or other models, to predict the performance of different candidate base strains under various conditions. As another example, the Al analysis and prediction component 303 may use mechanistic models 3104 to analyze biosynthetic pathways and / or may use hybrid models 3106 to combine multiple types of models to predict enzyme effectiveness within particular pathways. In embodiments, any of the Al models 3100 described herein may be used by the prototype system 204 for analysis and / or prediction, such as using protein language models to predict enzyme function, using Lin-Log models to estimate metabolic flux distributions, or using neural networks to predict strain performance from genetic modifications.

[0751] In embodiments, the prototype system 204 may include an experimental design component 304 that uses Al predictions and / or recommendations to generate expenmental plans. For example, the experimental design component 304 may generate assay testing plans for testing multiple strain variants under particular conditions, specify sets of genetic modifications to test in parallel, determine optimal sampling times, generate control experiments to validate specific hypotheses, and / or the like. As another example, the experimental design component 304 may generate experimental sequences that efficiently test combinations of pathway modifications in a way that minimizes the total number of experiments needed. The experimental design component 304 may specify7validation experiments (e.g., by generating control strain configurations, specifying replication requirements, determining which analytical measurements are needed to confirm predicted behaviors, etc.), allocate laboratory resources (e.g., by scheduling equipment usage based on experiment priorities and duration, determining optimal batch sizes for parallel testing, etc.), establish testing timelines (which may include analyzing predicted growth rates to determine testing durations, scheduling sampling points based on expected production curves, coordinating automated sample collection and analysis, etc.), and / or the like. In embodiments, the experimental design component 304 may interface with specialized solution components 1200, such as hardware assets 1206 and robotics / automation systems 1210, to enable efficient execution of experiments, as shown in FIG. 5. For example, the experimental design component 304 may output operational parameters including process parameters for adjusting automated equipment, output robotic handling instructions for automated strain construction, generate and / or coordinate data for input to Al-enabled fermenters, and the like. The experimental design component 304 may thereby implement real-time control based on Al predictions. For example, the component may dynamically adjust fermentation parameters (e.g., temperature, pH. oxygen levels) of bioreactors or other equipment based on real-time sensor data and model predictions derived therefrom, enabling automated optimization of grow th conditions. These and other automated control loops described herein can significantly improve experimental efficiency while reducing human error. Inembodiments, the experimental design component 304 may incorporate feedback from previous experiments to continuously improve experimental design. For example, the experimental design component 304 may adjust sampling frequencies to capture additional data as necessary based on previous experiments, modify various parameters based on unexpected strain behaviors, revise strain selections based on observed experimental performance and / or variability, and the like.

[0752] In embodiments, the prototype system 204 may include an integration and output component 305 that manages results, facilitates feedback loops, and prepares for subsequent development phases. More specifically, the integration and output component 305 layer may output experimental outcome data to other systems and / or users, provide data as feedback to the TEA system 202 or other systems, prepare successful prototypes for the optimization system 208, and / or the like. As specific examples, the integration and output component 305 may generate comparative analyses of strain performance across different conditions by synthesizing outputs of multiple experiments, create visualizations or other analyses of metabolic pathway performance, compile outcome data into training datasets that include correlations between genetic modifications and phenotypic outcomes, generate lists of strains that meet performance thresholds for advancement to an optimization phase, and / or the like. The integration and output component 305 may further generate analytical data that may be used by the TEA system to generate updated cost projections. This analytical data may include, for example, calculating actual versus predicted yields, identifying unexpected process requirements, quantifying resource usage across different strain variants, and the like. The integration and output component 305 may also update the platform's knowledge base with new insights about strain behavior, pathway effectiveness, and / or process parameters, thus providing more information for future prototy ping experiments. In embodiments, the integration and output component 305 implements efficient data structures and algorithms optimized for handling large-scale biological data. For example, the component 305 may employ specialized compression algorithms for biological sequence data, enabling efficient storage and retrieval of large-scale experimental results. These and other specialized structures and algorithms may enable reduced memory usage and faster uery performance compared to traditional databases while also maintaining data integrity across multiple experimental iterations.

[0753] In embodiments of a prototyping system 204, an Al model can be used, among other things, to understand and predict the behaviors of many different candidate base strains under many different kinds of conditions, to facilitate development of a candidate set of base strains and selection of ones on which to conduct further experimentation and development. For example, the Al analysis and prediction component 303 may use foundation models 3102 to predict strain tolerance to different process conditions, growth characteristics under various media formulations, and / or production capabilities for target molecules, as described in more detail elsewhere herein. The Al analysis and prediction component 303 may also analyze strain libraries to identify candidates with desired genetic characteristics and / or to predict the effects of specific genetic modifications on strain performance.

[0754] In other embodiments of a prototy ping system 204, an Al model can be used for pathway selection, such as to identify biosynthetic chemical pathways (i.e., efficient routes from an initialbiochemical state (e.g., chemical structure, physiological structure, or the like) to another. For example, the Al analysis and prediction component 303 may use mechanistic models 3104 to evaluate multiple potential pathways based on various requirements. The experimental design component 304 may then generate experiments to validate these predictions and identify optimal pathway configurations. Pathways for strain development, cultivation and a wide range of other applications can be prototyped with the assistance of an Al model, thereby accelerating the process of identification of a favorable pathway for a desired outcome (e g., production of a target molecule using a host strain).

[0755] In other embodiments of a prototyping system 204, an Al model can be used for enzy me selection, including which enzymes are likely to be effective within particular pathways. For example, the Al analysis and prediction component 303 may use protein language models to predict enzyme function, stability, and / or activity under different conditions. The Al analysis and prediction component 303 may also use hybrid models 3106 to evaluate enzyme compatibility within specific pathway configurations by leveraging different types of models within a hybrid architecture.

[0756] In other embodiments of a prototyping system 204, an Al model can be used for host organism selection, such as among bacteria, fungi, yeast, algae, mammalian cells, plants, or the like. For example, the Al analysis and prediction component 303 may evaluate potential host organisms based on their predicted ability to express target pathways, tolerance to process conditions, genetic manipulation requirements, scaling characteristics, etc. The TEA system 202 may also incorporate these predictions to assess the economic viability of different host organisms based on cultivation requirements and / or expected performance at scale.

[0757] In each case, an Al model 3100, or a set of them, may be configured and trained iteratively over time based on outcomes, to predict the biological states and flows of all entities involved in the production of a desired molecule by the operation of a host organism, via selected pathways, moderated by selected enzy mes, on an input (such as a feedstock) to produce an output. The integration and output component 305 may facilitate this iterative improvement by capturing experimental outcomes and updating the platform's knowledge base (e.g., including training and / or fine-tuning data sets), thereby enabling models to iteratively train to improve learning from each additional prototyping cycle and thereby improve predictive accuracy.

[0758] The above features and functionalities are only some examples of the operation of the prototype system 204. The disclosure provides additional details elsewhere herein of prototype workflows and services. It should be understood that any of these workflows and services can be performed by the prototype system 204 or the components thereof. It should also be understood that the workflows and services described above with respect to the prototype system 204 can be performed by other systems and components described elsewhere herein that are capable of implementing prototype workflows and services, executing Al models, and / or the like.OPTIMIZE SYSTEM

[0759] In the optimize system 208, an Al model 3100, or a set of them, may similarly be configured and trained iteratively over time based on outcomes, to predict the biological states andflows of all entities involved in the production of a desired molecule by the operation of a host organism, via selected pathways, moderated by selected enzymes, on an input (such as a feedstock) to product an output. The optimize system 208 may typically be involved at the stage of research and development where it is understood that a host can produce a desired output molecule, but there remains a large amount of uncertainty about operational parameters including the ideal inputs, genetics, process parameters, and other dimensions to enable commercially viable levels of production (i.e., ones in which the unit economics are expected to be favorable).

[0760] FIG. 8 illustrates additional details of an example optimize system 208. As shown in the figure, the optimize system 208 may include an optimization input processing component 310 that is configured to collect, process, and prepare data for optimization workflows. In embodiments, the input processing component 310 may receive and process outputs from the prototype system 204, including successful strain candidates, validated pathway configurations, initial performance data, and the like. The optimization input processing component may also collect optimizationspecific data such as scale-up parameters, process conditions, equipment specifications, and economic constraints (e.g., from the TEA system 202). In embodiments, the input processing component 310 may leverage the platform’s data intake pipeline and normalization capabilities to ensure consistency across different experimental scales and conditions, in a similar way as described for the prototype input processing 302.

[0761] In embodiments, the optimization input processing component 310 may maintain and update data sets that capture relationships between strain perfomrance and various optimization parameters. For example, these data sets may include correlations between genetic modifications and phenotypic outcomes at different scales, historical data about successful scale-up strategies, documented process parameter sensitivities, and / or optimization constraints specific to different market applications. The optimize system 208 may use these or similar data sets to identify patterns to inform optimization strategies, such as by recognizing common bottlenecks in similar pathways, identifying genetic modifications that consistently improve scale-up performance, determining process conditions that tend to maintain consistent performance in particular situations (e.g., for certain organisms, strains, processes, scales, etc.), or the like.

[0762] With reference to FIGS. 3 and 8, the optimization input processing component 310 may be implemented by the facility for synthetic biology sensor collection, processing, fusion, and staging for modeling and analytics 2100, as described herein. The component 310 may implement methods that are optimized for biological optimization and / or scale-up data. When processing biological data, the input processing component 310 may process input sequences representing process parameters with temporal information (e.g., temporal embeddings), for example, such that the inputs are annotated with time data for each parameter state. The input processing component 310 may collate training data to include paired examples of input and outcome data (e g., process parameters, scale-up outcomes) collected from laboratory and industrial-scale experiments. In embodiments, the input processing component 310 uses Al processing cores for processing multiple data streams from different scales simultaneously, thereby enabling real-time optimization of process parameters.

[0763] In embodiments, the optimization input processing component 310 may prepare data for use by various Al models 3100 that are involved in optimization tasks. For example, the optimization input processing component 310 may format genetic sequence data for analysis by protein language models, prepare process parameter datasets for mechanistic models 3104, structure experimental results for training hybrid models 3106, or perfonn other such training preparation steps as described elsewhere herein. In embodiments, the optimization input processing component 310 may also implement quality control measures for optimization data, such as byvalidating consistency of measurements across different scales, identifying potential experimental or data artifacts that may impact optimization predictions, and / or flagging unexpected deviations in performance for further investigation.

[0764] In embodiments, an optimize system 208 can be used to understand, analyze and optimize various biosynthetic pathways that are involved in the host’s production of a molecule. Existing pathways may be understood (e.g., from the prototyping phase), but adjustments to inputs, environmental parameters, and other factors may be explored and selected by Al models 3100 of the platform ASB Platform 100 to increase the amount of production for a given amount of feedstock, to improve the quality- of the outputs, or the like. For example, the genetic and pathway optimization component 311 may use Al models 3100 to identify opportunities to increase production yield for a given amount of feedstock, improve the purity or quality of outputs, reduce byproduct formation, and / or the like.

[0765] In other embodiments, an optimize system 208 can be used to design / engineer new pathways. For example, the genetic and pathway optimization component 311 may use mechanistic models 3104 to predict the effectiveness of novel pathw ay configurations, hybrid models 3106 to evaluate combinations of existing pathway elements, and / or foundation models 3102 to identify other pathways for desired products. In embodiments, the genetic and pathway optimization component 311 may generate and evaluate multiple pathway alternatives simultaneously, rank them based on predicted performance metrics, and / or recommend specific modifications for experimental validation.

[0766] In other embodiments, an optimize system 208 can be used to evaluate the impact of metabolic engineering (overexpressing gene, introducing new enzy me). For example, the genetic and pathway optimization component 311 may leverage protein language models to predict the effects of these genetic modifications, use mechanistic models 3104 to simulate changes resulting from these modifications, and / or employ hybrid models 3106 to evaluate the combined effects of multiple modifications. In embodiments, the genetic and pathway optimization component 311 may generate recommendations for specific genetic modifications based on predicted impacts on pathway efficiency, product yield, strain stability, and / or other performance metrics.

[0767] In other embodiments, an optimize system 208 can be used to optimize performance. For example, the genetic and pathway optimization component 311 may integrate output data from experimental results to iteratively refine its optimization strategies and predictions.

[0768] In other embodiments, an optimize system 208 can be used to identify problems, such as the presence of biosynthetic pathway bottlenecks that can be removed w ith adjustments to variousoperational parameters, including genetic modification, process parameters, environmental parameters, or the like. The genetic and pathway optimization component 311 may use Al models 3100 trained on pathway data, metabolomics data, and / or other experimental results to identify specific bottlenecks or inefficiencies. The genetic and pathway optimization component 311 may then recommend various adjustments to remove the bottlenecks using the various Al models 3100 described herein. In embodiments, the genetic and pathway optimization component 311 may prioritize recommended modifications based on predicted impact, implementation complexify, and / or economic considerations provided by the TEA system 202. For example, the genetic and pathway optimization component 311 may recommend overexpressing a particular gene if the models predict this modification would significantly improve yield with minimal process changes, while more complex modifications involving multiple genetic changes might be a lower priority despite potentially higher yields due to increased implementation complexify- and development time.

[0769] In other embodiments, an optimize system 208 can be used to optimize proteins. In such embodiments, the optimize system 208 can operate as a genetic generalization system (e.g., using genetic generalization models described elsewhere herein), such as to predict the effects of various prospective genetic edits process conditions are assumed to be held constant. A genetic generalization model may be trained to generalize and predict the effects of a set of edits that have not been observed based on the effects of edits that have historically been observed. Among other benefits, this may reduce the need for expensive, high throughput laboratory screening (such as high throughput assays, plates, and the like). As the model predicts the performance of as-yet- unobserved synthetic biology designs screening can be directed to more relevant process conditions earlier in the research and development process, thereby accelerating the overall timeline of development. In embodiments, this may include enabling design screening directly in bioreactors, which is otherwise very' challenging, because the rate of experimental throughput is much lower. Overall, such models may reduce the data requirements to find successes by applying genetic edits that have been seen to perform well and generalizing them to other designs that can perform as well or better in various applications.

[0770] The optimize system thus provides a technical improvement to the field of genetic engineering by enabling rapid assessment and prototyping of genetic edits to strains using a machine learning model. The optimize system can thus perform an automated search through a space of genetic edits to identify a combination of genetic edits that are predicted to enhance performance of a strain on a synthetic biologic task. The identified genetic edits can then be applied to the strain, and the optimized strain can be deployed to perfomi synthetic biology tasks.

[0771] In other embodiments, an optimize system 208 can be used to recommend genetic edits. Genetic information and other relevant data, such as process environment data, output product data, and the like can be fed into an Al Model 3100 that provides a set of embeddings that predict the outcome of a particular genetic edit given variations in the organism in which the modification takes place, modifications of the process environment, and modifications of the desired output product, among other factors. In embodiments, the genetic and pathway optimization component311 may rank recommended genetic edits based on predicted effectiveness, confidence levels, and / or alignment with optimization objectives provided by the TEA system 202 or other platform components.

[0772] In other embodiments, an optimize system 208 can be used to optimize strain genetics for performance at the target scale of commercial operations. This may include models that predict outcomes of strain genetics under imperfect conditions, such as where feedstocks are somewhat impure, temperature control is imperfect, and the like. For example, the genetic and pathway optimization component 311 may use hybrid models 3106 that combine mechanistic models of cellular responses with modes trained on empirical data from scale-up experiments to predict strain robustness under variable conditions. In embodiments, the genetic and pathway optimization component 311 may recommend genetic modifications specifically designed to improve strain stability and performance based on data indicating a set of imperfect conditions, such as by introducing certain genes that maintain pathway function across a broader range of conditions.

[0773] In other embodiments, an optimize system 208 can employ a set of gene function models, such as machine learning models that are pretrained generally on variety of data sets relevant to a host. For example, such models capture the broad characteristics of gene function that are stable across organisms. If there is data demonstrating the performance of some subset of genes for a particular molecule, a gene function model may also generalize what other genes might do that that have not yet been tested. In embodiments, this may include, for example, model predicted gene function with a mechanistic Al model and use the outputs to recommendations maximally informant set of initial screens to perfonn in order to explore the impact of a set of genes across function space. As additional rounds of data come in, performance of designs in a given proj ect or product can be used to recommend what designs should be tested next. This can enable discovery of high-performing gene edits, including ones that are not related to known biosynthetic pathways, early enough in a project to accelerate overall research and development success. As noted above, this can occur without the need for expensive high throughput screening or automation systems.

[0774] In these and certain other embodiments, gene function models are focused on predicting or understanding the function of genes in biosynthetic pathways. With a set of different gene function models, each comprising a representation of gene function, a dataset can be generated that captures the relative rate of growth of cells after particular sets of genes have been knocked out. A model can take a set of initial embeddings, concatenate them to each other, feed the concatenated data into a neural network, train the neural network on fitness data and use the training to develop not only a hybrid embedding for information from the existing models, but also additional information. Over time, with more and more supervised datasets, a better general purpose representation of gene edits emerges and performs very well across a range of tasks.

[0775] In embodiments, an optimize system 208 can combine a set of gene function models and with a set of pathway function models. The genetic and pathway optimization component 311 may use hybrid models 3106 that simultaneously process genetic modification data and pathway data. The hybrid models 3106 may predict how7specific genetic changes affect activity7within a pathw ay context, predict how pathway modifications influence the expression or regulation of particulargenes, identify synergistic effects between genetic modifications and pathway engineering, and / or optimize both genetic and pathway parameters simultaneously. Therefore, hybrid models may enable comprehensive optimization strategies that account for both genetic and metabolic factors affecting strain performance.

[0776] In embodiments, an optimize system 208 can employ a set of gene knockout models, which may be taught to predict behavior of single gene edits (knockouts) from phenotypes of knockouts of other genes. For example, the genetic and pathway optimization component 311 may train models to detect patterns in how different gene knockouts affect strain behavior, identify functional relationships between genes based on similarity' of knockout phenotypes, predict the effects of untested knockouts based on these relationships, recommend specific knockout experiments to produce desired outcomes, and / or the like. In embodiments, knockout predictions may be used to prioritize genetic modifications for testing and reduce the number of experiments needed to achieve optimization goals.

[0777] In embodiments, the scale translation component 312 may use supervised modeling to understand and optimize the relationship between different experimental scales. Scale translation is useful in a common situation in which the researcher does not know in advance what the best way is to undertake a process, such as fermentation. Depending on the end product sought, the host organism that may produce the product, the pathways of the host organism used, and the like, there is a need to learn the relationship between a laboratory’ assay (e.g., conducted on a plate) and a larger scale assay (e.g., conducted in a fermentation tank). The scale translation component 312 may be configured to predict and optimize the performance of a larger scale assay (e.g., a tank assay), given a set of data about the perfonnance in a smaller scale assay (e.g., a plate assay).

[0778] The scale translation component 312 may use distributed computing techniques to process multi-scale biological data. For example, the scale translation component 312 may allocate (or request allocation from another component of platform 100) processing nodes to process data from different experimental scales in parallel, with Al processing cores (e.g., GPUs, NPUs, TPUs, FPGAs, etc.) performing specific computational tasks such as sequence alignment, metabolic flux analysis, etc. These techniques may optimize processing of large datasets without causing excessive latency in generating scale-up predictions. Additionally or alternatively, the scale translation component 312 may dynamically adjust resource allocation (e.g., the number and / or type of processing nodes / cores assigned to the optimize system 208) based on computational demands to enable efficient processing of varying experimental loads.

[0779] The inputs to a supervised model trained by the scale translation component 312 may include, for each strain, the genetics of that strain (e.g., an encoded genotype), a set of process features (e.g., physical characteristics) that characterize the process environment in the smaller and larger scale environments, such as reactor volume, feed rate, and many others. The scale translation component 312 may then train models to predict targets at various different scales. These targets may range from basic metrics such as product yield to more sophisticated measures of granular characteristics or parameters of the process or the outputs, such as measures of salt densify, amount of acid, amount of substrate or feedstock consumed, and many others. The scale translationcomponent 312 may tram supervised models using very rich data sets that are collected in fermentation bioreactors, where very detailed characteristics of process and output product are measured in granular detail over defined periods of time. In embodiments of supervised modeling, the scale translation component 312 may run experiments in parallel with the same strain used in both small-scale environments (e.g., plates) and large-scale environments (e.g., fermentation tanks), so that the models can capture relationships by which small-scale and large-scale performance is correlated (e.g., a relationship between plate performance and tank performance). Where tank performance is poorly correlated and negative in relation to plate performance, the scale translation component 312 can identify and eliminate false positives in plate-based models; conversely, where tank performance is more positive than expected based on models of plate performance, the scale translation component 312 can recognize and address false negatives. Over time, the scale translation component 312 may iteratively improve a plate or other small-scale experiment model via supervised learning, in part based on correlation to large-scale experiment performance, to do a better and better job of predicting performance in a tank or other larger-scale environment.

[0780] In embodiments, over a period of time, the scale translation component 312 may train models that are more sophisticated in terms of how strain genetics are represented, with models reflecting gene embedding features being trained, based on the discovery of where small scale, (e.g., plate) performance is over- or under-estimated by the plate assay relative to large-scale performance (e.g., in tanks), as described elsewhere herein. Understanding what genetics are involved when prediction is difficult can help generalize to other similar examples to predict when false negatives or false positives are more likely to arise from a small-scale assay. With a set of examples of over- or under-estimation of large-scale performance in atraining set involving similar embeddings (such as of gene function), a model can be trained to predict which results from a plate-based or other small-scale model are most likely to produce false negatives, and those instances can be elevated in priority for further experimentation or screening, notwithstanding unfavorable predictions in a small-scale model.

[0781] In embodiments, the scale translation component 312 may evolve genetic generalization models to sufficient predictive capability that plate-based or other small-scale assays are unnecessary. Selection of what strains and process environments to test in bioreactors can become sufficiently effective that it is economically advantageous to advance to that stage of experimentation, cutting out time and cost involved in laboratory screening. In other embodiments, a combination of genetic generalization models and plate-based assays can be used, with appropriate comparison, checks and balances, to create a fast, highly efficient pipeline of candidates for larger-scale experimentation, such as bioreactors or fermentation tanks.

[0782] In embodiments, the scale translation component 312 may train models that use richer plate assay data, such as by using inputs that include aspects other than genetic representation features. The input data may include analytical chemistry of media used on plate-based assays, tranportomics (i.e., the understanding of the array of ion channels and transporters expressed in cell membranes), and other representations that improve the ability7to create accurate signatureperformance in plates and that more accurately generalizes to predict what will happen in tanks with related hosts strains, genetic modifications, process environment features, and output products. Thus, training sets with similar effects on measurements (i.e., "‘assay fingerprints”) can be generalized to tank performance.

[0783] In some embodiments, the scale translation component 312 may, for example, generalize from successful tank experiments based on gene functions / embeddings. This can be done with tank data alone (i.e., screening from bioreactors), or related plate data can be supplied, which is likely to lead to better predictions. In other embodiments, the scale translation component 312 may generalize from tank experiment successes based on a plate data signature to recommend a set of genetic edits. These elements can also be combined to provide a richer model and a richer assay, with the expectation that gene embeddings and richer plate data could synergistically improve performance.

[0784] In embodiments, the scale translation component 312 can (instead of or in addition to using a single model) use an ensemble set of models and active learning, so that selection of strains, tests, and experiments provide together a balance of exploration and exploitation to identify regions of gene function space that are not well characterized in a model, as described elsewhere herein. Any single supervised model may have low predictive value and high uncertainty, especially with the expected limitations on dataset size. However, by incorporating model uncertainty into predictions (e.g., by generating model ensembles), a researcher can use active learning to balance exploration and exploitation. Supervised modeling may be used, for example: to generalize from tank experiment successes based on gene functions / embeddings; to generalize tank performance data based on plate signature data for gene edits; and / or to combine gene embeddings and rich plate data.

[0785] In other embodiments, an optimize system 208 can be used to design for scale. This may include, in embodiments, a knowledge and discovery7engine 313 for best practices. The knowledge and discover}7engine 313 may systematically collect, analyze, and leverage information from multiple sources to inform scale-up strategies. For example, the engine 313 may perform scientific and patent literature analysis using natural language processing models (e.g., LLMs) to extract relevant scale-up methodologies and to record documented successes and failures from published sources. Additionally or alternatively, the engine 313 may process historical scale-up data generated by the platform 100, including successful and unsuccessful attempts at scaling various strains and processes and the data captured therefrom. Additionally or alternatively, the engine 313 may analyze and process data indicating industry best practices for strain development and scale- up, such as strategies for maintaining strain stability at larger scales in general and / or for particular organisms, equipment, processes, media, and / or the like, methods for adapting strains to industrial feedstocks, method for improving strain robustness in variable conditions, guidelines for process parameter adjustment across scales and in varying conditions, and other methods for managing other strain performance characteristics during scale-up. In some embodiments, the engine 313 may generate training data using this data by translating natural language data into training data using various natural language models. These generated training data sets may be used for any ofthe models described herein. For example, the knowledge and discovery engine 313 may provide training data to the scale translation component 312 to train models for scale-up predictions and recommendations.

[0786] In embodiments, supervised modeling may not be possible due to the scale, location, timing, or other elements of the commercial scale-up environment. In this case, the scale translation component 312 may implement scale-down modeling strategies. For example, the scale translation component 312 may analyze parameters of a target condition and replicate, in a scale-down model, as many of the conditions as possible to make supervised learning possible. This may include collecting various "'omics" to characterize the strain biology7in the target condition; designing a platform host for robustness across conditions rather than peak performance in any one condition; identifying optimal fermentation processes for any particular strain in few experiments; developing a set of environmental requirements of the host that depend on the genetic modifications of the host to make the product, and the like.

[0787] In other embodiments, an optimize system 208 can use Al for screening experiment selection. For example, the genetic and pathway optimization component 311 may analyze strain modification data and send instructions to the prototype system 204 to conduct specific screening experiments. The instructions may indicate which genetic variants to test first, which pathway modifications to combine, what experimental conditions to use based on predictions of likely performance improvements, etc. The prototype system 204 may then execute the screening experiments and return the results to the optimize system 208 for further analysis / optimization.

[0788] In other embodiments, an optimize system 208 can use Al to predict outcomes of scaling production of a molecule. For example, the scale translation component 312 may analyze production data at different scales to generate predictions of performance at larger scales. The predictions may include anticipated yields, potential bottlenecks, required process adjustments, optimal operating conditions, etc. In some cases, the prototype system 204 may execute test runs to validate the predictions and return the actual performance data to the optimize system 208 for further analysis and / or to update the predictive models.

[0789] In other embodiments, an optimize system 208 can use Al for understanding plate to tank transitions. For example, the scale translation component 312 may analyze correlations between plate-based and tank-based experimental results to develop predictive models of scale-up behavior. These models may account for differences in operational parameters such as environmental conditions, strain behavior, metabolic changes, process parameters, etc. In some cases, the prototype system 204 may conduct parallel experiments at both scales to validate these correlations and return the results to the optimize system 208 for further analysis / optimization / training of the models.

[0790] In other embodiments, an optimize system 208 can use gene embedding to identify untested potential high performers and neural networks and hybrid models for combining plate and tank data. For example, various models described herein may use gene embeddings as inputs to predict which untested genetic variants are likely to perform well (including at larger scales). These predictions may incorporate plate-based screening data and / or tank-based production data usingvarious neural network models described elsewhere herein. In some cases, the prototype system 204 may test predicted...

Claims

CLAIMSPLATFORM FOR CELL OPTIMIZATION1. A platform for generating a set of recommendations for modifications to a set of genes of a biological strain for production of a functional output, comprising: a set of data integration facilities for integrating content of at least one publication dataset relating to the biological strain and at least one proprietary' data set including a set of parameters of a synthetic biological process for the production of the functional output by the biological strain, wherein the output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and at least one member of the set of Al-based learning models that is configured to generate the set of recommendations, wherein the set of recommendations relates to modifications to the set of genes of the biological strain, such that the set of recommendations enhances the production of the functional output by the biological strain.

2. The platform of claim 1, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

3. The platform of claim 1, wherein the at least one publication dataset includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzy me characterization datasets, case study datasets, or patent literature.

4. The platform of claim 1, wherein the at least one proprietary dataset includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

5. The platform of claim 1, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

6. The platform of claim 1, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmacal applications and solutions, or medical applications and solutions.

7. The platform of claim 1, further comprising a simulation engine, the simulation engine configured to:generate a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to the set of genes; execute simulations for the plurality of simulated process scenarios; and generate simulation data based on the executed simulations; wherein the set of Al-based learning models is further configured to: receive the simulation data as additional input; and generate the set of recommendations based at least in part on the simulation data.

8. The platform of claim 7, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.

9. A method, comprising: integrating, by a set of data integration facilities, content of at least one publication data set relating to a biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process for production of a functional output by the biological strain; providing the integrated content as input to a set of artificial intelligence (Al)-based learning models; and generating, by at least one member of the set of Al-based learning models, a set of recommendations wherein the set of recommendations relates to modifications to a set of genes of the biological strain, such that the set of recommendations enhances the production of the functional output by the biological strain.

10. The method of claim 9, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

11. The method of claim 9, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

12. The method of claim 9, wherein the at least one proprietary data set includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy’ consumption parameters.

13. The method of claim 9, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codonoptimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

14. The method of claim 9, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, phamiaceutical applications and solutions, or medical applications and solutions.

15. The method of claim 9, further comprising: generating, by a simulation engine, a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to the set of genes; executing simulations for the plurality of simulated process scenarios; generating simulation data based on the executed simulations; receiving the simulation data as additional input to the set of Al-based learning models; and generating the set of recommendations based at least in part on the simulation data.

16. The method of claim 15, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.PLATFORM FOR ENVIRONMENTAL / PERFORMANCE OPTIMIZATION17. A platform for generating a set of recommendations for modifications to a set of environmental parameters for a synthetic biological process for production of a functional output by a biological strain, comprising: a set of data integration facilities for integrating content of at least publication data set relating to the biological strain and at least one proprietary' data set including a set of parameters of the synthetic biological process for the production of the functional output by the biological strain, wherein the output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and at least one member of the set of Al-based learning models that is configured to generate the set of recommendations wherein the set of recommendations relate to modifications to the set of environmental parameters of the synthetic biological process in which the biological strain produces the functional output such that the recommendations enhance the production of the functional output by the biological strain.

18. The platform of claim 17, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

19. The platform of claim 17, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets,bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

20. The platform of claim 17, wherein the at least one proprietary data set includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

21. The platform of claim 17, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity management, pressure, or salinity.

22. The platform of claim 17, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

23. The platform of claim 17, further comprising a simulation engine, the simulation engine configured to: generate a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to the set of environmental parameters; execute simulations for the plurality of simulated process scenarios; and generate simulation data based on the executed simulations; wherein the set of Al-based learning models is further configured to: receive the simulation data as additional input; and generate the set of recommendations based at least in part on the simulation data.

24. The platform of claim 23, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.

25. A method for generating a set of recommendations for modifications to a set of environmental parameters for a synthetic biological process for production of a functional output by a biological strain, comprising: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of the synthetic biological process for the production of the functional output by the biological strain; providing the integrated content as input to a set of artificial intelligence (Al)-based learning models; and generating, by at least one member of the set of Al-based learning models, the set of recommendations wherein the set of recommendations relates to modifications to the set of environmental parameters of the synthetic biological process such that the recommendations enhance the production of the functional output by the biological strain.

26. The method of claim 25. wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

27. The method of claim 25, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory7study datasets, enzy me characterization datasets, case study datasets, or patent literature.

28. The method of claim 25, wherein the at least one proprietary data set includes at least one of genetic parameters, metabolic parameters, grow th and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

29. The method of claim 25, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity7management, pressure, or salinity.

30. The method of claim 25, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

31. The method of claim 25, further comprising: generating, by a simulation engine, a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to the set of environmental parameters; executing simulations for the plurality of simulated process scenarios; generating simulation data based on the executed simulations; receiving the simulation data as additional input to the set of Al-based learning models; and generating the set of recommendations based at least in part on the simulation data.

32. The method of claim 31, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.PLATFORM FOR PATHWAY OPTIMIZATION33. A platform for generating a set of recommendations for modifications to a set of biological pathways associated with a process for production of a functional output by a biological strain, comprising: a set of data integration facilities for integrating content of at least one publication data set relating to the biological strain and at least one proprietary7data set including a set ofparameters of a synthetic biological process for the production of the functional output by the biological strain, wherein the output of data integration facilities is configured as an input to a set of Al-based learning models; and at least one member of the set of Al-based learning models that is configured to generate the set of recommendations wherein the set of recommendations relates to modifications to the set of biological pathways, such that the recommendations enhance the production of the functional output by the biological strain.

34. The platform of claim 33, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

35. The platform of claim 33, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

36. The platform of claim 33, wherein the at least one proprietary data set includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy' consumption parameters.

37. The platform of claim 33, wherein the set of recommendations relates to at least one of: identification and overexpression of key enzymes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

38. The platform of claim 33, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

39. The platform of claim 33, further comprising a simulation engine, the simulation engine configured to: generate a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to a set of pathways; execute simulations for the plurality of simulated process scenarios: and generate simulation data based on the executed simulations; wherein the set of Al-based learning models is further configured to: receive the simulation data as additional input; andgenerate the set of recommendations based at least in part on the simulation data.

40. The platform of claim 39, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a synthetic biological process digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enz me digital twin.

41. A method for generating a set of recommendations for modifications to a set of biological pathways associated with a process for production of a functional output by a biological strain, comprising: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary' data set including a set of parameters of a synthetic biological process for the production of the functional output by the biological strain; providing the integrated content as input to a set of Al-based learning models; and generating, by at least one member of the set of Al-based learning models, the set of recommendations wherein the set of recommendations relates to modifications to the set of biological pathways such that the recommendations enhance the production of the functional output by the biological strain.

42. The method of claim 41. wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

43. The method of claim 41, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

44. The method of claim 41, w herein the at least one proprietary data set includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

45. The method of claim 41. wherein the set of recommendations relates to at least one of identification and overexpression of key enzymes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

46. The method of claim 41, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

47. The method of claim 41, further comprising: generating, by a simulation engine, a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to a set of pathways: executing, by the simulation engine, simulations for the plurality of simulated process scenarios; generating, by the simulation engine, simulation data based on the executed simulations; receiving, by the set of Al-based learning models, the simulation data as additional input; and generating, by the set of Al-based learning models, the set of recommendations based at least in part on the simulation data.

48. The method of claim 47, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a synthetic biological process digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.PLATFORM FOR PROTEIN / ENZYMES OPTIMIZATION49. A platform for generating a set of recommendations for modification of a set of proteins and / or enzymes associated with a biological strain, comprising: a set of data integration facilities for integrating content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process for production of a functional output by the biological strain, wherein the output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and at least one member of the set of Al-based learning models that is configured to generate the set of recommendations wherein the set of recommendations relates to modifications to the set of proteins and / or enzymes such that the recommendations enhance the production of the functional output by the biological strain.

50. The platform of claim 49, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural netw ork, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

51. The platform of claim 49, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

52. The platform of claim 49, wherein the at least one proprietary data set includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenoty pic parameters, omics parameters, scale-up parameters, or energy' consumption parameters.

53. The platform of claim 49, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site-directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

54. The platform of claim 49, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

55. The platform of claim 49, further comprising a simulation engine, the simulation engine configured to: generate a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to the set of proteins and / or enzymes; execute simulations for the plurality of simulated process scenarios; and generate simulation data based on the executed simulations; wherein the set of Al-based learning models is further configured to: receive the simulation data as additional input; and generate the set of recommendations based at least in part on the simulation data.

56. The platform of claim 55, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzy me digital twin.

57. A method for generating a set of recommendations for modification of a set of proteins and / or enzy mes associated with a biological strain, comprising: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary' data set including a set of parameters of a synthetic biological process for production of a functional output by the biological strain; providing the integrated content as input to a set of artificial intelligence (Al)-based learning models; and generating, by at least one member of the set of Al-based learning models, the set of recommendations wherein the set of recommendations relates to modifications to the set of proteins and / or enzymes associated with the biological strain, such that the recommendations enhance the production of the functional output by the biological strain.

58. The method of claim 57, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

59. The method of claim 57, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzyme characterization datasets, case study datasets, or patent literature.

60. The method of claim 57, wherein the at least one proprietary' data set includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory' and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy' consumption parameters.

61. The method of claim 57, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site-directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

62. The method of claim 57, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmacal applications and solutions, or medical applications and solutions.

63. The method of claim 57, further comprising: generating, by a simulation engine, a plurality of simulated synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to the set of proteins and / or enzymes; executing, by the simulation engine, simulations for the plurality' of simulated process scenarios; generating, by the simulation engine, simulation data based on the executed simulations; receiving, by the set of Al-based learning models, the simulation data as additional input; and generating, by the set of Al-based learning models, the set of recommendations based at least in part on the simulation data.

64. The method of claim 63, wherein the simulations involve a set of digital twins representing at least one of a biological strain digital twin, a gene digital twin, a genome digital twin, a pathway digital twin, a bioreactor digital twin, a protein digital twin, a metabolite digital twin, or an enzyme digital twin.RAPID SAMPLING SYSTEM65. A rapid sampling system for obtaining samples from a fennentation system, comprising: a sample inlet fluidly connected to the fermentation system; a pump fluidly connected to the sample inlet and configured to draw a sample from the fermentation system; a first valve fluidly connected to an outlet of the pump;a second valve fluidly connected to a liquid nitrogen chamber; a multi-well filter plate, wherein an individual well of the multi-well filter plate is configured to collect and filter the sample; a motorized base operatively connected to the multi-well filter plate configured to adjust a position of the multi-well filter plate; and a control unit including one or more processors and one or more memories operatively connected to the pump, the first valve, the second valve, and the motorized base, the control unit configured to automatically initiate and perform a plurality of sampling operations at predetermined time intervals, wherein each sampling operation comprises: controlling the operation of the pump to obtain the sample, controlling the operation of the first valve to dispense the sample into a first well of the multi-well filter plate; controlling the operation of the second valve to dispense liquid nitrogen into the first well of the multi-well filter plate; and controlling the operation of the motorized base to move the multi-well filter plate to position a second well beneath the first valve and the second valve.

66. The rapid sampling system of claim 65, further comprising a purge compressed air inlet fluidly connected to the first valve and operatively connected to the control unit, wherein the control unit is further configured to control operation of the first valve to dispense compressed air into a selected well before receiving the sample.

67. The rapid sampling system of claim 65, further comprising a purge solvent inlet fluidly connected to the first valve and operatively connected to the control unit, wherein the control unit is further configured to control operation of the first valve to dispense solvent into a selected well before obtaining the sample.

68. The rapid sampling system of claim 65, further comprising a vacuum base wherein the vacuum base is operatively connected to the multi-well filter plate and operatively connected to the control unit wherein the control unit is further configured to control operation of the vacuum base to filter one or more wells of the multi-well filter plate.

69. The rapid sampling system of claim 65, further comprising a carbon source inlet fluidly connected to the fermentation system and configured to dispense a carbon source into the fermentation system wherein the carbon source inlet is operatively connected to the control unit and wherein the initiation of the plurality of sampling operations is dependent on a dispensing of carbon by the carbon source inlet.

70. The rapid sampling system of claim 65, further comprising a sampling loop.

71. The rapid sampling system of claim 65, wherein the rapid sampling system is configured for a pilot scale.

72. The rapid sampling system of claim 65, wherein the rapid sampling system is configured for industrial scale.

73. The rapid sampling system of claim 65, wherein the first valve is an HPLC valve.

74. The rapid sampling system of claim 65, wherein the second valve is a cry ogenic valve.

75. The rapid sampling system of claim 65, wherein the rapid sampling system is represented as a digital twin.

76. The rapid sampling system of claim 65, wherein the rapid sampling system is integrated with a mass and / or optical analytical system and an automated omics for generalization system.

77. A method for obtaining samples from a fermentation system, comprising: drawing, by a pump fluidly connected to a sample inlet, a sample from the fermentation system; dispensing, by a first valve fluidly connected to an outlet of the pump, the sample into a first well of a multi-well filter plate; dispensing, by a second valve fluidly connected to a liquid nitrogen chamber, liquid nitrogen into the first well of the multi-well filter plate; adjusting, by a motorized base operatively connected to the multi-well filter plate, a position of the multi-well filter plate to position a second well beneath the first valve and the second valve; and automatically initiating and performing, by a control unit, a plurality of sampling operations at predetermined time intervals.

78. The method of claim 77, further comprising dispensing, by the first valve, compressed air from a purge compressed air inlet into a selected well before receiving the sample.

79. The method of claim 77, further comprising dispensing, by the first valve, solvent from a purge solvent inlet into a selected well before obtaining the sample.

80. The method of claim 77, further comprising filtering, by a vacuum base operatively connected to the multi-well filter plate, one or more wells of the multi-well filter plate.

81. The method of claim 77, further comprising dispensing, by a carbon source inlet fluidly connected to the fermentation system, a carbon source into the fermentation system, wherein initiation of the plurality of sampling operations is dependent on the dispensing of the carbon source.

82. The method of claim 77, further comprising utilizing a sampling loop.

83. The method of claim 77, wherein the method is performed at pilot scale.

84. The method of claim 77, wherein the method is performed at industrial scale.

85. The method of claim 77, wherein the first valve is an HPLC valve.

86. The method of claim 77, wherein the second valve is a cryogenic valve.

87. The method of claim 77, wherein the method is represented as a digital twin.

88. The method of claim 77. wherein the method is integrated with a mass and / or optical analytical system and an automated omics for generalization system.AUTOMATED “O ICS” FOR GENERALIZATION89. A method for converting raw data from an analytical and mass spectrometry instrument to model-ready data, the method comprising: receiving, by computing hardware, data from the analytical and mass spectrometry instrument wherein the data includes measurement data from a set of control samples and a set of test samples;extracting, by the computing hardware, a set of peak lists comprising a set of test peak lists and a set of control peak lists from the received data; compressing, by the computer hardware, the extracted set of peak lists using a compression algorithm; providing, by the computer hardware, a set of mass-to-charge ratios and a set of retention times associated with a set of peaks from the set of compressed peak lists to a set of Al-based learning models, wherein at least one member of the set of Al-based learning models is trained to identify metabolites associated with the set of peaks; identifying, by the computer hardw are, a set of metabolites associated with the set of peaks; calculating, by the computer hardw are, a set of peak areas corresponding to the set of peaks; generating, by the computer hardw are, a calibration curve for each identified metabolite based on the calculated area from its corresponding peaks from the compressed set of control peak lists and its known concentration; calculating, by the computer hardware, a set of concentrations for the set of identified metabolites associated with the peaks from the compressed set of test peak lists using the generated calibration curves; and generating, by the computer hardware, a compilation of results.

90. The method of claim 89, further comprising analyzing, by the computer hardware, the identified peaks to determine a need for a deconvolution and / or window adjustment on one or more of the identified peaks, and, upon determination of said need, performing deconvolution and / or window adjustment on the one or more of the identified peaks.

91. The method of claim 89, further comprising generating, by the computer hardware, a quality control website, wherein the qualify control w ebsite presents a set of calibration curves representing the control samples and test samples for each of the metabolites of the set of metabolites.

92. The method of claim 89, w herein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry (LC-MS) instrument, a gas chromatography -mass spectrometry (GC-MS) instrument, a quadruple time-of-flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, a free induction decay (FID) instrument, a quadrupole mass spectrometry (QMS) instrument, a time-of-flight mass spectrometry (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry instrument, a sector mass spectrometry instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, and an atmospheric pressure photoionization (APPI) instrument, among many others.

93. The method of claim 89, further comprising, providing, by the computer hardware, a set of fragmentation patterns associated with the set of peaks to the set of Al-based learning models,wherein at least one member of the set of Al-based learning models is trained to identify the metabolites based on the provided fragmentation patterns.

94. The method of claim 89. further comprising applying, by the computer hardware, a dilution factor to the set of concentrations.

95. The method of claim 94, further comprising normalizing, by the computer hardware, the concentrations to biomass content.

96. A system for converting raw data from an analytical and mass spectrometry instrument to model-ready data, comprising: computing hardware configured to: receive data from the analytical and mass spectrometry instrument wherein the data includes measurement data from a set of control samples and a set of test samples; extract a set of peak lists comprising a set of test peak lists and a set of control peak lists from the received data; compress the extracted peak lists using a compression algorithm; provide a set of mass-to-charge ratios and a set of retention times associated with a set of peaks from the set of compressed peak lists to a set of Al-based learning models, wherein at least one member of the set of Al-based learning models is trained to identify metabolites associated with the set of peaks; identify a set of metabolites associated with the set of peaks; calculate a set of peak areas corresponding to the set of peaks; generate a calibration curve for each identified metabolite based on the calculated area from its corresponding peaks from the compressed set of control peak lists and its known concentrations; calculate a set of concentrations for the set of identified metabolites associated with the peaks from the compressed set of test peak lists using the generated calibration curves: and generate a compilation of results.

97. The system of claim 96, wherein the computing hardware is further configured to analyze the identified peaks to determine a need for a deconvolution and / or window adjustment on one or more of the identified peaks, and, upon determination of said need, perform deconvolution and / or window adjustment on the one or more of the identified peaks.

98. The system of claim 96, wherein the computing hardware is further configured to generate a quality control website wherein the quality control website presents a set of calibration curves for control samples and test samples for each of the metabolites of the set of metabolites.

99. The system of claim 96, wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry (LC-MS) instrument, a gas chromatography -mass spectrometry (GC-MS) instrument, a quadruple time-of-flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, a free induction decay (FID) instrument, a quadrupole mass spectrometry (QMS) instrument, a time-of-flight mass spectrometry (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry' instrument,a sector mass spectrometry instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, or an atmospheric pressure photoionization (APPI) instrument.

100. The system of claim 96, wherein the computing hardware is further configured to provide a set of fragmentation patterns associated with the set of peaks to the set of Al-based learning models, wherein at least one member of the set of Al-based learning models is trained to identify the metabolites based on the provided fragmentation patterns.

101. The system of claim 96, wherein the computing hardware is further configured to apply a dilution factor to the set of concentrations.

102. The system of claim 101, wherein the computing hardware is further configured to normalize the concentrations to biomass content.RAPID SAMPLING SYSTEM + AUTO-OMG103. A system, comprising: a rapid sampling system configured to collect a set of samples from a fermentation system at predetermined time increments; a robotic handling system configured to obtain the set of samples from the rapid sampling system and prepare the samples for an analytical and mass spectrometry instrument; the analytical and mass spectrometry instrument configured to generate raw measurement data associated with the set of samples and provide the raw measurement data to an automated omics for generalization system; and the automated omics for generalization system configured to determine a set of concentrations for a set of metabolites in the set of samples based on the raw measurement data and output the set of concentrations.

104. The system of claim 103, wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry (LC-MS) instrument, a gas chromatography-mass spectrometry (GC-MS) instrument, a quadruple time-of-flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, a free induction decay (FID) instrument, a quadrupole mass spectrometry (QMS) instrument, a time-of-flight mass spectrometry' (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry instrument, a sector mass spectrometry' instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, and an atmospheric pressure photoionization (APPI) instrument, among many others.

105. The system of claim 103, wherein the system is further configured to provide the set of concentrations to an artificial intelligence (Al)-based learning model training system configured to train and / or retrain a set of Al-based learning models.

106. The system of claim 103, wherein the system is further configured to provide the set of concentrations to a set of artificial intelligence (Al)-based learning models, wherein at least onemember of the set of Al-based learning models is trained to identify one or more metabolite bottlenecks.

107. The system of claim 106. wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

108. The system of claim 103, wherein the system is further configured to provide the set of concentrations to a set of artificial intelligence (Al)-based learning models, wherein at least one member of the set of Al-based learning models is trained to generate a set of recommendations for an intervention to a fermentation process in the fermentation system, wherein the set of recommendations includes at least one of a genetic modification, a process optimization, or an environmental adjustment.

109. The system of claim 108, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

110. The system of claim 103, wherein the system is further configured to calculate a flux of a metabolic pathway from the set of metabolite concentrations.

111. The system of claim 103, wherein the system is further configured to provide the set of concentrations to a digital twin system and wherein the digital twin system is configured to generate a digital twin representing a metabolic flux associated with a fermentation process in the fermentation system.

112. The system of claim 103, wherein the system is further configured to calculate at least one of a predicted product yield measure, a fermentation productivity measure, a set of metabolite kinetic rates, or a set of pathway efficiency measures for a fermentation process in the fermentation system.

113. The system of claim 103, wherein the system is configured to build a set of kinetic models for a fermentation process in the fermentation system.

114. A method for determining a set of concentrations for a set of metabolites from a fermentation system, the method comprising: collecting, by a rapid sampling system, a set of samples from the fermentation system at predetermined time increments; preparing, by a robotic handling system, the set of samples for an analytical and mass spectrometry instrument; generating, by the analytical and mass spectrometry instrument, raw measurement data associated with the set of samples; providing, by the analytical and mass spectroscopy instrument, the raw measurement data to an automated omics for generalization system;determining, by the automated omics for generalization system, the set of concentrations for the set of metabolites in the set of samples based on the raw measurement data; and outputting the set of concentrations.

115. The method of claim 114, wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry (LC-MS) instrument, a gas chromatography-mass spectrometry (GC-MS) instrument, a quadruple time-of-flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, a free induction decay (FID) instrument, a quadrupole mass spectrometry (QMS) instrument, a time-of-flight mass spectrometry' (TOF-MS) instrument, an ion trap mass spectrometry' instrument, an orbitrap mass spectrometry' instrument, a sector mass spectrometry' instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, or an atmospheric pressure photoionization (APPI) instrument.

116. The method of claim 114, further comprising providing the set of concentrations to an artificial intelligence (Al)-based learning model training system configured to train and / or retrain a set of Al-based learning models.

117. The method of claim 114, further comprising providing the set of concentrations to a set of artificial intelligence (Al)-based learning models, wherein at least one member of the set of AI- based learning models is trained to identify one or more metabolite bottlenecks.

118. The method of claim 117, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short- tenn memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

119. The method of claim 114, further comprising providing the set of concentrations to a set of artificial intelligence (Al)-based learning models, wherein at least one member of the set of AI- based learning models is trained to generate a set of recommendations for an intervention to a fermentation process in the fermentation system, wherein the set of recommendations includes at least one of a genetic modification, a process optimization, or an environmental adjustment.

120. The method of claim 119, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptron, lin-log model, a large language model, a large protein model, or a protein language model.

121. The method of claim 114, further comprising calculating a flux of a metabolic pathway from the set of metabolite concentrations.

122. The method of claim 114, further comprising: providing the set of concentrations to a digital twin system; and generating, by the digital twin system, a digital twin representing a metabolic flux associated with a fermentation process in the fermentation system.

123. The method of claim 114, further comprising calculating at least one of a predicted product yield measure, a fermentation productivity measure, a set of metabolite kinetic rates, or a set of pathway efficiency measures for a fermentation process in the fennentation system.

124. The method of claim 114, further comprising building a set of kinetic models for a fermentation process in the fennentation system.PLATFORM FOR SCALE-UP SYSTEM WITH Al GUIDED OPERATION MODIFICATIONS125. A synthetic biology development platform, comprising: a prototype system configured to evaluate biological strains that produce biological outputs; an optimization system configured to improve performance of the biological strains in producing the biological outputs; a scale-up system configured to adapt laboratory-scale biological processes associated with the biological strains to commercial-scale production of the biological outputs using at least one of the biological strains; and a set of artificial intelligence models trained on biological data from each of the prototy pe system, the optimization system, and the scale-up system, wherein the biological data comprises at least one of genetic modification data, metabolic pathway data, or process environment data, wherein the synthetic biology development platform is further configured to: receive performance data from one or more of the prototype system, the optimization system, or the scale-up system; update the set of artificial intelligence models based on the performance data; and adjust operational parameters for at least one of the prototy pe system, the optimization system, or the scale-up system using the updated set of artificial intelligence models.

126. The synthetic biology' development platform of claim 125, wherein the set of artificial intelligence models includes a scale-up prediction model trained on production process data, and wherein the synthetic biology development platform is configured to modify strain selection criteria in the prototy pe system based on outputs from the scale-up prediction model.

127. The synthetic biology7development platform of claim 125, wherein the set of artificial intelligence models includes a model trained to predict a scale-up performance of a corresponding biological strain based on genetic modification data for the corresponding biological strain and process condition data.

128. The sy nthetic biology development platform of claim 127. wherein the synthetic biology development platform is configured to: adjust strain screening parameters of the prototype system based on the predicted scale-up performance; and modify genetic modification targets in the optimization system based on the predicted scale-up performance.

129. The synthetic biology development platform of claim 127, wherein the synthetic biology7development platform is configured to identify process conditions in the scale-up system thatcorrelate with increased performance for specific genetic modifications, and wherein adjusting the operational parameters is based on the identified process conditions.

130. The synthetic biology development platform of claim 125. wherein the platform is configured to generate strain development priorities by: generating rankings of the biological strains based on an associated predicted scale-up performance for each of the biological strains; and allocating development resources based on the rankings.

131. The synthetic biology development platform of claim 125, wherein updating the set of artificial intelligence models comprises retraining using data from failed development attempts recorded by the prototype system, the optimization system, or the scale-up system.

132. The synthetic biology development platform of claim 125, wherein the performance data comprises real-time monitoring data from each of the prototype system, the optimization system, and the scale-up system, wherein the synthetic biology development platform is configured to adjust the operational parameters of one or more of the prototype system, the optimization system, or the scale-up system based on the real-time monitoring data.

133. The synthetic biology development platform of claim 125, wherein the biological data further comprises downstream processing data, and wherein adjusting the operational parameters for the scale-up system comprises optimizing downstream processing operations for the biological outputs.

134. A synthetic biology development platform, comprising: a prototype system configured to evaluate biological strains that produce biological outputs; an optimization system configured to improve performance of the biological strains in producing the biological outputs; a scale-up system configured to adapt laboratory-scale processes associated with the biological strains to commercial-scale production of the biological outputs using at least one of the biological strains; a set of artificial intelligence models trained on biological and economic data; and a techno-economic analysis system configured to: analyze economic factors associated with operational parameters of one or more of the prototype system, the optimization system, or the scale-up system; and generate economic predictions for a plurality of development scenarios using the set of artificial intelligence models, wherein the synthetic biology development platform is configured to: adjust the operational parameters of one or more of the prototype system, the optimization system, or the scale-up system based on the economic predictions; and prioritize the biological strains based on the economic predictions.

135. The synthetic biology development platform of claim 134, wherein the set of artificial intelligence models includes an economic prediction model trained to predict commercial viability of strains based on laboratory-scale performance data and market condition data.

136. The synthetic biology' development platform of claim 134, wherein the synthetic biology'development platform is configured to: identify economic thresholds for strain commercial viability; monitor strain performance data with respect to the economic thresholds; and automatically adjust development priorities when performance data indicates a particular economic threshold will not be met.

137. The synthetic biology development platform of claim 134, wherein generating economic predictions comprises: simulating scale-up costs for each of the plurality7of development scenarios; predicting market-dependent revenue potential; and calculating economic metrics, including return on investment and payback period.

138. The synthetic biology7development platform of claim 134, wherein adjusting the operational parameters comprises: identifying process parameters associated with high costs; generating modified process parameters to optimize economic metrics; and implementing the modified process parameters by adjusting the operational parameters of the scale-up system.

139. The synthetic biology development platform of claim 134, wherein the synthetic biology development platform is configured to: develop multiple biological strain candidates in parallel; generate comparative economic predictions for each of the multiple biological strain candidates; and dynamically allocate development resources among the multiple biological strain candidates based on the comparative economic predictions.

140. The synthetic biology development platform of claim 134, wherein prioritizing biological strains comprises: generating risk-adjusted economic predictions for each of the biological strains; generating rankings of the biological strains based on the risk-adjusted economic predictions; and adjusting development resource allocation based on the rankings.

141. The synthetic biology development platform of claim 134, wherein the economic predictions include correlations between process parameters and economic outcomes.

142. The synthetic biology development platform of claim 134, wherein the set of artificial intelligence models includes a cost prediction model trained on historical cost data from previous development efforts, wherein the cost prediction model is configured to predict costs associated with various operational parameters. wherein the synthetic biology development platform is configured to adjust the operational parameters of one or more of the prototype system, the optimization system, or the scale-up system based on the predicted costs.

143. The synthetic biology development platform of claim 134, wherein the set of artificial intelligence models includes a model configured to identify correlations between commercialviability and performance metrics associated with one or more of the prototype system or the optimization system. wherein the synthetic biology development platform is configured to adjust operational parameters of one or more of the prototype system or the optimization system based on the identified correlations.

144. The synthetic biology development platform of claim 134, wherein adjusting operational parameters comprises at least one of: adjusting fermentation conditions in bioreactors, including one or more of temperature, pH, nutrient concentrations, or dissolved oxygen levels; modifying sample collection frequencies or parameters for biological sensors; or adjusting bioreactor operating conditions, including one or more of mixing speed, gas flow rates, or nutrient feeding rates.AI-GUIDED SYNTHETIC BIOLOGY DATA TO GENERATE PREDICTIVE MODEL FOR SYNTHETICBIOLOGY DESIGN145. A computer-implemented method for data integration in an AI-guided analytic platform for development of biologic synthesis processes, comprising: receiving, by a platform, biologic data from a plurality of databases, wherein the biologic data use different data formats and / or semantics; converting the received biologic data into at least one standardized data format to create an integrated dataset; processing the integrated dataset through at least one data normalization process to minimize batch-specific systemic variation; storing the normalized biologic data in a structured format that describes biologic components and their relationships to other components; applying at least one machine learning method to the normalized biologic data to generate at least one predictive model for synthetic biology design; and outputting at least one specification for biologic system design based on the at least one predictive model.

146. The method of claim 145, wherein the at least one data normalization process includes applying a Bayesian statistical model that incorporates prior knowledge about strain behavior.

147. The method of claim 145, wherein the at least one data normalization process includes modeling different sources of vanation, including biological effects and technical factors.

148. The method of claim 145, wherein the at least one data normalization process includes estimating strain performance while accounting for batch effects and other sources of systematic variability.

149. The method of claim 145, wherein the at least one data normalization process includes batch effect correction, wherein a batch effect correction addresses systematic variations across at least one of a plurality of experimental runs, equipment, or operators.

150. The method of claim 145, wherein the at least one data normalization process includes multi-modal data integration.

151. The method of claim 150, wherein the multi-modal data integration includes data relating to at least one of an enzyme level, a metabolite concentration, or a gene expression level.

152. The method of claim 145, wherein the at least one data normalization process standardizes nomenclature across different data sources.

153. The method of claim 145, wherein the at least one data normalization process includes quality control normalization.

154. The method of claim 153, wherein the quality control normalization flags an anomalous data point.

155. The method of claim 153, wherein the quality control normalization flags a well or sample that failed during an experiment.

156. The method of claim 145, wherein the at least one data normalization process includes experiment normalization.

157. The method of claim 156, wherein an experiment normalization account for a variation across a plurality of experimental runs using a similar strain or condition.

158. The method of claim 156, wherein the experiment normalization implements a statistical method to minimize impact of a technical variation.

159. The method of claim 156, wherein the experiment normalization uses a control sample and spike-in standard for validation.

160. The method of claim 145, wherein the at least one data normalization process includes cross-platform data harmonization.

161. The method of claim 160, wherein the cross-platform data harmonization standardizes data from a plurality of experimental platforms and setups.

162. The method of claim 145, wherein the at least one data normalization process includes time series data normalization.

163. The method of claim 162, wherein the time series data normalization includes normalizing data relating to time-varying growth conditions.

164. The method of claim 162, wherein the time series data normalization includes normalizing data relating to variations in a feed profile or fermentation parameter.

165. The method of claim 145, wherein the at least one data normalization process includes knowledge graph-based normalization.

166. The method of claim 165, wherein the knowledge graph-based normalization represents biological entities and relationships in standardized format.

167. The method of claim 165, wherein the knowledge graph-based normalization associates information across a plurality of experiments or organisms.

168. The method of claim 165, wherein the knowledge graph-based normalization integrates a plurality of biological data types.

169. The method of claim 145, wherein the predictive model is a long-short term memory model.

170. The method of claim 145, wherein the predictive model is a transformer model.

171. The method of claim 145, wherein the predictive model is a convolutional neural network model.

172. The method of claim 145, wherein the predictive model is a perceptron model.AI-GUIDED SYNTHETIC BIOLOGY DATA IN KNOWLEDGE GRAPH STRUCTURE TO TRACK DATA PROVENANCE FROM RAW EXPERIMENTAL MEASUREMENT TO PROCESSED VALUE173. A computer-implemented method for data quality assurance in an Al -guided analytic platfonn for development of biologic synthesis processes, comprising: collecting raw experimental data associated with a strain perfonnance measurement; implementing a data normalization and quality' control procedure to process the raw experimental data; validating a genotype of a strain through a data intake process; generating an analytical measure associated with quality control for the experimental data; identifying an outlier in an experimental dataset; maintaining metadata about an experimental condition or processing step; and storing processed and validated data in a knowledge graph structure that tracks data provenance from a raw experimental measurement to a processed value.

174. The method of claim 173, wherein collecting the raw experimental data comprises measuring key metabolites across a population of engineered strains.

175. The method of claim 173, wherein collecting the raw experimental data comprises detecting and flagging anomalous data points through automated quality' control.

176. The method of claim 173, wherein collecting the raw experimental data comprises identifying wells or samples that exhibit contamination or produce readouts outside expected ranges based on historical data.

177. The method of claim 173, wherein the strain performance measurement is an expression level.

178. The method of claim 173, wherein the strain performance measurement is a metabolite concentration.

179. The method of claim 173, wherein the strain performance measurement is grow th rate measurement.

180. The method of claim 173, wherein the strain performance measurement is enzyme activity level.

181. A system for ensuring data quality in an Al-guided analytic platform for development of a biologic synthesis process, comprising: one or more processors; memory' storing instructions that, when executed by the one or more processors, cause the platform to implement a multi-objective optimization sy stem for performing multi-objective optimizations of the biologic synthesis process, wherein the multiobjective optimization system comprises:a data intake and staging pipeline configured to: collect raw data from a plurality of experimental sources; convert the raw data into at least one standardized format; apply a quality assurance step to identify and correct at least one of an error or an inconsistency in the data; apply a normalization technique to remove a batch effect or technical variation; validate that the normalization technique preserves a specified biologic signal; and a knowledge management system configured to: maintain a log and audit trail for a platform data processing activity7; track data lineage from a raw measurement to a processed value; and enable verification of a data processing step to confirm scientific validity.AI-GUIDED SYNTHETIC BIOLOGY DATA INTEGRATION AND HIT IDENTIFICATION PLATFORM182. A method for hit identification in an AI-guided analytic platform for development of biologic synthesis processes, comprising: collecting raw experimental data on strain performance; normalizing the experimental data using a probabilistic approach to generate normalized strain performance data; representing strains as probability distributions over possible performance levels, wherein the probability distributions capture both a point estimate of the strain performance and uncertainty around the estimate; defining a hit based on the probability distributions by determining the strains having a specified probability7of outperforming a parent strain by a predetermined margin; and identifying a promising strain for further investigation based on the defined hit.

183. The method of claim 182, wherein defining the hit comprises setting a threshold for minimum performance improvement over the parent strain.

184. The method of claim 182, wherein defining the hit comprises calculating a probability that each strain exceeds a threshold.

185. The method of claim 182, wherein defining the hit comprises ranking strains based on their full performance distribution rather than point estimates.

186. A method for hit identification in an AI-guided analytic platform for development of biologic synthesis processes, comprising: one or more processors; and memory7storing instructions that, when executed by the one or more processors, cause the platform to implement a multi-objective optimization system for performing multi-objective optimizations of the biologic synthesis processes, wherein the multiobjective optimization system comprises: performing data quality assurance on experimental strain performance data; applying a Bayesian data normalization process to the experimental strain performance data;generating probability distributions representing strain performance and associated uncertainty for a plurality of strains; identifying hits by comparing the probability distributions to at least one defined performance threshold, wherein the hits comprise strains exhibiting improved performance regarding a performance criterion relative to a reference strain; and outputting the identified hits for further optimization and investigation.

187. The method of claim 186, wherein the data quality assurance includes collecting metadata about experimental conditions.

188. The method of claim 186, wherein the data quality assurance includes tracking data provenance from raw measurements through processing steps.

189. The method of claim 186, wherein the data quality assurance includes identifying and correcting errors or inconsistencies in the data.

190. A system for integrating synthetic biology data in an Al-guided analytic platform for development of a biologic synthesis process, comprising: one or more processors; and memory' storing instructions that, when executed by the one or more processors, cause the platform to implement a multi -objective optimization system for performing multi-objective optimizations of biologic synthesis processes, wherein the multi-objective optimization system comprises: a data intake and staging pipeline configured to: collect biologic data from a plurality of data sources; integrate the collected biologic data into a computationally appropriate form; normalize the integrated biologic data using batch effect correction; validate quality and consistency of the normalized biologic data; and store the validated biologic data in a structured format describing relationships between biologic entities; and a machine learning model configured to analyze the stored validated biologic data to generate at least one prediction for synthetic biology system design.

191. The system of claim 190, wherein the structured data format is a bipartite graph database structure.

192. The system of claim 191, wherein the bipartite graph database structure organizes data into at least one molecule node and at least one process node.

193. The system of claim 192, wherein the at least one molecule node represents at least one of molecules, atomic elements, ions, compounds, nucleic acids, proteins, or macromolecules.

194. The system of claim 192, wherein the at least one process node represents at least one of chemical reactions, protein folding, transport, regulator ' interactions, or active site binding.

195. The system of claim 192, wherein connections between nodes indicate roles that create the relationships between a molecule and a process.

196. The system of claim 190. wherein the structured data format is non-relational database format.

197. The system of claim 190. wherein the structured data format is a knowledge graph structure.DATA NORMALIZATION198. A computer-implemented method for normalizing synthetic biology data in an Al-guided analytic platform for development of biologic synthesis processes, comprising: receiving experimental data associated with synthetic biology development from a plurality of sources; performing a data quality assurance on the received experimental data to identify at least one anomalous data point; applying a Bayesian statistical normalization model to the experimental data to: model a batch-specific systemic variation; account for a technical factor contributing to a batch effect; separate a biologic signal from the technical factor; and generate normalized synthetic biology data; and outputting the normalized synthetic biology data for use in a machine learning application.

199. The method of claim 198, wherein performing the data quality assurance comprises detecting a well or sample that failed to grow properly.The method of claim 198, wherein performing the data quality assurance comprises identifying samples exhibiting contamination.The method of claim 198, wherein performing the data quality assurance comprises flagging a readout that fall outside an expected range based on historical data for a similar strain.

200. The method of claim 198, wherein performing the data quality assurance comprises identify ing a potential measurement error or mislabel in the experimental data.

201. The method of claim 198, wherein modeling the batch-specific systemic variation comprises constructing a plate notation model representing at least one strain effect.

202. The method of claim 198, wherein modeling the batch-specific systemic variation comprises constmcting a plate notation model representing at least one experimental effect.

203. The method of claim 198, wherein modeling the batch-specific systemic variation comprises constructing a plate notation model representing at least one plate-to-plate variation.

204. The method of claim 198, wherein modeling the batch-specific systemic variation comprises constructing a plate notation model representing at least one plate lot effect.

205. The method of claim 198, wherein modeling the batch-specific systemic variation comprises constructing a plate notation model representing at least one position effect of a sample on a plate.

206. The method of claim 198, wherein a plate notation model provides a formal representation of at least one factor contributing to observed data.

207. A system for normalizing synthetic biology experimental data in an Al-guided analytic platform for development of a biologic synthesis process, comprising: one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the platform to implement a multi-objective optimization system for performing multi-objective optimizations of the biologic synthesis process, wherein the multiobjective optimization system comprises: intake raw experimental data from a plurality of synthetic biologyexperiments; apply a quality control process to identify an anomalous experimental data point; construct a hierarchical Bayesian model representing: a strain performance measurement; an experimental variability factor; and a batch effect; fit the hierarchical Bayesian model to the experimental data to infer underlying strain performance while accounting for at least one confounding factor; generate at least one uncertainty estimate for a nonnalized performance value; and output nonnalized experimental data with associated uncertainty estimates.

208. The system of claim 207, wherein the qualify control process comprises analyzing repeated measurements of strains across multiple plates.

209. The system of claim 207, wherein the qualify- control process comprises identify ing a strain exhibiting inconsistent behavior when measured multiple times.

210. The system of claim 207, wherein the quality control process comprises detecting a systematic variation between a plurality of experimental runs of genetically identical strains.

211. The system of claim 207, wherein the qualify control process comprises flagging data points where strain performance variance exceeds an expected threshold.

212. The system of claim 207, wherein constructing the hierarchical Bayesian model comprises incorporating prior data relating to expected strain behavior.

213. The system of claim 207, wherein constructing the hierarchical Bayesian model comprises modeling multiple sources of experimental variability.

214. The system of claim 207, wherein constructing the hierarchical Bayesian model comprises representing relationships between a small-scale and a large-scale experiment.

215. The system of claim 207, wherein constructing the hierarchical Bayesian model comprises generating at least one probability distribution that captures uncertainty in strain performance measurements.DATA BATCH EFFECTS AND ITERATIVE SPLITTING216. A computer-implemented method for handling batch effects in an Al -guided analytic platform for development of a biologic synthesis process, comprising: receiving biologic experimental data from a plurality’ of experiments; detecting a systematic variation between the experiments that is not related to a biologic factor of interest; applying a data normalization technique to minimize batch-specific systemic variation while preserving underlying biologic signals; generating probability’ distributions representing experimental outcomes to provide a summary’ of uncertainty7; using a machine learning model to identify and correct batch effects directly from the data without requiring explicit modeling of all possible sources of variation; and outputting normalized biologic data with reduced batch effects for use in strain engineering.

217. A method for managing batch effects in synthetic biology experiments in an Al-guided analytic platform for development of a biologic synthesis process, comprising: one or more processors; and memory’ storing instructions that, when executed by the one or more processors, cause the platform to implement a multi-objective optimization system for performing multi-objective optimizations of biologic synthesis processes, wherein the multi-objective optimization system comprises: collect raw experimental data on strain performance across a plurality of experiments; implement a data normalization and qualify control process to address variability' between experiments of genetically identical strains; represent hits and non-hits as probability’ distributions; allow definition of at least one threshold for hit identification; apply an iterative splitting process to account for variation between constructs with identical genetic makeup; and output batch-effect corrected data suitable for machine learning model training and strain optimization.

218. A computer-implemented method for iterative splitting in synthetic biology development in an Al-guided analytic platform for development of biologic synthesis processes. comprising: receiving data associated with sequences having identical genetic makeup but exhibiting different behaviors; initially labeling constructs with identical sequences as distinct entities; fitting a probabilistic model to observations of the constructs, wherein the model accounts for experimental conditions and measurement techniques that influence construct behavior;processing the data through a data quality assurance pipeline to identify and validate variations between genetically identical constructs; and generating normalized data across different experimental sources based on a probabilistic batch correction model.

219. The method of claim 218, further comprising: identifying an observation that is unlikely to have been generated by a current probabilistic batch correction model; splitting the identified observation into separate entries with independent parameters; and refitting the probabilistic batch correction model after each splitting iteration.

220. The method of claim 218, wherein fitting the probabilistic batch correction model comprises starting with a prior parameter that assumes constructs with identical sequences have identical activity.

221. The method of claim 218, wherein fitting the probabilistic batch correction model comprises requiring empirical evidence to override a prior parameter.

222. The method of claim 218, wherein fitting the probabilistic batch correction model comprises adjusting at least one model parameter based on an observed variation between identical sequences.

223. A system for iterative data processing in synthetic biology development in an Al-guided analytic platform for development of biologic synthesis processes, comprising: one or more processors; memory’ storing instructions that, when executed by the one or more processors, cause the system to: receive biologic sequencing data containing systemic variation across multiple batches; implement an iterative splitting process that: identifies constructs with identical genetic sequences exhibiting different behaviors; labels the identified constructs as separate entities; applies a probabilistic model to account for experimental condition variations; flags observations that deviate from predicted model behavior to identify potential measurement errors or data inconsistencies; and generate normalized datasets that account for validated variations between genetically identical constructs while maintaining data quality assurance.

224. The system of claim 223, wherein implementing the iterative splitting process further comprises: maintaining sufficient anchor points between datasets to enable data combination across experimental sites; identifying when anchor points exhibit significantly different behaviors; and adjusting at least one model parameter to account for a validated difference while preserving ability- to combine datasets.

225. The system of claim 223, wherein the instructions further cause the system to: estimate a scaffold parameter based on a validated construct variation; use the estimated scaffoldparameter to calculate a more accurate expression estimate for a strain; and update the probabilistic model based on a refined expression estimate.

226. The system of claim 223. wherein flagging observations that deviate from predicted model behavior comprises: identifying a vertical outlier in a model fit visualization; calculating a probability assignment for each observation; and selecting an observation with a low probability assignment as a candidate for splitting.TRAINING MODELS WITH SPECIALIZED DATA (GENE EXPRESSION, REACTION FLUX,METABOLITE LEVELS)227. A computer-implemented method for training artificial intelligence models with specialized biologic data in an Al-guided analytic platform for development of a biologic synthesis process, comprising: collecting multimodal biologic data including at least one of a gene expression level, mRNA, metabolic reaction fluxes, or intracellular metabolite concentrations from biologic systems; processing the collected biologic data through data normalization and quality assurance steps to create model-ready data; and generating at least one output predicting an effect of genetic modification on a metabolite level or a reaction flux.

228. The method of claim 227, wherein the nonnalized biologic data is converted from a first structured format to a second format suitable for model training.

229. The method of claim 227, wherein one or more artificial intelligence models is trained using the model -ready data to predict a cellular phenotype based on a genetic perturbation.

230. The method of claim 229, wherein training the one or more artificial intelligence models comprises: using a knowledge graph to represent biological entities as nodes; representing relationships between entities as edges; and capturing biological relationships in a format appropriate for use by machine learning algorithms.

231. The method of claim 227, wherein collecting multimodal biological data comprises: obtaining RNA sequencing data for genome-wide gene expression levels; measuring metabolic reaction fluxes; and collecting metabolite concentration data using mass spectrometry.

232. The method of claim 231 , wherein the mass spectrometry is liquid chromatography-mass spectrometry.

233. The method of claim 231, wherein the mass spectrometry is gas chromatography-mass spectrometry.

234. The method of claim 227, wherein processing the collected multimodal biological data comprises: identifying and correcting batch-specific systemic variation: standardizing nomenclature across different data sources; and correcting for missing data to ensure consistency across experimental setups.

235. A system for specialized biologic data processing and model training in an Al-guided analytic platform for development of a biologic synthesis process, comprising:one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the platform to implement a multi-objective optimization system for performing multi-objective optimizations of biologic synthesis processes, wherein the multi-objective optimization system comprises: a data collection system configured to collect time-resolved metabolomics data from living cells; and a data processing pipeline configured to: integrate multiple ty pes of high-dimensional biologic data; normalize and correct batch effects in the biologic data; and transform the biologic data into a format suitable for machine learning.

236. The system of claim 235, wherein the data collection system is a rapid sampling system.

237. The system of claim 236, wherein the rapid sampling system comprises: automated sampling mechanisms for collecting standardized samples; near-instantaneous quenching of cellular metabolism; and integration with liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry for metabolite analysis.

238. The system of claim 235, wherein one or more artificial intelligence models are trained in processed data to predict a cellular phenotype.

239. The system of claim 235, wherein the data processing pipeline is further configured to: track data lineage from a raw experimental measurement to a processed value; maintain detailed metadata about experimental conditions; and validate a normalization method using a control sample.

240. The system of claim 235, wherein integrating multiple ty pes of high-dimensional biological data comprises: combining gene expression data from RNA sequencing; incorporating flux data from an isotope-labeled experiment; and merging a metabolite concentration measurement from mass spectrometry'.

241. A system for training specialized biologic models in an Al-guided analytic platform for development of biologic synthesis processes, comprising instructions that when executed cause a processor to: collect multimodal biologic data; process the collected multimodal biologic data through quality' assurance steps to identify and correct errors or inconsistencies; employ multi-modal deep learning architectures with a separate encoding branch for different data modalities; combine encoded representations through fusion layers; and generate a prediction about cellular phenotypes based on the processed multimodal biologic data.

242. The system of claim 241, wherein the multimodal biologic data derives from at least one integrated sensor.

243. The system of claim 241, wherein the multimodal biologic data derives from at least one automated sampling system.

244. The system of claim 241, wherein the multi-modal deep learning architectures comprise: the separate encoding branches for gene expression data; dedicated pathways for metabolite profile processing; and specialized branches for reaction flux analysis.

245. The system of claim 241, wherein processing the collected multimodal biologic data comprises: applying batch effect correction across experimental runs; normalizing data across different organisms and conditions; and ensuring data consistency for machine learning applications.

246. The system of claim 241, wherein generating the prediction comprises: evaluating effects of genetic modifications on metabolic pathways; predicting changes in metabolite concentrations; and estimating reaction flux distributions in response to genetic perturbations.

247. The system of claim 241, wherein the multi-modal deep learning architecture is at least one of a feed forward neural network, a feedback neural network, a convolutional neural network, a gated recurrent neural network, a long short-term memory network, a transformer model, a foundation model, a large language model, a single and multi-layer perceptron network, a recurrent neural network, a dual-process artificial neural network, a radial basis function neural network, a self-organizing neural network, a modular neural network, a physical neural network, multi-layered neural network, an autoencoder neural network, a probabilistic neural network, a time delay neural network, a regulatory feedback neural network, a hopfield neural network, boltzmann machine neural network, self-organizing map (SOM) neural network, a learning vector quantization (LVQ) neural network, an echo state neural netw ork, a bi-directional neural network, hierarchical neural network, a stochastic neural netw ork, a genetic scale RNN neural netw ork, a committee of machines neural network, an associative neural network, an instantaneously trained neural network, a spiking neural network, a neocognitron neural network, a dynamic neural netw ork, a cascading neural network, a neuro-fuzzy neural network, a compositional pattern-producing neural netw ork, a memory neural netw ork, a hierarchical temporal memory neural network, a deep feed forward neural network, a gated recurrent unit neural network, a variational auto encoder neural netw ork, a de-noising auto encoder neural netw ork, a sparse auto-encoder neural network, a markov chain neural network, a restricted boltzmann machine neural netw ork. a deep belief neural netw ork, a deep convolutional neural network, a de-convolutional neural network, a deep convolutional inverse graphics neural network, a generative adversarial neural network, a liquid state machine neural network, a extreme learning machine neural network, a deep residual neural network, a neural turing machine neural network, or a holographic associative memory neural network.

248. The system of claim 247, wherein the multi-modal deep learning architecture is a combination of a plurality of multi-modal deep learning architectures.GENETIC GENERALIZATION MODEL TRAINED TO PREDICT PERFORMANCE OF A STRAIN BASED ON TRAINING DATA249. A method for predicting performance associated with genetic edits, the method comprising: receiving, by a platform, information about a strain of a microorganism, wherein the information about the strain comprises infomiation describing a plurality of genetic edits to a base strain of the microorganism; generating, by the platform, a set of genetic embeddings based on the information about the strain, wherein the generating comprises processing the information about the strain using one or more embedding models, wherein each of the one or more embedding models: receives the information about the strain of the microorganism as input; and applies computational transformations to the input using a corresponding embedding model to generate a multi-dimensional vector representation for each of the plurality of genetic edits, wherein each multi-dimensional vector representation generated by the one or more embedding models is added to the set of genetic embeddings; and generating, by the platform, a performance prediction for the strain based on inputting the set of genetic embeddings to a pre-trained model, wherein the pre-trained model is a neural network trained to generate the performance prediction based on training data including. information about genetic edits corresponding to a plurality of strains of the microorganism; and target data indicating a performance for each of the plurality of strains of the microorganism, wherein the pre-trained model applies computational transfonnations to the set of genetic embeddings to generate the performance prediction.

250. The method of claim 249, wherein the one or more embedding models include two or more of a GenePT model, a Proteinfer model, a pFBA-PCA model, or a GO-PCA model, the method further comprising aggregating each of the multi-dimensional vector representations generated by the two or more embedding models to create the set of genetic embeddings.

251. The method of claim 250, wherein each token of the set of genetic embeddings corresponds to a genetic edit of the plurality of genetic edits.

252. The method of claim 249, wherein the pre-trained model comprises a first stage that generates a strain embedding characterizing the strain of the microorganism and a second stage that generates the performance prediction based on the strain embedding.

253. The method of claim 252, wherein the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model.

254. The method of claim 252, wherein the second stage is a multi-layer perceptron.

255. The method of claim 249, wherein the performance prediction comprises at least one of a predicted growth rate, a predicted metabolite production rate, a predicted byproduct formation rate, or a predicted protein expression level.

256. The method of claim 249, further comprising receiving process condition information, wherein the pre-trained model is trained to predict performance with respect to a set of process conditions as indicated by process inputs, and wherein generating the performance prediction for the strain is further based on process inputs corresponding to the process condition information.

257. The method of claim 256, wherein the process condition infonnation comprises at least one of bioreactor volume, temperature, pH, oxygen levels, or substrate concentrations.

258. The method of claim 249, wherein the pre-trained model is trained using a process including, pre-training the model using the training data; and fine-tuning the model using additional strain-specific data, wherein the training data is a larger data set compared to the additional strain-specific data.

259. The method of claim 249, further comprising updating the pre-trained model using an active learning process including, generating a set of candidate genetic modifications; generating a corresponding performance prediction for each of the set of candidate genetic modifications using the pre-trained model; receiving experimental data associated with at least a portion of the set of candidate genetic modifications; updating the training data using the experimental data; and re-training the pre-trained model using the updated training data.

260. The method of claim 259, further comprising determining which portion of the set of genetic modifications to test via experiment based at least in part on an uncertainty quantification generated by the pre-trained model.2 1. The method of claim 249, wherein the pre-trained model is an ensemble of multiple pretrained models.

262. The method of claim 249, wherein the set of genetic embeddings captures functional relationships between genes and metabolic pathways.

263. The method of claim 249, wherein the pre-trained model is trained to predict performance across multiple strains of different microorganisms.

264. The method of claim 249, wherein the information about the strain comprises information about the base strain.

265. The method of claim 249, wherein the information about the strain comprises information about genetic edits to the base strain, wherein the information about genetic edits comprises information indicating that each genetic edit is at least one of a gene knockout, a gene overexpression, or a gene underexpression.

266. The method of claim 249, wherein generating the set of genetic embeddings occurs at prediction time.

267. The method of claim 249, wherein generating the set of genetic embeddings occurs prior to training, the method further comprising caching the generated set of genetic embeddings for later use at prediction time.PRE-TRAINED GENETIC GENERALIZATION MODEL APPLIED TO SET OF EDITS268. A method for predicting performance associated with genetic edits, the method comprising: receiving, by a platform, information about a biologic product; generating, by the platform, a set of representations based on the information about the biologic product; generating, by the platform, a set of edits of the biologic product based on the set of representations; and generating, by the platform, a performance prediction for each edit of the set of edits of the biologic product based on a pre-trained genetic generalization model applied to each edit of the set of edits.

269. The method of claim 268, wherein the information about the biologic product further comprises information describing a plurality of genetic edits to the biologic product.

270. The method of claim 268, wherein the set of representations further comprises a set of embeddings based on the information about the biologic product, the generating comprises processing the information about the biologic product using one or more embedding models, and each of the one or more embedding models: receives the information about the biologic product as input; and applies computational transformations to the input using a corresponding embedding model to generate a multi-dimensional vector representation for each of the set of edits, wherein each multi-dimensional vector representation generated by the one or more embedding models is added to the set of embeddings.

271. The method of claim 270, wherein the performance prediction of the biologic product is based on inputting the set of embeddings to the pre-trained genetic generalization model, wherein the pre-trained genetic generalization model includes at least one a neural network trained to predict performance of the biologic product based on training data including, information about a plurality of edits; and target data indicating a performance of each of the set of edits of the biologic product, wherein the pre-trained genetic generalization model applies computational transformations to the set of embeddings to generate the performance prediction.

272. The method of claim 270, wherein the one or more embedding models include two or more of, a GenePT model, a Proteinfer model, a pFBA-PCA model, or a GO-PCA model, the method further comprising aggregating the multi-dimensional vector representations generated by the two or more embedding models to create the set of embeddings.

273. The method of claim 270, wherein each token of the set of embeddings corresponds to an edit of the set of edits.

274. The method of claim 270, wherein the set of embeddings captures functional relationships between genes and metabolic pathways.

275. The method of claim 270, wherein generating the set of embeddings occurs at prediction time.

276. The method of claim 270, wherein generating the set of embeddings occurs pnor to training, the method further comprising caching the generated embeddings for later use at prediction time.

277. The method of claim 268, wherein the pre-trained genetic generalization model comprises a first stage that generates a strain embedding characterizing the biologic product and a second stage that generates the performance prediction based on the strain embedding.

278. The method of claim 277, wherein the first stage is one or more of a long-short term memory' (LSTM) model, a transformer model, or a convolutional neural network (CNN) model.

279. The method of claim 277, wherein the second stage is a multi-layer perceptron.

280. The method of claim 268, wherein the performance prediction comprises at least one of a predicted growth rate, a predicted metabolite production rate, a predicted byproduct formation rate, or a predicted protein expression level.

281. The method of claim 268, further comprising receiving process condition information, wherein the pre-trained genetic generalization model is trained to predict performance with respect to a set of process conditions as indicated by process inputs, and wherein generating the performance prediction for each edit of the set of edits of the biologic product is further based on process inputs corresponding to the process condition information.

282. The method of claim 281, wherein the process condition information comprises at least one of bioreactor volume, temperature, pH, oxygen levels, or substrate concentrations.

283. The method of claim 268, wherein the pre-trained genetic generalization model is trained using a two-step process including, pre-training the genetic generalization model using training data; and fine-tuning the genetic generalization model using additional strain-specific data, wherein the training data is a larger data set compared to the strain-specific data.

284. The method of claim 268, further comprising updating the pre-trained genetic generalization model using an active learning process including, generating a set of candidate genetic modifications; generating a corresponding performance prediction for each of the set of candidate genetic modifications using the pre-trained genetic generalization model; receiving experimental data associated with at least a portion of the set of candidate genetic modifications; updating training data using the experimental data; and re-training the pre-trained genetic generalization model using the updated training data.

285. The method of claim 284, further comprising determining which portion of the set of genetic modifications to test via experiment based at least in part on an uncertainty quantification generated by the pre-trained genetic generalization model.

286. The method of claim 268, wherein the pre-trained generalization model is an ensemble of multiple pre-trained genetic generalization models.

287. The method of claim 268, wherein the pre-trained genetic generalization model is trained to predict performance across multiple strains of different microorganisms.

288. The method of claim 268, wherein the information about the biologic product comprises information about a base strain of the biologic product.

289. The method of claim 268, wherein the information about the biologic product comprises information about genetic edits to a base strain of the biologic product, wherein the infonnation about genetic edits comprises information indicating that each genetic edit is at least one of a gene knockout, a gene overexpression, or a gene underexpression.

290. A platform comprising: one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the platform to perform steps including, receiving information about a strain of a microorganism, wherein the information about the strain comprises information describing a plurality of genetic edits to a base strain of the microorganism, generating a set of genetic embeddings based on the information about the strain, wherein the generating comprises processing the information about the strain using one or more embedding models, wherein each of the one or more embedding models, receives the information about the strain of the microorganism as input; and applies computational transformations to the input using a corresponding embedding model to generate a multi-dimensional vector representation for each of the plurality of genetic edits, wherein each multi-dimensional vector representation generated by the one or more embedding models is added to the set of genetic embeddings, and generating a performance prediction for the strain based on inputting the set of genetic embeddings to a pre-trained genetic generalization model, wherein the pre-trained genetic generalization model is a neural network trained to predict a performance of a strain based on training data including, information about a plurality of genetic edits, and target data indicating a performance of each of a plurality of strains of the microorganism, wherein the pre-trained genetic generalization model applies computational transformations to the set of genetic embeddings to generate the performance prediction. COMPARATIVE ANALYSIS APPROACHES TO SELECT BIOLOGIC PRODUCTS BASED ON BIOLOGICAL PARENTS291. A method of generating a biologic product of a biologic synthesis process, comprising: selecting a first biologic parent having a first feature; selecting a second biologic parent having a second feature; and selecting the biologic product based on an evaluation of a set of combinations of the first biologic parent and the second biologic parent.

292. The method of claim 291, wherein the biologic product includes at least one of an enzyme protein, a non-enzyme protein, a DNA sequence, an RNA sequence, a plasmid, a metabolite, a biologic strain, a bioreactor process, or a downstream purification process.

293. The method of claim 291, wherein the biologic synthesis process includes at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

294. The method of claim 291, wherein at least one of the first feature or the second feature includes at least one of a product expression feature, a product activation feature, a product reaction feature, an enzyme cleaning feature, a product stabi 1 i ty feature, a product biocompatibility feature, a process rate feature, a process catalyzation rate feature, a process efficiency feature, a process cost feature, or a process yield feature.

295. The method of claim 291, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes conserving a distance of the set of combinations relative to the first biologic parent.

296. The method of claim 295, wherein the distance includes at least one of an edit distance between the first biologic parent and each combination, a number of edits between the first biologic parent and each combination, a degree of edits between the first biologic parent and each combination, a difference between a measure of the first feature of each combination relative to a measurement of the first feature of the first biologic parent, a structural feature of each combination relative to a corresponding structural feature of the first biologic parent, or a viability score of each combination relative to a corresponding viability score of the first biologic parent.

297. The method of claim 291, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes selectively evaluating combinations that at least maintain the first feature of the first biologic parent.

298. The method of claim 291, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes selectively evaluating combinations based on a measurement of the second feature.

299. The method of claim 291, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes for a respective combination of the first biologic parent and the second biologic parent, jointly measuring the first feature of the respective combination and the second feature of the respective combination.

300. The method of claim 299, wherein jointly measuring the first feature of the respective combination and the second feature of the respective combination includes. determining the first feature of the respective combination according to a first dimension of an evaluation space, determining the second feature of the respective combination according to a second dimension of the evaluation space, andevaluating the respective combination according to a vector representation in the evaluation space, wherein the vector representation is based on the first feature according to the first dimension of the evaluation space and the second feature according to the second dimension of the evaluation space.

301. The method of claim 299, wherein jointly measuring the first feature of the respective combination and the second feature of the respective combination includes. generating a weighted evaluation of the first feature of the respective combination according to a first weight associated with the first feature, generating a weighted evaluation of the second feature of the respective combination according to a second weight associated with the second feature, and evaluating the respective combination according to a combination of the weighted evaluation of the first feature and the weighted evaluation of the second feature.

302. The method of claim 291, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes evaluating a respective combination of the first biologic parent and the second biologic parent based on at least one of: a first evaluation threshold of the first feature of the respective combination, or a second evaluation threshold of the second feature of the respective combination.

303. The method of claim 291, wherein the evaluation includes at least one of: a measurement of an edit distance between a respective combination and at least one of the first biologic parent or the second biologic parent, a measurement of the first feature of the respective combination and a corresponding measurement of the first feature of the first biologic parent, a measurement of the second feature of the respective combination and a corresponding measurement of the second feature of the second biologic parent, or a measurement of a third feature of the respective combination and a corresponding measurement of the third feature of at least one of the first biologic parent or the second biologic parent.

304. The method of claim 291, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes, generating a representation of a portion of a respective combination according to a biologic product language, and evaluating the representation of the portion of the respective combination according to the biologic product language.

305. The method of claim 304, wherein the biologic product language includes a protein language, and evaluating the representation includes evaluating the representation of the portion of the respective combination in the protein language according to a protein language model.

306. The method of claim 291, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes evaluating the set of combinations according to a ranking order of the set of combinations.

307. The method of claim 306, wherein the evaluation of the set of combinations according to the ranking order of the set of combinations includes, for a respective combination, determining a score based on a comparison between the respective combination and at least one of the first biologic parent or the second biologic parent, and determining the ranking order based on the score of the respective combination.

308. The method of claim 306, wherein evaluating the set of combinations according to the ranking order includes: selecting, from the set of combinations, a first set of candidate combinations based on the ranking order; evaluating the first set of candidate combinations based on at least one of the first feature of respective combinations of the first set of candidate combinations and the second feature of respective combinations of the first set of candidate combinations; and based on evaluating the first set of candidate combinations, selecting a second set of candidate combinations for evaluation.

309. The method of claim 308, wherein evaluating the first set of candidate combinations includes at least one of evaluating a simulation of respective combinations of the first set of candidate combinations, or evaluating an experimental result of respective combinations of the first set of candidate combinations.

310. The method of claim 308, wherein the second set of candidate combinations includes at least one of at least one variant of at least one candidate combination of the first set of candidate combinations, or at least one combination of the set of combinations that is not included in the first set of candidate combinations.

311. The method of claim 308, wherein the first set of candidate combinations includes at least two alternative variants of the first biologic parent having an edit location, wherein each of the at least two alternative variants includes a different edit of the edit location.

312. The method of claim 308, wherein the first set of candidate combinations includes at least one combination that includes a single edit of the first biologic parent, and the second set of candidate combinations includes at least one combination that includes at least two edits of the first biologic parent.

313. The method of claim 291, wherein at least one feature of the biologic product is based on at least one of a technical feature or an economic feature, and the evaluation of a set of combinations of the first biologic parent and the second biologic parent includes a techno- economic analysis of the at least one feature for the set of combinations.

314. The method of claim 291, wherein selecting the biologic product based on an evaluation of a set of combinations of the first biologic parent and the second biologic parent increases anumber of determined combinations that improve at least one of the first feature of the first biologic parent or the second feature of the second biologic parent.COMPARATIVE ANALYSIS APPROACHES TO SELECT BIOLOGIC PRODUCTS BASED ON TWO OBJECTIVES FOR VARIANTS OF BIOLOGICAL PARENT315. A method of generating a biologic product of a biologic synthesis process, comprising: selecting at least two obj ectives of the biologic product; selecting a biologic parent of the biologic product; and detennining the biologic product based on an evaluation of the at least two objectives for a set of variants of the biologic parent.

316. The method of claim 315, wherein the biologic synthesis process includes at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

317. The method of claim 315, wherein the biologic product includes at least one of an enzyme protein, a non-enzyme protein, a DNA sequence, an RNA sequence, a plasmid, a metabolite, a biologic strain, a bioreactor process, or a downstream purification process.

318. The method of claim 315, wherein the at least two objectives includes at least one of an product expression objective, a product activation objective, a product reaction objective, an enzyme cleaning objective, a product stability objective, a product biocompatibility objective, a process rate objective, a process catalyzation rate objective, a process efficiency objective, a process cost objective, or a process yield objective.

319. The method of claim 315, wherein the biologic product includes a variant of the biologic parent having an edit distance that is within an edit distance threshold of the biologic parent.

320. The method of claim 315, wherein the evaluation of the set of variants includes conserving a distance of the set of variants relative to the biologic parent.

321. The method of claim 320, wherein the distance includes at least one of an edit distance between the biologic parent and each variant, a number of edits between the biologic parent and each variant, a degree of edits between the biologic parent and each variant, a difference between a measurement of an objective of the at least two objectives of each variant relative to a corresponding measurement of the objective of the biologic parent, a structural feature of each variant relative to a corresponding structural feature of the biologic parent, or a viability score of each variant relative to a corresponding vi abi 1 i ty score of the biologic parent.

322. The method of claim 315, wherein the evaluation of the set of variants of the biologic parent includes selectively evaluating variants that at least maintain at least one of the at least two objectives relative to the biologic parent.

323. The method of claim 315, wherein the evaluation of the set of variants of the biologic parent includes, for a respective variant of the biologic parent, j ointly measuring each of the at least two objectives of the respective variant.

324. The method of claim 323, wherein jointly measuring each of the at least two objectives of the respective variant includes:determining a first objective of the at least two objectives for the respective variant according to a first dimension of an evaluation space, determining a second objective of the at least two objectives for the respective variant according to a second dimension of the evaluation space, and evaluating the respective variant according to a vector representation in the evaluation space, wherein the vector representation is based on a first objective of the at least two objectives according to the first dimension of the evaluation space and the second objective according to the second dimension of the evaluation space.

325. The method of claim 324, wherein jointly measuring the first objective of the respective variant and the second objective of the respective variant includes, generating a weighted evaluation of the first objective of the at least two objectives for the respective variant according to a first weight associated with the first objective, generating a weighted evaluation of the second objective of the at least two objectives for the respective variant according to a second weight associated with the second objective, and evaluating the respective variant according to a combination of the weighted evaluation of the first objective and the weighted evaluation of the second objective.

326. The method of claim 325, wherein the evaluation of the respective variant of the biologic parent includes evaluating a respective variant of the biologic parent based on an evaluation threshold of at least one objective of the at least two objectives for the respective variant.

327. The method of claim 325, wherein the evaluation of the respective variant includes at least one of a measurement of an edit distance between a respective variant and the biologic parent, or a measurement of an objective of the at least two objectives of the respective variant and a corresponding measurement of the objective of the biologic parent.

328. The method of claim 325, wherein the evaluation of the set of variants of the biologic parent includes, generating a representation of a portion of a respective variant according to a biologic product language, and evaluating the representation of the portion of a respective variant according to the biologic product language.

329. The method of claim 328, wherein the biologic product language includes a protein language, and evaluating the representation includes evaluating the representation of the portion of the respective variant in the protein language according to a protein language model.

330. The method of claim 315, wherein the evaluation of the set of variants of the biologic parent includes evaluating the set of variants according to a ranking order of the set of variants.

331. The method of claim 330, wherein the evaluation of the set of variants according to the ranking order of the set of variants includes, for a respective variant of the set of variants, determining a score based on a comparison between the respective variant and the biologic parent, and determining the ranking order based on the score of the respective variant.

332. The method of claim 330, wherein evaluating the set of variants according to the ranking order includes. selecting, from the set of variants, a first set of candidate variants based on the ranking order; evaluating the first set of candidate variants based on each of at least two objectives of respective variants of the first set of candidate variants; and based on evaluating the first set of candidate variants, selecting a second set of candidate variants for evaluation.

333. The method of claim 332, wherein evaluating the first set of candidate variants includes at least one of: evaluating a simulation of respective variants of the first set of candidate variants, or evaluating an experimental result of respective variants of the first set of candidate variants.

334. The method of claim 332, wherein the second set of candidate variants includes at least one of at least one further variant of at least one variant of the first set of candidate variants, or at least one variant of the set of variants that is not included in the first set of candidate variants.

335. The method of claim 332, wherein the first set of candidate variants includes at least two alternative variants of the biologic parent having an edit location, wherein each of the at least two alternative variants includes a different edit of the edit location.

336. The method of claim 332, wherein the first set of candidate variants includes at least one variant that includes a single edit of the biologic parent, and the second set of candidate variants includes at least one variant that includes at least two edits of the biologic parent.

337. The method of claim 315, wherein selecting the biologic product based on an evaluation of a set of variants of the biologic parent increases a number of determined variants that improve at least one of the at least two objectives relative to the biologic parent.MULTI-OBJECTIVE OPTIMIZATION338. An Al-guided analytic platform for development of biologic synthesis processes, comprising: a multi-objective optimization system for performing multi-objective optimizations of the biologic synthesis processes; at least one multi-objective evaluation artificial intelligence model configured to evaluate a biologic product according to each of at least two objectives; and at least one variant evaluation module configured to, generate a set of variants of a biologic parent of the biologic product, and evaluate each variant of the set of variants of the biologic parent using the at least one multi-objective evaluation artificial intelligence model.

339. The Al-guided analytic platform of claim 338, wherein the biologic synthesis processes include at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesisprocess, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

340. An Al-guided analytic platform for development of biologic synthesis processes, comprising: one or more processors; and memory' storing instructions that, when executed by the one or more processors, cause the Al-guided analytic platform to implement a multi-objective optimization system for performing multi-objective optimizations of the biologic synthesis processes, and the multi-objective optimization system includes at least one biologic synthesis simulation system that is configured to evaluate multiple objectives of the biologic synthesis processes based on simulation of the biologic synthesis processes.

341. The Al-guided analytic platform of claim 340, wherein the biologic synthesis processes include at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

342. The Al-guided analytic platform of claim 340, further comprising a set of machine learning systems, a set of artificial intelligence systems, and / or a set of neural networks configured to simultaneously’ optimize a microbe, a bioreactor process, and a downstream purification process.

343. The Al-guided analytic platform of claim 340. further comprising a set of machine learning systems, a set of artificial intelligence systems, and / or a set of neural networks configured to maximize production without minimizing growth.

344. The Al-guided analytic platform of claim 340, further comprising a set of machine learning systems, a set of artificial intelligence systems, and / or a set of neural networks configured to increase expression without loss of activity'.

345. The Al-guided analytic platform of claim 340, wherein the multi-objective optimization system is further configured to design towards a property using a protein language model.

346. The Al-guided analytic platform of claim 340, further comprising a comparative analysis system configured to determine a set of genetic modifications to make to a first protein such that the first protein exhibits one or more features of a second protein while maintaining one or more features of the first protein.

347. The Al-guided analytic platform of claim 340, further comprising a comparative analysis system configured to detennine a genetic sequence similarity between a first protein and a second protein.

348. The Al-guided analytic platform of claim 340. further comprising a comparative analysis system configured to detennine which residue positions differ between a first protein and a second protein.

349. The Al-guided analytic platform of claim 340, further comprising a comparative analysis system configured to generate a set of mutants of a protein based on each differing residue position between a first protein and a second protein.

350. The Al-guided analytic platform of claim 340, further comprising a comparative analysis system configured to generate a set of mutants of a protein based on each differing residue position between a first protein and a second protein and having a set of protein language models that embed the set of mutants and calculate an embedding distance of each mutant to both proteins.

351. The Al-guided analytic platform of claim 340, further comprising a comparative analysis system configured to generate a set of mutants of a protein based on each differing residue position between a first protein and a second protein and having a set of protein language models configured to embed the set of mutants and calculate an embedding distance of each mutant to both proteins and having a system configured to graphically represent the embedding distance of each mutant to both proteins.

352. The Al-guided analytic platform of claim 340, further comprising a comparative analysis system having a set of protein language models configured to calculate a viability score for each mutant in a set of mutants that represents a likelihood of each mutation.

353. The Al-guided analytic platform of claim 340, further comprising a comparative analysis system having a set of protein language models configured to calculate embedding distances for each mutation.

354. The Al-guided analytic platform of claim 340. further comprising a comparative analysis system having a set of protein language models configured to build out multiple sets of mutations.PATHWAY OPTIMIZATION METHODS FOR PROCESS BOTTLENECKS355. A method of optimizing a biologic synthesis process, comprising: identifying at least one bottleneck in the biologic synthesis process; evaluating a set of variants of the biologic synthesis process; and selecting an adjusted biologic synthesis process, wherein the adjusted biologic synthesis process includes at least one variant of the set of variants that reduces the at least one bottleneck of the biologic synthesis process.

356. The method of claim 355, wherein the biologic synthesis process includes at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

357. The method of claim 355, wherein the set of variants include at least one of a process temperature variant, a process pressure variant, a process volume variant, a process timing variant, a process order variant, a biologic product concentration variant, a biologic product addition variant, a biologic product substitution variant, a biologic product elimination variant, a biologic product expression variant, a biologic product activation variant, a biologic product activity variant, or a biologic product transformation variant.

358. The method of claim 355, wherein the at least one bottleneck includes at least one of a grow th rate bottleneck, a metabolite production rate bottleneck, a byproduct formation rate bottleneck, a protein expression level bottleneck, a process scale bottleneck, a process ratebottleneck, a product expression bottleneck, a product activation bottleneck, a process stability bottleneck, a process efficiency bottleneck, a process cost bottleneck, or a process yield bottleneck.

359. The method of claim 355, wherein evaluating the set of variants of the biologic synthesis process includes at least one of: comparing a simulation of the biologic synthesis process with a simulation of each variant of the set of variants of the biologic synthesis process, or comparing an experimental result of the biologic synthesis process with an experimental result of a respective experiment of each variant of the set of variants of the biologic synthesis process.

360. The method of claim 355, wherein evaluating the set of variants of the biologic synthesis process includes determining, within an evaluation space, a location of each variant of the set of variants of the biologic synthesis process.

361. The method of claim 360, wherein the evaluation space includes at least two dimensions that respectively represent a feature of the biologic synthesis process, and the location of a respective variant of the set of variants further comprises a vector within the evaluation space, wherein respective dimensions of each vector correspond to a feature of the respective variant of the biologic synthesis process.

362. The method of claim 361, wherein evaluating a set of variants of the biologic synthesis process further comprises identifying, within the evaluation space, at least one region of variants that reduce at least one bottleneck of the biologic synthesis process.

363. The method of claim 362, wherein evaluating the set of variants of the biologic synthesis process further comprises: selectively evaluating the set of variants of the set of variants that is within at least one of the at least one region of variants that reduces the at least one bottleneck of the biologic synthesis process.

364. The method of claim 360, further comprising: representing the evaluation space as a heat map, wherein each location within the evaluation space is associated with a temperature that is related to an effect of a variant at the location on the at least one bottleneck of the biologic synthesis process.

365. The method of claim 355, wherein evaluating the set of variants of the biologic synthesis process further comprises: evaluating respective variants of the set of variants according to a ranking order of the set of variants.

366. The method of claim 365, wherein evaluating of the set of variants according to the ranking order of the set of variants further comprises: for a respective variant of the set of variants, determining a score based on a comparison between the respective variant and the biologic synthesis process, and determining the ranking order based on the score of the respective variant.

367. The method of claim 366, wherein the comparison includes at least one of: a distance between the respective variant and the biologic synthesis process,a measurement of at least one objective of the respective variant and a corresponding measurement of the at least one objective of the biologic synthesis process, or a measurement of a feature of the respective variant and a corresponding measurement of the feature of the biologic synthesis process.

368. The method of claim 365, wherein evaluating the set of variants according to the ranking order further comprises: selecting, from the set of variants, a first set of candidate variants based on the ranking order; evaluating the first set of candidate variants based on at least one objective of respective variants of the first set of candidate variants; and based on evaluating the first set of candidate variants, selecting a second set of candidate variants for evaluation.

369. The method of claim 365, wherein evaluating the first set of candidate variants includes at least one of: evaluating a simulation of respective variants of the first set of candidate variants, or evaluating an experimental result of respective variants of the first set of candidate variants.

370. The method of claim 365, wherein the second set of candidate variants includes at least one of: at least one further variant of at least one variant of the first set of candidate variants, or at least one variant of the set of variants that is not included in the first set of candidate variants.

371. The method of claim 365, wherein the first set of candidate variants includes at least two alternative variants of the biologic synthesis process having a feature, wherein each of the at least two alternative variants includes a different variations of the feature.

372. The method of claim 365, wherein the first set of candidate variants includes at least one variant that includes a single variation of a feature of the biologic synthesis process, and the second set of candidate variants includes at least one variant that includes variations of at least two different features of the biologic synthesis process.

373. The method of claim 372, wherein selecting the adjusted biologic synthesis process based on an evaluation of a set of variants of the biologic synthesis process reduces at least one bottleneck of the biologic synthesis process.

374. The method of claim 355, wherein evaluating the set of variants of the biologic synthesis process further comprises: generating at least one explanation of at least one variant of the biologic synthesis process, wherein the at least one explanation indicates an effect of the at least one variant on the at least one bottleneck of the biologic synthesis process.

375. The method of claim 355, further comprising: identifying at least one additional bottleneck in the adjusted biologic synthesis process; evaluating a set of further variants of the adjusted biologic synthesis process; andselecting a further adjusted biologic synthesis process, wherein the further adjusted biologic synthesis process includes at least one variant of the set of further variants that reduces the at least one additional bottleneck of the adjusted biologic synthesis process.

376. A method of optimizing a biologic synthesis process, comprising: identifying at least one bottleneck in the biologic synthesis process; determining, by at least one simulation of the biologic synthesis process, at least one cause of the at least one bottleneck; and selecting an adjusted biologic synthesis process, wherein the adjusted biologic synthesis process alters the biologic synthesis process to at least reduce the at least one cause of the at least one bottleneck of the biologic synthesis process.

377. The method of claim 376, wherein the biologic synthesis process includes at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

378. The method of claim 376, wherein the adjusted biologic synthesis process includes at least one of a process temperature adjustment, a process pressure adjustment, a process volume adjustment, a process timing adjustment, a process order adjustment, a biologic product concentration adjustment, a biologic product addition adjustment, a biologic product substitution adjustment, a biologic product elimination adjustment, a biologic product expression adjustment, a biologic product activation adjustment, a biologic product activity adjustment, or a biologic product transformation adjustment.

379. The method of claim 376, wherein the at least one bottleneck includes at least one of a growth rate bottleneck, a metabolite production rate bottleneck, a byproduct formation rate bottleneck, a protein expression level bottleneck, a process scale bottleneck, a process rate bottleneck, a product expression bottleneck, a product activation bottleneck, a process stability' bottleneck, a process efficiency bottleneck, a process cost bottleneck, or a process yield bottleneck.

380. The method of claim 376, wherein selecting the adjusted biologic synthesis process includes at least one of: comparing a simulation of the biologic synthesis process with a simulation of the adjusted biologic synthesis process, or comparing an expenmental result of the biologic synthesis process with an experimental result of a respective experiment of the adjusted biologic synthesis process.

381. The method of claim 376, wherein selecting the adjusted biologic synthesis process includes determining, within an evaluation space, a location of the adjusted biologic synthesis process.

382. The method of claim 381, wherein the evaluation space includes at least two dimensions that respectively represent a feature of the biologic synthesis process, and the location of the adjusted biologic synthesis process further comprises a vector within the evaluation space,wherein respective dimensions of each vector correspond to a feature of the adjusted biologic synthesis process.

383. The method of claim 382, wherein selecting the adjusted biologic synthesis process further comprises identifying, within the evaluation space, at least one region of adjusted biologic synthesis processes that reduce at least one bottleneck of the biologic synthesis process.

384. The method of claim 383, wherein selecting the adjusted biologic synthesis process further comprises: selectively evaluating adjusted biologic synthesis processes that are within at least one of the at least one region of adjusted biologic synthesis processes that reduce the at least one bottleneck of the biologic synthesis process.

385. The method of claim 381, further comprising: representing the evaluation space as a heat map, wherein each location within the evaluation space is associated with a temperature that is related to an effect of an adjusted biologic synthesis processes at the location on the at least one bottleneck of the biologic synthesis process.

386. The method of claim 382, wherein selecting the adjusted biologic synthesis process further comprises: evaluating a set of adjusted biologic synthesis processes according to a ranking order of the set of adjusted biologic synthesis processes.

387. The method of claim 386, wherein evaluating the set of adjusted biologic synthesis processes according to the ranking order of the set of adjusted biologic synthesis processes further comprises: for each adjusted biologic synthesis process, determining a score based on a comparison between the adjusted biologic synthesis process and the biologic synthesis process, and determining the ranking order based on respective scores of each adjusted biologic synthesis process.

388. The method of claim 387, wherein the comparison includes at least one of: a distance between a respective adjusted biologic synthesis process and the biologic synthesis process, a measurement of at least one objective of the adjusted biologic synthesis process and a corresponding measurement of the at least one objective of the biologic synthesis process, or a measurement of a feature of the adjusted biologic synthesis process and a corresponding measurement of the feature of the biologic synthesis process.

389. The method of claim 387, wherein evaluating the set of adjusted biologic synthesis processes according to the ranking order of the set of adjusted biologic synthesis processes further comprises: selecting, from the set of adjusted biologic synthesis processes, a first set of candidate adjusted biologic synthesis processes based on the ranking order; evaluating the first set of candidate adjusted biologic synthesis processes based on at least one objective of respective adjusted biologic synthesis processes; and based on evaluating the first set of candidate adjusted biologic synthesis processes, selecting a second set of candidate adjusted biologic synthesis processes for evaluation.

390. The method of claim 389, wherein evaluating the first set of candidate adjusted biologic synthesis processes includes at least one of: evaluating a simulation of respective adjusted biologic synthesis processes of the first set of candidate adjusted biologic synthesis processes, or evaluating an experimental result of respective adjusted biologic synthesis processes of the first set of candidate adjusted biologic synthesis processes.

391. The method of claim 389, wherein the second set of candidate adjusted biologic synthesis processes includes at least one of: at least one further adjusted biologic synthesis process of at least one adjusted biologic synthesis processes of the first set of candidate adjusted biologic synthesis processes, or at least one adjusted biologic synthesis process of the set of adjusted biologic synthesis processes that is not included in the first set of candidate adjusted biologic synthesis processes.

392. The method of claim 389, wherein the first set of candidate adjusted biologic synthesis processes includes a set of alternative adjusted biologic synthesis processes of the biologic synthesis process having a feature, wherein each of the set of alternative adjusted biologic synthesis processes includes a different variations of the feature.

393. The method of claim 392, wherein the first set of candidate adjusted biologic synthesis processes includes at least one adjusted biologic synthesis processes that includes a single variation of the feature of the biologic synthesis process, and the second set of candidate adjusted biologic synthesis processes includes at least one selecting an adjusted biologic synthesis process that includes variations of at least two different features of the biologic synthesis process.

394. The method of claim 393, wherein selecting the adjusted biologic synthesis process based on an evaluation of a set of adjusted biologic synthesis processes of the biologic synthesis process reduces at least one bottleneck of the biologic synthesis process.

395. The method of claim 382, wherein evaluating the adjusted biologic synthesis process further comprises: generating at least one explanation of at least one adjusted biologic synthesis process, wherein the at least one explanation indicates an effect of the adjusted biologic synthesis process on the at least one bottleneck of the biologic synthesis process.

396. The method of claim 382, further comprising: identifying at least one additional bottleneck in the adjusted biologic synthesis process; evaluating a set of further adjusted biologic synthesis processes of the adjusted biologic synthesis process; and selecting a further adjusted biologic synthesis process, wherein the further adjusted biologic synthesis process includes at least one further adjusted biologic synthesis processes of the set of further adjusted biologic synthesis processes that reduces the at least one additional bottleneck of the adjusted biologic synthesis process.AI-GUIDED PLATFORMS FOR PATHWAY OPTIMIZATION AND REDUCING PROCESS BOTTLENECKS397. An Al-guided analytic platform for development of biologic synthesis processes, comprising:one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the Al-guided analytic platform to perform steps including. identifying at least one bottleneck in a biologic synthesis process; evaluating a set of variants of the biologic synthesis process; and selecting an adjusted biologic synthesis process, wherein the adjusted biologic synthesis process includes at least one variant of the set of variants that reduces the at least one bottleneck of the biologic synthesis process.

398. The Al-guided analytic platform of claim 397, wherein the biologic synthesis processes include at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

399. The Al-guided analytic platform of claim 397, wherein the steps further include running simulations to determine enzyme bottlenecks in pathway optimization.

400. The Al-guided analytic platform of claim 397, wherein the steps include raking biologic synthesis processes in protein optimization.

401. The Al-guided analytic platform of claim 397, wherein the steps include ranking biologic synthesis processes in genetic generalization.

402. The Al-guided analytic platform of claim 397. wherein the steps include ranking biologic synthesis processes in predictions in fermentation tanks.

403. The Al-guided analytic platform of claim 397, wherein the steps include providing an explanation of an evaluation of the biologic synthesis process.

404. An Al-guided analytic platform for development of biologic synthesis processes, comprising: one or more processors; and memory storing instructions that, w hen executed by the one or more processors, cause the Al-guided analytic platform to implement a system that evaluates the biologic synthesis processes, wherein the system includes at least one simulation system that is configured to simulate biologic synthesis processes to identify’ bottlenecks in the biologic synthesis processes.

405. The Al-guided analytic platform of claim 404, wherein the biologic synthesis processes include at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

406. The Al-guided analytic platform of claim 404. wherein the system is further configured to run simulations to determine enzyme bottlenecks in pathway optimization.

407. The Al-guided analytic platform of claim 404. wherein the system is further configured to rank biologic synthesis processes in protein optimization.

408. The Al-guided analytic platform of claim 404, wherein the system is further configured to rank biologic synthesis processes in genetic generalization.

409. The Al-guided analytic platform of claim 404, wherein the system is further configured to rank biologic synthesis processes in predictions in fermentation tanks.

410. The Al-guided analytic platform of claim 404. further comprising a set of models configured to evaluate biologic synthesis processes wherein the set of models provides an explanation of an evaluation of the biologic synthesis processes.OPTIMIZATION PLATFORM411. A platform for generating a set of recommendations associated with a production of a functional output by a biological strain, comprising: a set of data integration facilities for integrating content of at least one publication data set relating to the biological strain and at least one proprietary' data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein an output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and at least one member of the set of Al-based learning models that is configured to generate the set of recommendations wherein the set of recommendations relate to at least one of a set of modifications to a set of genes of the biological strain, a set of modifications to a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output, a set of modifications to a set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, or a set of modifications to a set of proteins or enzymes associated with the biological strain, wherein that the set of recommendations enhances the production of the functional output by the biological strain.

412. The platform of claim 411, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzy me characterization datasets, case study datasets, or patent literature.

413. The platform of claim 411, wherein the at least one proprietary data set includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

414. The platform of claim 411. wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

415. The platform of claim 411, w herein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity' management, pressure, or salinity7.

416. The platform of claim 411, wherein the set of recommendations relates to at least one of identification and overexpression of key enzymes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

417. The platform of claim 411, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site-directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

418. The platform of claim 411, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

419. The platform of claim 411, wherein the set of Al-based learning models is configured to process inputs in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

420. The platform of claim 411. wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model’s computational complexity based on input complexity.

421. The platform of claim 411, wherein the data integration facilities use dedicated processing cores to perform data transformation or integration operations.

422. A method for generating a set of recommendations associated with a production of a functional output by a biological strain, comprising: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary' data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein an output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and generating, by at least one member of the set of Al-based learning models, the set of recommendations wherein the set of recommendations relate to at least one of a set of modifications to a set of genes of the biological strain, a set of modifications to a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output, a set of modifications to a set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, or a set of modifications to a set of proteins or enzymes associated with the biological strain; wherein that the set of recommendations enhances the production of the functional output by the biological strain.

423. The method of claim 422, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

424. The method of claim 422, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzy me characterization datasets, case study datasets, or patent literature.

425. The method of claim 422, wherein the at least one proprietary7data set includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

426. The method of claim 422, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory elements, or application of advanced genome editing technologies.

427. The method of claim 422, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity7management, pressure, or salinity.

428. The method of claim 422, wherein the set of recommendations relates to at least one of identification and overexpression of key enzymes, use of stronger or inducible promoters, knockout of competing pathways, pathway engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

429. The method of claim 422, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site-directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

430. The method of claim 422, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, phamiaceutical applications and solutions, or medical applications and solutions.

431. The method of claim 422, wherein processing the inputs by the set of Al-based learning models includes processing in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

432. The method of claim 422, wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

433. The method of claim 422, wherein integrating the content includes using dedicated processing cores to perform data transformation or integration operations.OPTIMIZATION PLATFORM WITH SIMULATIONS FOR GENERATING RECOMMENDATIONS434. A platform for generating a set of recommendations associated with a production of a functional output by a biological strain, comprising: a set of data integration facilities configured to integrate content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein an output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; and a simulation engine configured to: generate a plurality of synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to at least one of: a set of genes of the biological strain. a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output, a set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, or a set of proteins or enzymes associated with the biological strain; execute simulations for the plurality7of simulated process scenarios; generate simulation data based on the executed simulations, wherein the simulation data is configured as an input to the set of Al-based learning models; and at least one member of the set of Al-based learning models that is configured to generate the set of recommendations, wherein the set of recommendations relates to at least one of: a set of modifications to a set of genes of the biological strain, a set of modifications to a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output. a set of modifications to the set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, ora set of modifications to the set of proteins or enzymes associated with the biological strain, wherein the set of recommendations enhances the production of the functional output by the biological strain.

435. The platform of claim 434. wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

436. The platform of claim 434, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzy me characterization datasets, case study datasets, or patent literature.

437. The platform of claim 434, wherein the at least one proprietary data set include at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

438. The platform of claim 434. wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory' elements, or application of advanced genome editing technologies.

439. The platform of claim 434, w herein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity' management, pressure, or salinity7.

440. The platform of claim 434, wherein the set of recommendations relates to at least one of identification and overexpression of key7enzymes, use of stronger or inducible promoters, knockout of competing pathways, pathw ay engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

441. The platform of claim 434, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site-directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

442. The platform of claim 434, w herein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

443. The platform of claim 434, wherein the set of Al-based learning models is configured to process inputs in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

444. The platform of claim 434. wherein the set of Al-based learning models uses adaptive computation techniques that dynamically adjust a model’s computational complexity based on input complexity.

445. The platform of claim 434, wherein the data integration facilities use dedicated processing cores to perform data transformation or integration operations.

446. The platform of claim 434, wherein the simulation engine uses distributed computing to parallelize the execution of the simulations across a plurality of computing nodes.

447. The platform of claim 434, wherein the simulation engine uses distributed computing to execute multiple simulations by batching neural network computations or distributing ODE integrations across a plurality of processing cores.

448. A method for generating a set of recommendations associated with a production of a functional output by a biological strain, comprising: integrating, by a set of data integration facilities, content of at least one publication data set relating to the biological strain and at least one proprietary data set including a set of parameters of a synthetic biological process in which the biological strain produces the functional output, wherein an output of data integration facilities is configured as an input to a set of artificial intelligence (Al)-based learning models; generating, by a simulation engine, a plurality of synthetic biological process scenarios in which the biological strain produces the functional output, wherein each process scenario has a different set of modifications to at least one of a set of genes of the biological strain, a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output, a set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, or a set of proteins or enzymes associated with the biological strain; executing, by the simulation engine, simulations for the plurality of simulated process scenarios; generating, by the simulation engine, simulation data based on the executed simulations wherein the simulation data is configured as an input to the set of Al-based learning models; and generating, by at least one member of the set of Al-based learning models, the set of recommendations wherein the set of recommendations relate to at least one of a set of modifications to a set of genes of the biological strain, a set of modifications to a set of environmental parameters for the synthetic biological process in which the biological strain produces the functional output, a set of modifications to the set of biological pathways associated with the synthetic biological process in which the biological strain produces the functional output, or a set of modifications to the set of proteins or enzymes associated with the biological strain;wherein that the set of recommendations enhances the production of the functional output by the biological strain.

449. The method of claim 448, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

450. The method of claim 448, wherein the at least one publication data set includes at least one of: gene function description datasets, datasets from metabolic pathway databases, comparative genomics datasets, omics datasets, functional assay datasets, experiment result datasets, bioinformatics analyses datasets, regulatory study datasets, enzy me characterization datasets, case study datasets, or patent literature.

451. The method of claim 448, wherein the at least one proprietary data set includes at least one of genetic parameters, metabolic parameters, growth and physiological parameters, environmental and culture conditions, process parameters, functional output parameters, regulatory and control parameters, phenotypic parameters, omics parameters, scale-up parameters, or energy consumption parameters.

452. The method of claim 448, wherein the set of recommendations relates to at least one of knockout mutations, overexpression of target genes, activation of specific genes, insertion of specific genes, gene knockdowns, site-directed mutagenesis, promoter engineering, codon optimization, gene fusion, allele replacement, creation of synthetic gene circuits, introduction of regulatory' elements, or application of advanced genome editing technologies.

453. The method of claim 448, wherein the set of recommendations relates to modifications of at least one of temperature, pH level, oxygen supply, nutrient composition, fermentation time, stirring and mixing, inoculum size, light conditions, toxicity' management, pressure, or salinity'.

454. The method of claim 448, wherein the set of recommendations relates to at least one of identification and overexpression of key enzymes, use of stronger or inducible promoters, knockout of competing pathways, pathw ay engineering, optimization of substrate utilization, feedback regulation modification, cofactor engineering, pathway flux redistribution, integration of pathways, or environmental adaptations.

455. The method of claim 448, wherein the set of recommendations relates to at least one of enzyme overexpression, use of stronger promoters, site-directed mutagenesis, construction of chimeric proteins, enhancement of cofactor interactions, alleviation of feedback inhibition, application of post-translational modifications, modification of enzyme localization, gene knockouts of competing enzymes, allosteric modulation, or integration of modular enzyme assemblies.

456. The method of claim 448, wherein the functional output includes at least one of fuel applications and solutions, industrial applications and solutions, consumer product applications and solutions, pharmaceutical applications and solutions, or medical applications and solutions.

457. The method of claim 448, wherein processing the inputs by the set of Al-based learning models includes processing in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

458. The method of claim 448, wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

459. The method of claim 448, wherein integrating the content includes using dedicated processing cores to perform data transformation or integration operations.

460. The method of claim 448, wherein executing the simulations includes using distributed computing to parallelize the execution of the simulations across a plurality of computing nodes.

461. The method of claim 448, wherein executing the simulations includes using distributed computing to execute multiple simulations by batching neural network computations or distributing ODE integrations across a plurality of processing cores.OPTIMIZATION PLATFORM FOR CONVERTING RAW DATA TO MODEL-READY DATA462. A system for converting raw data from an analytical and mass spectrometry instrument to model-ready data, comprising: computing hardware configured to: receive data from the analytical and mass spectrometry instrument, wherein the data includes measurement data from a set of control samples and a set of test samples; extract a set of peak lists comprising a set of test peak lists and a set of control peak lists from the received data; compress the extracted peak lists using a compression algorithm; identify a set of metabolites that correspond to a set of peaks from the compressed peak lists by comparing a set of mass-to-charge ratios and a set of retention times associated with the set of peaks with the mass-to-charge ratios and retention times associated with known metabolites from a set of spectral databases; calculate a set of peak areas corresponding to the set of peaks; generate a calibration curve for each identified metabolite based on the calculated area from its corresponding peaks from the compressed set of control peak lists and its known concentrations; calculate a set of concentrations for the set of identified metabolites associated with the peaks from the compressed set of test peak lists using the generated calibration curves; and generate a compilation of results.

463. The system of claim 462, wherein the computing hardware is further configured to analyze the identified peaks to determine a need for a deconvolution and / or window adjustment on one or more of the identified peaks, and, upon determination of said need, perform deconvolution and / or window adjustment on the one or more of the identified peaks.

464. The system of claim 462, wherein the computing hardware is further configured to generate a qualify control website, wherein the qualify control w ebsite presents a set ofcalibration curves for control samples and test samples for each of the metabolites of the set of metabolites.

465. The system of claim 462. wherein the analytical and mass spectrometry instrument is a liquid chromatography -mass spectrometry (LC-MS) instrument, a gas chromatography-mass spectrometry (GC-MS) instrument, a quadruple time-of-flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, or a free induction decay (FID) instrument, a quadrupole mass spectrometry (QMS) instrument, a time-of-flight mass spectrometry (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry' instrument, a sector mass spectrometry' instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, or an atmospheric pressure photoionization (APPI) instrument466. The system of claim 462, wherein the computing hardware is further configured to apply a dilution factor to the set of concentrations.

467. The system of claim 466, wherein the computing hardware is further configured to normalize the concentrations to biomass content.

468. The system of claim 462, wherein the system is integrated with a fermentation system and a rapid sampling system.

469. The system of claim 462, further comprising comparing a set of fragmentation patterns associated with the set of peaks with the fragmentation patterns for a set of known metabolites from the set of spectral databases.

470. A method for converting raw data from an analytical and mass spectrometry' instrument to model-ready data, comprising: receiving, by computing hardware, data from the analytical and mass spectrometry instrument wherein the data includes measurement data from a set of control samples and a set of test samples; extracting, by the computing hardware, a set of peak lists comprising a set of test peak lists and a set of control peak lists from the received data; compressing, by the computing hardware, the extracted peak lists using a compression algorithm; identifying, by the computing hardware, a set of metabolites that correspond to a set of peaks from the compressed peak lists by comparing a set of mass-to-charge ratios and a set of retention times associated with the set of peaks with the mass-to-charge ratios and retention times associated with known metabolites from a set of spectral databases; calculating, by the computing hardware, a set of peak areas corresponding to the set of peaks; generating, by the computing hardware, a calibration curve for each identified metabolite based on the calculated area from its corresponding peaks from the compressed set of control peak lists and its known concentrations;calculating, by the computing hardware, a set of concentrations for the set of identified metabolites associated with the peaks from the compressed set of test peak lists using the generated calibration curves; and generating, by the computing hardware, a compilation of results.

471. The method of claim 470, further comprising analyzing the identified peaks to determine a need for a deconvolution and / or window adjustment on one or more of the identified peaks, and, upon determination of said need, performing deconvolution and / or window adjustment on the one or more of the identified peaks.

472. The method of claim 470, further comprising generating a quality control website wherein the quality' control website presents a set of calibration curves for control samples and test samples for each of the metabolites of the set of metabolites.

473. The method of claim 470, wherein the analytical and mass spectrometry' instrument is a liquid chromatography-mass spectrometry (LC-MS) instrument, a gas chromatography-mass spectrometry (GC-MS) instrument, a quadruple time-of-flight (QTOF) mass spectrometry instrument, an ultraviolet-visible (UV-Vis) instrument, or a free induction decay (FID) instrument, a quadrupole mass spectrometry (QMS) instrument, a time-of-flight mass spectrometry (TOF-MS) instrument, an ion trap mass spectrometry instrument, an orbitrap mass spectrometry instrument, a sector mass spectrometry instrument, an electrospray ionization (ESI) instrument, a chemical ionization (CI) instrument, an electron ionization (El) instrument, an atmospheric pressure chemical ionization (APCI) instrument, or an atmospheric pressure photoionization (APPI) instrument.

474. The method of claim 470, further comprising applying a dilution factor to the set of concentrations.

475. The method of claim 474, further comprising normalizing the concentrations to biomass content.

476. The method of claim 470, wherein the method is integrated with a fermentation system and a rapid sampling system.

477. The method of claim 470, further comprising comparing a set of fragmentation patterns associated with the set of peaks with the fragmentation patterns for a set of known metabolites from the set of spectral databases.AI-DRIVEN FERMENTATION SYSTEM WITH SENSORS FOR OPTIMIZATION478. A fermentation system comprising: a fermentation chamber configured to contain a fermentation medium; a plurality of sensors configured to measure fermentation parameters; and a control system operatively coupled to the fermentation chamber and the plurality of sensors, the control system comprising: at least one processor; and memory storing instructions that, when executed by the at least one processor, cause the control system to: receive sensor data from the plurality of sensors;process the sensor data using a set of Al-based learning models to determine a set of improved fermentation parameters; generate control signals based on the determined set of improved fermentation parameters; and adjust operating conditions of the fermentation chamber based on the control signals.

479. The fermentation system of claim 478, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

480. The fermentation system of claim 478, wherein the fermentation system includes or is integrated with a rapid sampling system.

481. The fermentation system of claim 478, wherein the fermentation system includes or is integrated with a rapid sampling system, an analytical and mass spectroscopy instrument, and an automated omics for generalization system.

482. The fennentation system of claim 478, wherein the set of Al-based learning models is configured to process input data in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

483. The fennentation system of claim 478. wherein the set of Al-based learning models uses adaptive computation techniques that dynamically adjust a model’s computational complexity based on input complexity.

484. The fermentation system of claim 478, wherein the plurality of sensors comprises at least two of: temperature sensors, pH sensors, dissolved oxygen sensors, biomass sensors, substrate concentration sensors, redox potential sensors, foam formation sensors, gas composition sensors, pressure sensors, flow rate sensors, conductivity sensors, turbidity sensors, viscosity sensors, cell viability sensors, weight sensors, acoustic sensors, optical density sensors, infrared sensors, fluorescence-based detection systems, enzymatic electrodes, biosensors, ion-selective electrodes, imaging sensors, and heat flux sensors.

485. The fermentation system of claim 478, wherein the plurality of sensors comprises at least one of a Raman sensor and a Near-Infrared (NIR) sensor.

486. The fermentation system of claim 478. wherein the set of fermentation parameters comprise at least one of: temperature of the fermentation medium, pH level of the fermentation medium, dissolved oxygen concentration, pressure within the fermentation chamber, agitation rate, nutrient feed rate, substrate concentration, metabolite concentration, cell density, gas flow rate, foam level, viscosity of the fermentation medium, redox potential, carbon dioxide evolution rate, oxygen uptake rate, osmotic pressure, specific growth rate, product formation rate, yield coefficients, mass transfer coefficients, power input, mixing time, shear stress, or biomass morphology.

487. The fermentation system of claim 478, wherein the control signals comprise signals to adjust at least one of: agitation speed of an impeller within the fermentation chamber, temperature of a heating or cooling element, flow rate of a nutrient feed pump, flow rate of an acid or base addition pump for pH control, flow rate of an antifoam addition pump, gas flow rate through a sparger, pressure within the fermentation chamber, substrate feed rate, harvest rate, mixing rate, aeration rate, or recirculation rate.

488. The fermentation system of claim 478, wherein the fermentation system is configured as a mobile laboratory' unit for deployment at remote locations.

489. A method of controlling a fermentation process comprising: containing a fermentation medium in a fermentation chamber; measuring fermentation parameters using a plurality of sensors; receiving sensor data from the plurality of sensors; processing the sensor data using a set of Al-based learning models to determine a set of improved fermentation parameters; generating control signals based on the determined set of improved fermentation parameters; and adjusting operating conditions of the fermentation chamber based on the control signals.

490. The method of claim 489, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

491. The method of claim 489, further comprising sampling the fermentation medium using a rapid sampling system.

492. The method of claim 489, further comprising: sampling the fermentation medium using a rapid sampling system; analyzing samples using an analytical and mass spectroscopy instrument; and processing sample data using an automated omics for generalization system.

493. The method of claim 489, wherein processing the sensor data comprises processing input data in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

494. The method of claim 489, wherein processing the sensor data compnses using adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

495. The method of claim 489, wherein measuring the fermentation parameters comprises measuring at least two of: temperature, pH, dissolved oxygen, biomass, substrate concentration, redox potential, foam formation, gas composition, pressure, flow rates, conductivity, turbidity, viscosity, cell viability, weight, acoustic properties, optical density, infrared measurements, fluorescence, enzymatic activity, biosensor readings, ion concentrations, imaging data, and heat flux.

496. The method of claim 489, wherein measuring the fermentation parameters comprises using at least one of a Raman sensor and a Near-Infrared (NIR) sensor.

497. The method of claim 489, wherein the set of fermentation parameters comprise at least one of: temperature of the fermentation medium, pH level of the fermentation medium, dissolved oxygen concentration, pressure within the fermentation chamber, agitation rate, nutrient feed rate, substrate concentration, metabolite concentration, cell density, gas flow rate, foam level, viscosity of the fermentation medium, redox potential, carbon dioxide evolution rate, oxygen uptake rate, osmotic pressure, specific grow th rate, product fomiation rate, yield coefficients, mass transfer coefficients, power input, mixing time, shear stress, or biomass morphology.

498. The method of claim 489, wherein adjusting the operating conditions comprises adjusting at least one of: agitation speed of an impeller within the fermentation chamber, a temperature of a heating or cooling element, a How rate of a nutrient feed pump, a flow rate of an acid or base addition pump for pH control, a flow rate of an antifoam addition pump, gas flow rate through a sparger, a pressure within the fermentation chamber, a substrate feed rate, a harvest rate, a mixing rate, an aeration rate, or a recirculation rate.

499. The method of claim 489, further comprising deploying the fermentation chamber, the plurality of sensors, and control system as a mobile laboratory unit at a remote location.AI-DRIVEN FERMENTATION SYSTEM WITH SENSORS FOR DATA COLLECTION500. A fermentation system comprising: a fermentation chamber configured to contain a fermentation medium; a plurality of sensors configured to measure fermentation parameters; a control system operatively coupled to the fermentation chamber and the plurality of sensors, the control system comprising: at least one processor; memory7storing instructions that, when executed by the at least one processor, cause the control system to: receive sensor data from the plurality of sensors; process the sensor data using a set of Al-based learning models to determine a set of fermentation parameters, wherein the determined fermentation parameters are configured to generate additional training data for improving the set of Al-based learning models; generate control signals based on the determined fermentation parameters; adjust operating conditions of the fermentation chamber based on the control signals; collect response data indicating effects of the adjusted operating conditions; update the set of Al-based learning models using the collected response data as training data.

501. The fermentation system of claim 500. wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long short-term memory7(LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

502. The fermentation system of claim 500, wherein the fermentation system includes or is integrated with a rapid sampling system.

503. The fermentation system of claim 500. wherein the fermentation system includes or is integrated with a rapid sampling system, an analytical and mass spectroscopy instrument, and an automated omics for generalization system.

504. The fermentation system of claim 500, wherein the set of Al-based learning models are configured to process input data in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

505. The fermentation system of claim 500, wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model’s computational complexity based on input complexity7.

506. The fermentation system of claim 500, wherein the plurality of sensors comprises at least two of: temperature sensors, pH sensors, dissolved oxygen sensors, biomass sensors, substrate concentration sensors, redox potential sensors, foam formation sensors, gas composition sensors, pressure sensors, flow rate sensors, conductivity sensors, turbidity sensors, viscosity sensors, cell viability sensors, weight sensors, acoustic sensors, optical density sensors, infrared sensors, fluorescence-based detection systems, enzymatic electrodes, biosensors, ion-selective electrodes, imaging sensors, and heat flux sensors.

507. The fermentation system of claim 500. wherein the plurality of sensors comprises at least one of a Raman sensor and a Near-Infrared (NIR) sensor.

508. The fermentation system of claim 500, wherein the set of fermentation parameters comprise at least one of: temperature of the fermentation medium, pH level of the fermentation medium, dissolved oxygen concentration, pressure within the fennentation chamber, agitation rate, nutrient feed rate, substrate concentration, metabolite concentration, cell density7, gas flow rate, foam level, viscosity7of the fermentation medium, redox potential, carbon dioxide evolution rate, oxygen uptake rate, osmotic pressure, specific growth rate, product formation rate, yield coefficients, mass transfer coefficients, power input, mixing time, shear stress, or biomass morphology.

509. The fermentation system of claim 500, wherein the control signals comprise signals to adjust at least one of: an agitation speed of an impeller within the fermentation chamber, a temperature of a heating or cooling element, a flow rate of a nutrient feed pump, a flow rate of an acid or base addition pump for pH control, a flow rate of an antifoam addition pump, a gas flow rate through a sparger, a pressure within the fermentation chamber, a substrate feed rate, a harvest rate, a mixing rate, an aeration rate, and a recirculation rate.

510. The fermentation system of claim 500. wherein the fermentation system is configured as a mobile laboratory7unit for deployment at remote locations.

511. A method for controlling a fennentation process, comprising: receiving, by a control system, sensor data from a plurality7of sensors configured to measure fermentation parameters of a fermentation chamber containing a fermentation medium;processing, by the control system, the sensor data using a set of Al-based learning models to determine a set of fermentation parameters, wherein the determined fermentation parameters are configured to generate additional training data for improving the set of Al-based learning models; generating, by the control system, control signals based on the detennined fermentation parameters; adjusting, by the control system, operating conditions of the fermentation chamber based on the control signals; collecting, by the control system, response data indicating effects of the adjusted operating conditions; and updating, by the control system, the set of Al-based learning models using the collected response data as training data.

512. The method of claim 511, wherein the set of Al-based learning models includes at least one of a transformer model, a convolutional neural network, a deep learning model, a supervised model, a semi-supervised model, an unsupervised model, a reinforcement model, a long shortterm memory (LSTM) model, a multi-layer perceptrons, a lin-log model, a large language model, a large protein model, or a protein language model.

513. The method of claim 511, further comprising integrating the fermentation process with a rapid sampling system.

514. The method of claim 511, further comprising integrating the fennentation process with a rapid sampling system, an analytical and mass spectroscopy instrument, and an automated omics for generalization system.

515. The method of claim 511, wherein processing the sensor data comprises processing input data in parallel across multiple Al Processing cores, wherein each processing core handles a subset of the input data.

516. The method of claim 511, wherein the set of Al-based learning models use adaptive computation techniques that dynamically adjust a model's computational complexity based on input complexity.

517. The method of claim 511, wherein receiving the sensor data comprises receiving data from at least two of: temperature sensors, pH sensors, dissolved oxygen sensors, biomass sensors, substrate concentration sensors, redox potential sensors, foam formation sensors, gas composition sensors, pressure sensors, flow rate sensors, conductivity sensors, turbidity sensors, viscosity sensors, cell viability sensors, weight sensors, acoustic sensors, optical density sensors, infrared sensors, fluorescence-based detection systems, enzymatic electrodes, biosensors, ion-selective electrodes, imaging sensors, and heat flux sensors.

518. The method of claim 511, wherein receiving the sensor data comprises receiving data from at least one of a Raman sensor and a Near-Infrared (NIR) sensor.

519. The method of claim 511, wherein the set of fennentation parameters comprise at least one of: a temperature of the fermentation medium, a pH level of the fermentation medium, adissolved oxygen concentration, a pressure within the fermentation chamber, an agitation rate, a nutrient feed rate, a substrate concentration, a metabolite concentration, a cell density, a gas flow rate, a foam level, a viscosity' of the fermentation medium, a redox potential, a carbon dioxide evolution rate, an oxygen uptake rate, an osmotic pressure, a specific growth rate, a product formation rate, a yield coefficients, a set of mass transfer coefficients, a power input, a mixing time, a shear stress, or a biomass morphology.

520. The method of claim 511, wherein generating the control signals comprises generating signals to adjust at least one of: an agitation speed of an impeller within the fermentation chamber, a temperature of a heating or cooling element, a flow rate of a nutrient feed pump, a flow rate of an acid or base addition pump for pH control, a flow rate of an antifoam addition pump, a gas flow rate through a sparger, a pressure within the fermentation chamber, a substrate feed rate, a harvest rate, a mixing rate, an aeration rate, or a recirculation rate.DATA-AS-A-SERVICE METHODS FOR NORMALIZATION IN AI-GUIDED SYNTHETIC BIOLOGY PLATFORM521. A computer-implemented method for data integration in an Al-guided synthetic biology development platform, comprising: receiving biological data from a plurality' of experimental sources and databases; converting the received biological data into at least one standardized data format through a data intake and staging pipeline; processing the standardized biological data through a data nonnalization facility to minimize batch-specific systemic variation; storing the normalized biological data in a structured format that describes biological components and their relationships; applying at least one machine learning method to the normalized biological data to generate a predictive model for synthetic biology' design; and outputting a specification for biological system optimization based on the predictive model.

522. The method of claim 521, wherein the data normalization facility applies a Bayesian statistical model that incorporates prior knowledge about strain behavior.

523. The method of claim 521, wherein processing the biological data includes modeling a source of variation including a biological effect.

524. The method of claim 521, wherein the structured format comprises a bipartite graph database structure organizing data into molecule nodes and process nodes.

525. The method of claim 524, wherein the molecule nodes represent at least one of a molecule, atomic element, ion, compound, nucleic acid, protein, or macromolecule.

526. The method of claim 524, wherein the process nodes represent at least one of a chemical reaction, protein folding, transport, regulatory interaction, or active site binding.

527. The method of claim 521, wherein the data intake and staging pipeline includes an automated sampling mechanism for collecting a standardized sample.

528. The method of claim 521, further comprising tracking data lineage from a raw experimental measurement to a processed value.

529. The method of claim 521, wherein processing includes batch effect correction addressing systematic variation across experimental runs, equipment, or operators.

530. The method of claim 521, further comprising validating data quality using a control sample.

531. The method of claim 521, wherein receiving biological data includes collecting time- resolved metabolomic data from living cells.

532. The method of claim 521, further comprising integrating a plurality' of high-dimensional biological data ty pes including at least one of gene expression data, flux data, or metabolite concentration measurement.

533. The method of claim 521, wherein the machine learning method includes a neural network configured for processing biological parameter data.

534. The method of claim 521, further comprising implementing an edge computing architecture for local processing of sensor data.

535. The method of claim 521, further comprising maintaining metadata relating to an experimental condition.

536. The method of claim 521, further comprising generating a visualization output of metabolic pathway performance.DATA-AS-A-SERVICE METHODS FOR AUDIT AND VALIDATION IN AI-GUIDED SYNTHETICBIOLOGY PLATFORM537. A system for analytics-as-a-service in an Al-guided synthetic biology platform, comprising: one or more processors; and memory storing instructions that, when executed by the one or more processors, cause a platform to: identify an appropriate analytic method based on assessment of a biological data characteristic; implement a data preparation procedure specific to a synthetic biology application; apply a machine learning model to analyze biological data and generate a prediction; perform a model validation procedure to ensure analytical reliability; create an audit trail documenting an analytic procedure and result; and generate technical documentation and visualization of an analytic finding.

538. The system of claim 537, wherein identifying the appropriate analytical method includes evaluating at least one of a data type, distribution, or relationship in biological data.

539. The system of claim 537, wherein the data preparation procedure includes automated feature engineering for a biological data type.

540. The system of claim 537, wherein the machine learning model includes a protein language model for analyzing a protein sequence.

541. The system of claim 537. further comprising implementing a distributed computing capability for handling computationally intensive analysis.

542. The system of claim 537, wherein model validation includes both in-sample and out-of- sample testing.

543. The system of claim 537. further comprising monitoring model performance over time and implementing a procedure to detect model degradation.

544. The system of claim 537, wherein technical documentation includes at least one of a methodology description, assumption, or limitation.

545. The system of claim 537, wherein the machine learning model includes a hybrid model combining mechanistic understanding with a machine learning method.

546. The system of claim 537, further comprising implementing an automated model selection procedure.

547. The system of claim 537, wherein model validation includes sensitivity analysis to evaluate model robustness.

548. The system of claim 537, further comprising implementing a caching mechanism to improve processing efficiency.

549. The system of claim 537, further comprising maintaining documentation of a standardization procedure.

550. The system of claim 537, further comprising implementing a resource allocation procedure to optimize computational efficiency.

551. A system for data quality management in an Al-guided synthetic biology platform, comprising: a data intake and staging pipeline configured to: collect raw data from an experimental source; convert raw data into a standardized format; apply a quality assurance step to identify and correct an error; apply a normalization technique to remove a batch effect; validate that normalization preserves a biological signal; and a knowledge management system configured to: maintain an audit trail of data processing; track data lineage from a raw measurement to a processed value; enable verification of a data processing step; store validated data in a structured format describing a biological relationship; and generate a quality metric.

552. The system of claim 551, wherein the qualify assurance step includes detecting a well or sample that failed to grow properly.

553. The system of claim 551, wherein the quality assurance step includes identifying a sample exhibiting contamination.

554. The system of claim 551, wherein the quality assurance step includes flagging a readout that falls outside an expected range.

555. The system of claim 551. wherein the normalization technique includes Bayesian statistical normalization.

556. The system of claim 551. wherein the structured format includes a bipartite graph database structure.

557. The system of claim 551, further comprising implementing an automated validation check.

558. The system of claim 551, wherein tracking data lineage includes maintaining detailed metadata.

559. The system of claim 551, further comprising implementing error handling and retry7logic.

560. The system of claim 551, wherein the quality metric includes completeness analysis.

561. The system of claim 551, further comprising implementing a cross-reference validation technique.

562. The system of claim 551, wherein the normalization technique includes batch effect correction.

563. The system of claim 551, further comprising implementing an automated classification process.

564. The system of claim 551, further comprising implementing a data enrichment capability. DATA-AS-A-SERVICE METHODS FOR MACHINE LEARNING FOR GENERATING PREDICTIONS FOR SYSTEM DESIGNS565. A method for multi-modal data integration in an Al-guided synthetic biology platform, comprising: collecting time-resolved metabolomics data from a living cell through an automated sampling mechanism; integrating multiple types of high-dimensional biological data including at least one of gene expression, metabolic flux, or protein concentration measurement; normalizing the integrated biological data using batch effect correction; validating qualify and consistency of the normalized biological data; storing the validated biological data in a structured format describing relationships between biological entities; and analyzing the stored validated biological data using a machine learning model to generate a prediction for synthetic biology system design.

566. The method of claim 565, wherein the automated sampling mechanism includes near- instantaneous quenching of cellular metabolism.

567. The method of claim 565, wherein integrating includes combining gene expression data from RNA sequencing.

568. The method of claim 565, wherein integrating includes incorporating flux data from an isotope-labeled experiment.

569. The method of claim 565, wherein integrating includes merging a metabolite concentration measurement from mass spectrometry.

570. The method of claim 565, wherein normalizing includes applying a Bayesian statistical model.

571. The method of claim 565, wherein the structured format is a knowledge graph structure.

572. The method of claim 565, further comprising tracking data lineage from a raw measurement.

573. The method of claim 565, further comprising maintaining detailed metadata about an experimental condition.

574. The method of claim 565, wherein the machine learning model includes a neural network with a multi-headed attention mechanism.

575. The method of claim 565, further comprising implementing a distributed computing capability.

576. The method of claim 565, wherein validating includes using a control sample.

577. The method of claim 565, further comprising generating a visualization output.

578. The method of claim 565, wherein analyzing includes predicting strain performance.

579. The method of claim 565, further comprising implementing an edge computing architecture.

580. The method of claim 565, wherein storing includes maintaining an audit trail.DATA-AS-A-SERVICE METHODS FOR PARALLEL DATA STREAMS AND GRAPH DATABASES INAI-GUIDED SYNTHETIC BIOLOGY PLATFORM581. A system for real-time data processing in an Al-guided synthetic biology platform, comprising: one or more processors, each configured with an Al processing core optimized for biological datatypes; a data collection system configured to collect a continuous data stream from laboratory equipment; and a data processing pipeline configured to: perform real-time normalization; integrate a plurality of data streams in parallel; implement edge computing for local data processing; apply a machine learning model for real-time analysis; and generate an automated alert or recommendation based on processed data.

582. The system of claim 581, wherein the Al processing core includes a GPU configured for protein structure prediction.

583. The system of claim 581, wherein the Al processing core includes an NPU optimized for metabolic pathway analysis.

584. The system of claim 581, wherein the data stream includes bioreactor sensor data.

585. The system of claim 581, wherein the data stream includes mass spectrometry data.

586. The system of claim 581, wherein real-time normalization includes batch effect correction.

587. The system of claim 581, further comprising implementing a load balancing algorithm.

588. The system of claim 581, further comprising implementing an automated failover mechanism.

589. The system of claim 581, wherein the machine learning model is a hybrid model.

590. The system of claim 581, further comprising implementing a distributed computing capability.

591. The system of claim 581, wherein the alert includes a quality control notification.

592. The system of claim 581, further comprising generating a real-time visualization.

593. The system of claim 581, wherein the recommendation includes a process parameter adjustment.

594. The system of claim 581, further comprising implementing an automated validation check.

595. A method for data management in an Al-guided synthetic biology platform, comprising: implementing a knowledge graph structure to represent at least one biological entity; integrating experimental data, literature data, and proprietary data into the knowledge graph; maintaining data lineage and provenance tracking; applying a machine learning model to analyze graph relationships; generating a recommendation based on graph analysis; and providing an interactive visualization of the knowledge graph.

596. The method of claim 595, wherein the biological entity includes at least one of a gene, protein, or metabolite.

597. The method of claim 595, wherein relationships include a regulatory interaction and metabolic pathway.

598. The method of claim 595, wherein the experimental data includes a time-series measurement.

599. The method of claim 595, wherein literature data includes a published research finding.

600. The method of claim 595, wherein proprietary data includes a strain performance datum.

601. The method of claim 595, further comprising implementing automated data validation.

602. The method of claim 595, wherein the machine learning model is a graph neural networks.

603. The method of claim 595, further comprising maintaining an audit trails of changes.

604. The method of claim 595, wherein visualization includes a network diagram.

605. The method of claim 595, wherein the recommendation includes a strain optimization strategy.DATA STORAGE GRAPH STRUCTURES FOR QUERY CAPABILITY IN AI-GUIDED SYNTHETICBIOLOGY PLATFORM606. A system for managing biological data in an Al-guided synthetic biology platform, comprising: a knowledge graph structure configured to: represent biological entities as nodes and their relationships as edges; store validated experimental data describing relationships between biological components; maintain data lineage from a raw measurement to a processed value; track a relationship between a strain, genetic design, experimental condition, and a performance datum; a machine learning system configured to: analyze the knowledge graph structure to identify a pattern or relationship; generate a prediction for synthetic biology system design; and provide a query capability for retrieving interconnected biological data.

607. The system of claim 606, wherein biological entities include at least one of a gene, protein, metabolite, or strain.

608. The system of claim 606, wherein relationships include at least one of a metabolic pathway, regulatory interaction, or protein-protein interaction.

609. The system of claim 606, wherein experimental data includes time-resolved metabolomics data.

610. The system of claim 606, wherein the knowledge graph enables retrieval of a strain that modifies a particular metabolic pathway.

611. The system of claim 606, further comprising a visualization capability for exploring a graph relationship.

612. The system of claim 606, wherein the machine learning system includes a graph neural network.

613. The system of claim 606, further comprising automated validation of a data relationship.

614. The system of claim 606, wherein data lineage includes experimental conditions metadata.

615. The system of claim 606, further comprising version control for tracking graph changes.

616. The system of claim 606, wherein a prediction includes a strain optimization recommendation.

617. The system of claim 606, wherein the query capability includes filtering by pathway modifications.

618. The system of claim 606, further comprising integration with an external biological database.

619. The system of claim 606, wherein the knowledge graph maintains an audit trail.

620. The system of claim 606, further comprising real-time updates from experimental data.DATA STORAGE GRAPH STRUCTURES TO GENERATE PREDICTIONS AND DECISION SUPPORT IN AI-GUIDED SYNTHETIC BIOLOGY PLATFORM621. A computer-implemented method for structured biological data storage in an Al-guided synthetic biology platform, comprising: implementing a bipartite graph database structure; organizing data into molecule nodes and process nodes; storing biological components and their relationships in the graph database structure; maintaining connections between nodes indicating roles in biological processes; integrating a plurality of high-dimensional biological data types; applying a machine learning method to analyze a graph relationship; and generating a prediction for synthetic biology optimization based on graph analysis.

622. The method of claim 621, wherein molecule nodes represent at least one of an atomic element, ion, compound, nucleic acid, protein, or macromolecule.

623. The method of claim 621, wherein process nodes represent at least one of a chemical reaction, protein folding, transport, regulatory interaction, or active site binding.

624. The method of claim 621, wherein high-dimensional biological data includes gene expression data from RNA sequencing.

625. The method of claim 621, wherein high-dimensional biological data includes flux data from isotope-labeled experiments.

626. The method of claim 621, wherein high-dimensional biological data includes metabolite concentration measurements.

627. The method of claim 621, further comprising implementing data normalization procedures.

628. The method of claim 621, wherein the machine learning method is a hybrid model.

629. The method of claim 621, further comprising maintaining data provenance tracking.

630. The method of claim 621, wherein the prediction includes pathway bottleneck identification.

631. The method of claim 621, further comprising implementing a quality control mechanism.

632. The method of claim 621, wherein the graph relationship includes a metabolic pathway connection.

633. The method of claim 621, further comprising generating a visualization output.

634. The method of claim 621, wherein the machine learning method includes a neural network.

635. The method of claim 621, further comprising implementing an automated validation check.

636. The method of claim 621, wherein predictions include strain performance estimates.

637. A system for multi-modal data storage in an Al-guided synthetic biology platform, comprising: one or more processors; andmemory storing instructions that, when executed by the one or more processors, cause the platform to: implement a specialized data structure optimized for a biological data type; store time-series experimental data in a vector database; maintain a knowledge graph for biological relationship mapping; integrate structured and unstructured biological data; apply a machine learning model to analyze a cross-structure relationship; and generate a unified data presentation for decision support.

638. The system of claim 637, wherein the specialized data structure includes a bipartite graph database.

639. The system of claim 637, wherein time-series data includes a bioreactor sensor measurement.

640. The system of claim 637, wherein time-series data includes a metabolomics measurement.

641. The system of claim 637, wherein the knowledge graph represents a strain lineage.

642. The system of claim 637, wherein structured data includes an experimental parameter.

643. The system of claim 637, wherein unstructured data includes scientific literature.

644. The system of claim 637, further comprising implementing a data normalization procedure.

645. The system of claim 637, wherein the machine learning model is a hybrid architecture.

646. The system of claim 637, further comprising maintaining an audit trail.

647. The system of claim 637, wherein the unified presentation includes a visualization.

648. The system of claim 637, further comprising implementing an automated validation check.

649. The system of claim 637, wherein relationships include a metabolic pathway.

650. The system of claim 637, wherein decision support includes a strain optimization recommendation.DATA STORAGE STRUCTURES WITH INTEGRATION LAYER FOR UNIFIED ACCESS IN AI-GUIDED SYNTHETIC BIOLOGY PLATFORM651. A system for integrated data processing in an Al-guided synthetic biology platform, comprising: a data storage layer configured to: maintain a knowledge graph structure representing biological entities and relationships; store time-series experimental data in at least one vector database; and track data lineage; an artificial intelligence layer configured to: analyze a data relationship using a machine learning model; generate a prediction for synthetic biology optimization; and maintain a model performance metric;an automated processing layer configured to: implement a standardized data collection protocol; perform a quality control check; apply a normalization procedure; and an integration layer configured to: coordinate a data flow between system components; maintain a synchronized state across layers; and provide a unified access to platform capabilities.

652. The system of claim 651, wherein the knowledge graph structure represents at least one of a gene, protein, metabolite or their interactions.

653. The system of claim 651, wherein the machine learning model includes at least one of a foundation model, a mechanistic model, or a hybrid model.

654. The system of claim 651, wherein quality control includes automated detection of anomalous data.

655. The system of claim 651, wherein normalization procedures include a Bayesian statistical model.

656. The system of claim 651, wherein data flow coordination includes automated staging and validation.

657. The system of claim 651, wherein the integration layer implements standardized APIs.

658. The system of claim 651, wherein the prediction includes a strain optimization recommendation.

659. The system of claim 651, wherein the model metric includes performance tracking and validation.

660. The system of claim 651, wherein data collection includes an automated sampling mechanism.

661. The system of claim 651, wherein quality control includes control sample validation.

662. The system of claim 651, wherein normalization preserv es a biological signal.

663. The system of claim 651, wherein coordination includes error handling.

664. The system of claim 651, wherein synchronization includes version control.

665. The system of claim 651, wherein access includes role-based permissions.

666. The system of claim 651 , wherein capabilities include a visualization tool.DATA STORAGE STRUCTURES WITH UNIFIED OUTPUT FOR DECISION SUPPORT AND TRACK WORKFLOW WITH DOCUMENTATION IN AI-GUIDED SYNTHETIC BIOLOGY PLATFORM667. A computer-implemented method for integrated synthetic biology data processing, comprising: receiving biological data through an automated collection mechanism; storing received data in a structured format optimized for a biological data type; processing stored data through a quality control and normalization pipeline; analyzing processed data using a machine learning model; maintaining a synchronized data state across platform components;generating a unified output for decision support; and tracking data transformation throughout the integrated process.

668. The method of claim 667, wherein the collection mechanism includes sensor integration.

669. The method of claim 667, wherein the structured format includes knowledge graphs.

670. The method of claim 667, wherein quality control includes automated validation.

671. The method of claim 667, wherein normalization includes batch effect correction.

672. The method of claim 667, wherein the machine learning model includes a hybrid architecture.

673. The method of claim 667, wherein synchronization includes state management.

674. The method of claim 667, wherein the output includes a visualization capability.

675. The method of claim 667, wherein tracking includes an audit trail.

676. The method of claim 667, wherein processing includes error handling.

677. The method of claim 667, wherein outputs include recommendations.

678. The method of claim 667, wherein automated collection includes metadata capture.

679. The method of claim 667, wherein validation includes a control sample.

680. The method of claim 667, wherein synchronization includes a failover mechanism.

681. A system for coordinated synthetic biology workflow execution, comprising: one or more processors; and memory storing instructions that, when executed by the one or more processors, cause a platform to: implement an automated data collection and storage process; coordinate a quality control and normalization workflow; manage a machine learning model execution; track workflow execution status; and generate integrated process documentation.

682. The system of claim 681, wherein the collection process includes sensor integration.

683. The system of claim 681, wherein quality control includes automated validation.

684. The system of claim 681, wherein normalization includes a Bayesian model.

685. The system of claim 681, wherein the machine learning includes model selection.

686. The system of claim 681, wherein documentation includes a quality metric.

687. The system of claim 681, wherein the workflow includes a validation step.

688. The system of claim 681, wherein execution includes version control.

689. The system of claim 681, wherein collection includes metadata capture.

690. The system of claim 681, wherein validation includes a control sample.AUTOMATED DATA HANDLING FOR ETL IN AI-GUIDED SYNTHETIC BIOLOGY PLATFORM691. A computer-implemented method for automated data handling in an Al -guided synthetic biology platform, comprising: receiving experimental data from a plurality of sources through an automated data sampling mechanism; implementing an automated validation check to ensure data integrity during transfer;applying an automated data normalization procedure to the received expenmental data to standardize at least one data format and remove batch effects; performing an automated quality control to identify data anomalies; storing processed data with automated lineage metadata; and generating documentation summarizing the automated data handling.

692. The method of claim 691, wherein the automated data sampling mechanism includes near-instantaneous quenching of cellular metabolism.

693. The method of claim 691, wherein the automated validation check verifies at least one of a data type, a value range, or a pattern.

694. The method of claim 691, wherein the automated data normalization procedure includes a Bayesian statistical model.

695. The method of claim 691, wherein quality control includes detecting a failed sample.

696. The method of claim 691, wherein lineage tracking maintains metadata about an experimental condition.

697. The method of claim 691, further comprising automated classification of a data sensitivity level.

698. The method of claim 691, further comprising automated error handling and retry logic.

699. The method of claim 691, wherein documentation includes a quality scorecard.

700. The method of claim 691, further comprising automated batch effect correction.

701. The method of claim 691, wherein validation includes cross-reference validation.

702. The method of claim 691, further comprising automated data enrichment.

703. The method of claim 691, wherein quality control includes a statistical check.

704. The method of claim 691, further comprising automated format conversion.

705. The method of claim 691, wherein documentation includes an audit trail.

706. A system for automated data processing in an Al-guided synthetic biology7platform, comprising: one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the platform to: implement an automated ETL process for a biological data source; perform automated data qualify assessment and validation; apply an automated normalization and standardization procedure; maintain an automated tracking of data transformation; generate automated documentation of a processing step; and provide an automated alert relating to a processing issue.

707. The system of claim 706, wherein an ETL process handles structured and unstructured data.

708. The system of claim 706, wherein qualify assessment includes completeness analysis.

709. The system of claim 706, wherein normalization includes batch effect correction.

710. The system of claim 706, wherein tracking includes data lineage documentation.

711. The system of claim 706, further comprising automated error detection.

712. The system of claim 706, wherein documentation includes a processing history.

713. The system of claim 706, further comprising automated data classification.

714. The system of claim 706, wherein validation includes a control sample check.

715. The system of claim 706, further comprising automated data format harmonization.

716. The system of claim 706, wherein the alert relates to a quality threshold violation.

717. The system of claim 706, further comprising automated metadata extraction.

718. The system of claim 706, wherein processing includes outlier detection.

719. The system of claim 706, further comprising automated version control.

720. The system of claim 706, wherein documentation includes a quality metric.

721. The system of claim 706, further comprising automated data staging.

722. A system for automated data integration in an Al-guided synthetic biology platform, comprising: a data intake pipeline configured to: automatically collect data from a plurality of experimental sources; perform automated data format standardization; implement an automated data quality control check; apply an automated data normalization procedure; and a data management system configured to: maintain automated tracking of data processing; generate automated documentation; implement an automated data validation procedure; and provide an automated alert regarding verification of completed processing steps.

723. The system of claim 722, wherein the plurality of experimental sources includes bioreactor sensors.

724. The system of claim 722, wherein the data format standardization includes unit conversion.

725. The system of claim 722, wherein the data quality control check includes anomaly detection.

726. The system of claim 722, wherein the data normalization procedure includes Bayesian models.

727. The system of claim 722, wherein the tracking of data processing includes an audit trail.

728. The system of claim 722, wherein the documentation includes a quality scorecard.

729. The system of claim 722, wherein the data validation procedure includes a control sample check.

730. The system of claim 722, wherein the alert includes an error notification.

731. The system of claim 722, further comprising automated data classification.

732. The system of claim 722, wherein the data processing includes batch correction.

733. The system of claim 722, further comprising automated metadata management.

734. The system of claim 722, wherein the data validation procedure includes crossreferencing.

735. The system of claim 722. further comprising automated data enrichment.

736. The system of claim 722, wherein the documentation includes a processing log.

737. The system of claim 722, further comprising automated version tracking.AUTOMATED DATA HANDLING WITH DEEP LEARNING ARCHITECTURE AND COMBINEDMODELS IN AI-GUIDED SYNTHETIC BIOLOGY PLATFORM738. A system for machine learning-based analysis in an Al-guided synthetic biology platform, comprising: one or more processors configured with an Al processing core; and memory storing instructions that, when executed by the one or more processors, cause the platform to: implement a multi-modal deep learning architecture with separate encoding branches for different data modalities; process gene expression data, metabolite profile, and reaction flux data through specialized neural network branches; combine encoded representations through fusion layers; generate at least one prediction about a cellular phenotype based on a processed multimodal biological data; and output a specification for biological system optimization based on the at least one prediction.

739. The system of claim 738, wherein the Al processing core includes GPUs, NPUs, TPUs, or FPGAs optimized for biological data processing.

740. The system of claim 738, wherein the multi-modal deep learning architecture includes transformer models.

741. The system of claim 738, wherein specialized neural network branches include protein language models.

742. The system of claim 738, wherein the at least one prediction includes a strain performance estimate.

743. The system of claim 738, further comprising implementing a distributed computing capability.

744. The system of claim 738, wherein fusion layers combine multiple types of biological embeddings.

745. The system of claim 738, further comprising implementing automated model selection.

746. The system of claim 738, wherein processing includes batch effect correction.

747. The system of claim 738, further comprising maintaining model performance metrics.

748. The system of claim 738, wherein the at least one prediction includes pathway bottleneck identification.

749. The system of claim 738, further comprising implementing model validation procedures.

750. The system of claim 738, wherein the deep learning architecture includes hybrid models.

751. The system of claim 738, further comprising implementing edge computing capabilities.

752. The system of claim 738, wherein the at least one prediction includes metabolic flux distributions.

753. The system of claim 738, further comprising generating visualization outputs.

754. A computer-implemented method for Al-guided synthetic biology optimization, comprising: receiving biological data from a plurality of experimental sources; processing the biological data through a foundation model to generate a biological entity embedding; analyzing the embedding using a mechanistic model to characterize a biological process; combining the foundation model and the mechanistic model outputs through hybrid models; generating a prediction for synthetic biology system design; and implementing automated model construction to iteratively improve predictions based on new data.

755. The method of claim 754, wherein the foundation model includes a genetic generalization model.

756. The method of claim 754, wherein the foundation model includes a process generalization model.

757. The method of claim 754, wherein the mechanistic model generates outputs characterizing a biological pathway.

758. The method of claim 754, wherein hybrid models leverage respective strengths of individual models.

759. The method of claim 754, further comprising implementing active learning capabilities.

760. The method of claim 754, wherein the prediction includes a strain design specification.

761. The method of claim 754, further comprising maintaining model performance tracking.

762. The method of claim 754, wherein processing includes data normalization.

763. The method of claim 754, further comprising implementing a validation procedure.

764. The method of claim 754, wherein the prediction includes a process parameter optimization.

765. The method of claim 754, further comprising implementing distributed computing.

766. The method of claim 754, wherein the embedding includes a strain representation.

767. The method of claim 754, further comprising maintaining an audit trail.

768. The method of claim 754, wherein the prediction includes scale-up performance.

769. The method of claim 754, further comprising generating a visualization output.DATA NORMALIZATION IN SYNTHETIC BIOLOGY PLATFORM770. A computer-implemented method for data normalization in an Al-guided synthetic biology platform, comprising: receiving experimental data associated with synthetic biology development from a plurality7of sources; andprocessing the experimental data through a Bayesian statistical normalization model configured to: model batch-specific systemic variation; account for a technical factor contributing to a batch effect; separate a biological signal from a technical factor; validate that normalization preserved a specified biological signal; store the normalized data with tracked data lineage; and provide the normalized data to a machine learning model for analysis.

771. The method of claim 770, wherein modeling batch-specific systemic variation includes constructing plate notation models representing a strain effect.

772. The method of claim 770, wherein modeling includes representing an experimental effect and plate-to-plate variations.

773. The method of claim 770, wherein the technical factor includes plate position effects.

774. The method of claim 770, wherein the biological signal includes a metabolite concentration.

775. The method of claim 770, wherein the biological signal includes an enzyme activity level.

776. The method of claim 770, wherein the biological signal includes a gene expression level.

777. The method of claim 770, further comprising implementing multi-modal data integration.

778. The method of claim 770, wherein data lineage includes experimental conditions metadata.

779. The method of claim 770, further comprising implementing cross-platform data harmonization.

780. The method of claim 770, wherein normalization includes time series data normalization.

781. The method of claim 770, further comprising implementing knowledge graph-based normalization.

782. The method of claim 770, wherein the machine learning model includes a transformer model.

783. The method of claim 770, wherein the machine learning model includes a neural network.

784. The method of claim 770, further comprising generating a visualization output.

785. The method of claim 770, further comprising maintaining an audit trail.IDENTIFY EXPERIMENTAL VALIDATION AND HIGH-PERFORMING STRAIN IN SYNTHETICBIOLOGY PLATFORM786. A system for quality control in an Al-guided synthetic biology platform, comprising: a data intake pipeline configured to: collect raw experimental data associated with a strain perfonnance measurement; implement data normalization and quality control procedures; validate a strain genotype through an automated process; identify outlier data in an experimental dataset; maintain metadata about an experimental condition; and a machine learning system configured to:analyze a quality control metric; generate an automated alert relating to detection of anomalous data; predict an expected measurement range based on historical data; and provide a recommendation for experimental validation.

787. The system of claim 786. wherein the strain performance measurement includes a metabolite measurement.

788. The system of claim 786. wherein the quality control procedure detects a failed growth sample.

789. The system of claim 786, wherein the uality control procedure identifies contamination.

790. The system of claim 786, wherein outlier detection uses statistical analysis.

791. The system of claim 786, wherein metadata includes processing step information.

792. The system of claim 786, further comprising implementing an automated validation check.

793. The system of claim 786, wherein the alert includes a quality threshold violation.

794. The system of claim 786, further comprising implementing an error handling procedure.

795. The system of claim 786, wherein the quality metric includes completeness analysis.

796. The system of claim 786, further comprising implementing cross-reference validation.

797. The system of claim 786, wherein the recommendation includes control sample validation.

798. The system of claim 786, further comprising implementing automated classification.

799. The system of claim 786, wherein the quality metric includes a statistical check.

800. The system of claim 786, further comprising generating a quality scorecard.

801. The system of claim 786, further comprising maintaining an audit trail.

802. A system for integrated data quality7management in an Al-guided synthetic biology7platform, comprising: one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the platform to: implement an automated sampling mechanism for standardized data collection; apply a Bayesian normalization model to experimental data; perform an automated quality7control check using a machine learning model; generate a probability distribution representing strain perfonnance; and identify a high-performing strain based on normalized measurements.

803. The system of claim 802, wherein the sampling mechanism includes metabolomics data collection.

804. The system of claim 802, wherein the Bayesian normalization model incorporates prior knowledge.

805. The system of claim 802, wherein the quality7control check includes anomaly detection.

806. The system of claim 802, wherein the probability7distribution includes an uncertainty estimate.

807. The system of claim 802. further comprising implementing batch effect correction.

808. The system of claim 802, wherein the machine learning model includes a hybrid model.

809. The system of claim 802. further comprising maintaining a performance metric.

810. The system of claim 802. wherein the quality control check includes control sample validation.

811. The system of claim 802. further comprising implementing data enrichment.

812. The system of claim 802. wherein the Bayesian normalization model preserves a biological signal.

813. The system of claim 802, further comprising implementing automated validation.

814. The system of claim 802, wherein the quality control check includes a statistical check.

815. The system of claim 802, further comprising generating documentation.

816. The system of claim 802, further comprising maintaining an audit trail.GENETIC GENERALIZATION - EXPRESSION LANGUAGES817. A method for predicting performance associated with genetic edits, the method comprising: receiving, by a platform, information about a biologic product, wherein the information includes a description of at least a portion of the biologic product in an expression language; generating, by the platform, a set of edits of the biologic product based on the description the at least a portion of the biologic product in the expression language; and generating, by the platform, a performance prediction for each edit of the set of edits of the biologic product based on a pre-trained genetic generalization model applied to each edit of the set of edits.

818. The method of claim 817, wherein the biologic product includes a protein, the expression language includes a protein expression language, and the information includes a description of at least a portion of the protein in the protein expression language.

819. The method of claim 817, wherein, the expression language is based on one or more embedding models, the embedding models include at least one of a GenePT model, a Proteinfer model, a pFBA-PCA model, or a GO-PCA model, and the method further comprising aggregating a set of multi-dimensional vectors generated by the two or more embedding models to create the set of edits.

820. The method of claim 817, wherein at least one edit of the set of edits includes an expression of the edit in the expression language.

821. The method of claim 817, wherein the description of the at least a portion of the biologic product includes a description of at least one of: a structural feature of the at least a portion of the biologic product, a functional feature of the at least a portion of the biologic product, a source of the at least a portion of the biologic product, a metabolic pathway associated with the at least a portion of the biologic product, or a biologic condition associated with the at least a portion of the biologic product.

822. The method of claim 817, wherein the description of at least a portion of the biologic product is generated from at least one of: a description of the at least a portion of the biologic product in at least one naturallanguage information source, or a representation of the at least a portion of the biologic product in a knowledge graph.

823. The method of claim 817, wherein the description of at least a portion of the biologic product is generated by a language machine learning model that has been trained to generate descriptions of at least portions of biologic products in the expression language.

824. The method of claim 817, wherein generating the set of edits includes generating a description of at least one edit of the set of edits, and the description of the at least one edit includes a description of at least one of: a structural feature of the at least one edit of the biologic product, a functional feature of the at least one edit of the biologic product, a source of the at least one edit of the biologic product, a metabolic pathway associated with the at least one edit of the biologic product, or a biologic condition associated with the at least one edit of the biologic product.

825. The method of claim 824, wherein the description of the at least one edit of the set of edits is generated from at least one of: a description of the at least a portion of the biologic product in at least one naturallanguage information source, or a representation of the at least a portion of the biologic product in a knowledge graph.

826. The method of claim 824, wherein the description of the at least one edit of the set of edits is generated by a language machine learning model that has been trained to generate descriptions of edits of biologic products.

827. The method of claim 817, further comprising: generating, by the platform, a representation of the biologic product edited by the set of edits, wherein the representation includes a description in the expression language of at least a portion of the biologic product edited by the set of edits.

828. The method of claim 817, wherein the pre-trained genetic generalization model comprises a first stage that generates a strain embedding characterizing the strain of a microorganism and a second stage that generates the performance prediction based on the strain embedding.

829. The method of claim 828, wherein the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model.

830. The method of claim 817, wherein the performance prediction comprises at least one of a predicted growth rate, a predicted metabolite production rate, a predicted byproduct formation rate, or a predicted protein expression level.

831. The method of claim 817, further comprising receiving process condition information, wherein the pre-trained genetic generalization model is trained to predict performance with respect to a set of process conditions as indicated by process inputs, and wherein generating theperformance prediction for each edit of the set of edits is further based on process inputs corresponding to the process condition information.

832. The method of claim 817, wherein the pre-trained genetic generalization model is trained using a two-step process including, pre-training the genetic generalization model using a set of training data, and fine-tuning the genetic generalization model using additional strain-specific data, wherein the set of training data is a larger data set compared to the strain-specific data.

833. The method of claim 832, further comprising updating the pre-trained genetic generalization model using an active learning process including, generating a set of candidate genetic modifications, generating a corresponding performance prediction for each of the set of candidate genetic modifications using the pre-trained genetic generalization model, receiving experimental data associated with at least a portion of the set of candidate genetic modifications, updating the set of training data using the experimental data, and re-training the pre-trained genetic generalization model using the updated training data.

834. The method of claim 833, further comprising determining which portion of the set of genetic modifications to test via experiment based at least in part on an uncertainty quantification generated by the pre-trained genetic generalization model.

835. The method of claim 817, wherein the pre-trained genetic generalization model is an ensemble of multiple pre-trained genetic generalization models.

836. The method of claim 817, wherein the set of edits captures functional relationships between genes and metabolic pathways.

837. The method of claim 817, wherein the pre-trained genetic generalization model is trained to predict performance across multiple strains of different microorganisms.

838. The method of claim 817, wherein at least one edit is based on an edit of a base strain, and the description of the at least one edit indicates that the at least one edit is at least one of a gene knockout, a gene overexpression, or a gene underexpression.

839. The method of claim 817, wherein the set of edits is generated at prediction time.

840. The method of claim 817, wherein, the set of edits is generated prior to training, and the method further comprises caching the set of edits for later use at prediction time.

841. The method of claim 817, wherein, the set of edits further comprises a set of embeddings based on the information about the biologic product, and the generating comprises processing the information about the biologic product using one or more embedding models, wherein each of the one or more embedding models is configured to: receive the information about the biologic product as input, and apply computational transformations to the input using a corresponding embedding model to generate a multi-dimensional vector representation for each edit of the set of edits, whereineach multi-dimensional vector representation generated by the one or more embedding models is added to the set of embeddings.COMPARATIVE ANALYSIS - COMPATIBILITY842. A method of generating a biologic product of a biologic synthesis process, comprising: selecting a first feature and a second feature of the biologic product; determining a first biologic parent having the first feature and not having the second feature, wherein the first feature is based on an aspect of the first biologic parent; determining a second biologic parent having the second feature and not having the first feature, wherein the second feature is based on an aspect of the first biologic parent, and the aspect of the second biologic parent can be combined with the aspect of the first biologic parent; and determining a biologic product having the first feature and the second feature, wherein the biologic product is determined based on an evaluation of a set of combinations of the aspect of the first biologic parent and the aspect of the second biologic parent.

843. The method of claim 842, where the aspect of each biologic parent of the first biologic parent and the second biologic parent includes at least one of: a portion of the biologic parent, a structural feature of the biologic parent, a functional feature of the biologic parent, a behavior of the biologic parent, a source of the biologic parent. a metabolic pathway associated with the biologic product, or a biologic condition associated with the biologic product.

844. The method of claim 842, wherein the determination that the aspect of the second biologic parent can be combined with the aspect of the first biologic parent is based on at least one of: a structural requirement of the aspect of each biologic parent, a functional requirement of the aspect of each biologic parent, an environmental requirement of the aspect of each biologic parent, a requirement of a source of the aspect of each biologic parent, a requirement of a metabolic pathway associated with the aspect of each biologic parent, or a requirement of a biologic condition associated with the aspect of each biologic parent.

845. The method of claim 842, wherein the first biologic parent is determined by a machine learning model including an attention feature, and the attention feature associates the aspect of the first biologic parent with the first feature of the first biologic parent.

846. The method of claim 842, wherein the second biologic parent is determined by a machine learning model including an attention feature, and the attention feature associates the aspect of the second biologic parent with the second feature of the second biologic parent.

847. The method of claim 842, wherein detennining the second biologic parent includes determining, by a machine learning model including an attention feature, that the aspect of the second biologic parent can be combined with the aspect of the first biologic parent.

848. The method of claim 842, wherein, the determination that the aspect of the second biologic parent can be combined with the aspect of the first biologic parent includes determining a modification of at least one of: the aspect of the first biologic parent, the aspect of the second biologic parent, the biologic synthesis process, or the biologic product, the determination that the aspect of the second biologic parent cannot be combined with the aspect of the first biologic parent based on an absence of the modification, and the determination that the aspect of the second biologic parent can be combined with the aspect of the first biologic parent based on the modification.

849. The method of claim 848, wherein determining the modification includes determining, by a machine learning model including an attention feature, and the attention feature associates the modification with at least one of: the aspect of the first biologic parent, the aspect of the second biologic parent, the biologic synthesis process, or the biologic product.

850. The method of claim 842, wherein the biologic product includes at least one of an enzyme protein, a non-enzy me protein, a DNA sequence, an RNA sequence, a plasmid, a metabolite, a biologic strain, a bioreactor process, or a downstream purification process.

851. The method of claim 842, wherein the biologic synthesis process includes at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

852. The method of claim 842, wherein at least one of the first feature or the second feature includes at least one of a product expression feature, a product activation feature, a product reaction feature, an enzyme cleaning feature, a product stability feature, a product biocompatibility feature, a process rate feature, a process catalyzation rate feature, a process efficiency feature, a process cost feature, or a process yield feature.

853. The method of claim 842, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes conserving a distance of the set of combinations relative to the first biologic parent.

854. The method of claim 853, wherein the distance includes at least one of an edit distance between the first biologic parent and each combination, a number of edits between the first biologic parent and each combination, a degree of edits between the first biologic parent and each combination, a difference between a measure of the first feature of each combination relative to ameasurement of the first feature of the first biologic parent, a structural feature of each combination relative to a corresponding structural feature of the first biologic parent, or a viability score of each combination relative to a corresponding viability score of the first biologic parent.

855. The method of claim 842, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes selectively evaluating combinations that at least maintain the first feature of the first biologic parent.

856. The method of claim 842, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes selectively evaluating combinations based on a measurement of the second feature.

857. The method of claim 842, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes for a respective combination of the first biologic parent and the second biologic parent, jointly measuring the first feature of the respective combination and the second feature of the respective combination.

858. The method of claim 857, wherein jointly measuring the first feature of the respective combination and the second feature of the respective combination includes, determining the first feature of the respective combination according to a first dimension of an evaluation space. determining the second feature of the respective combination according to a second dimension of the evaluation space, and evaluating the respective combination according to a vector representation in the evaluation space, wherein the vector representation is based on the first feature according to the first dimension of the evaluation space and the second feature according to the second dimension of the evaluation space.

859. The method of claim 857, wherein jointly measuring the first feature of the respective combination and the second feature of the respective combination includes, generating a weighted evaluation of the first feature of the respective combination according to a first weight associated with the first feature, generating a weighted evaluation of the second feature of the respective combination according to a second weight associated with the second feature, and evaluating the respective combination according to a combination of the weighted evaluation of the first feature and the weighted evaluation of the second feature.

860. The method of claim 842, the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes evaluating a respective combination of the first biologic parent and the second biologic parent based on at least one of: a first evaluation threshold of the first feature of the respective combination, or a second evaluation threshold of the second feature of the respective combination.

861. The method of claim 842, wherein the evaluation includes at least one of: a measurement of an edit distance between a respective combination and at least one of the first biologic parent or the second biologic parent,a measurement of the first feature of the respective combination and a corresponding measurement of the first feature of the first biologic parent, a measurement of the second feature of the respective combination and a corresponding measurement of the second feature of the second biologic parent, or a measurement of a third feature of the respective combination and a corresponding measurement of the third feature of at least one of the first biologic parent or the second biologic parent.

862. The method of claim 842, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes, generating a representation of a portion of a respective combination according to a biologic product language, and evaluating the representation of the portion of the respective combination according to the biologic product language.

863. The method of claim 862, wherein the biologic product language includes a protein language, and evaluating the representation includes evaluating the representation of the portion of the respective combination in the protein language according to a protein language model.

864. The method of claim 842, wherein the evaluation of the set of combinations of the first biologic parent and the second biologic parent includes evaluating the set of combinations according to a ranking order of the set of combinations.

865. The method of claim 864, wherein the evaluation of the set of combinations according to the ranking order of the set of combinations includes, for a respective combination, determining a score based on a comparison between the respective combination and at least one of the first biologic parent or the second biologic parent, and determining the ranking order based on the score of the respective combination.

866. The method of claim 864, wherein evaluating the set of combinations according to the ranking order includes, selecting, from the set of combinations, a first set of candidate combinations based on the ranking order; evaluating the first set of candidate combinations based on at least one of the first feature of respective combinations of the first set of candidate combinations or the second feature of respective combinations of the first set of candidate combinations; and based on evaluating the first set of candidate combinations, selecting a second set of candidate combinations for evaluation.

867. The method of claim 866, wherein evaluating the first set of candidate combinations includes at least one of evaluating a simulation of respective combinations of the first set of candidate combinations, or: evaluating an experimental result of respective combinations of the first set of candidate combinations.

868. The method of claim 866, wherein the second set of candidate combinations includes at least one of: at least one variant of at least one candidate combination of the first set of candidate combinations, or at least one combination of the set of combinations that is not included in the first set of candidate combinations.

869. The method of claim 866, wherein the first set of candidate combinations includes at least two alternative variants of the first biologic parent having an edit location, wherein each of the at least two alternative variants includes a different edit of the edit location.

870. The method of claim 866, wherein the first set of candidate combinations includes at least one combination that includes a single edit of the first biologic parent, and the second set of candidate combinations includes at least one combination that includes at least two edits of the first biologic parent.

871. The method of claim 842, wherein at least one feature of the biologic product is based on at least one of a technical feature or an economic feature, and the evaluation of a set of combinations of the first biologic parent and the second biologic parent includes a techno- economic analysis of the at least one feature for the set of combinations.

872. The method of claim 842, wherein selecting the biologic product based on an evaluation of a set of combinations of the first biologic parent and the second biologic parent increases a number of determined combinations that improve at least one of the first feature of the first biologic parent or the second feature of the second biologic parent.MULTI-OBJECTIVE TECHNO-ECONOMIC ANALYSIS873. A method of generating a biologic product of a biologic synthesis process, comprising: selecting a biologic parent of the biologic product; identifying at least two objectives of the biologic product, wherein each objective of the at least two objectives is based on a techno-economic analysis of the biologic synthesis process; and determining a variant of the biologic product based on the techno-economic analysis of the biologic synthesis process.

874. The method of claim 873, wherein, the techno-economic analysis includes an analysis of at least one techno-economic feature of the biologic synthesis process, and the at least one techno-economic feature of the biologic synthesis process includes at least one of: an efficiency of the biologic synthesis process, a rate of the biologic synthesis process, an environment of the biologic synthesis process, a yield of the biologic synthesis process, a variance of the biologic synthesis process, a byproduct of the biologic synthesis process, or a feature of the biologic product of the biologic synthesis process, andat least one objective of the at least two objectives is based on the at least one techno- economic feature included in the techno-economic analysis.

875. The method of claim 873, wherein, the techno-economic analysis is based on a simulation of the biologic synthesis process, and the variant of the biologic product is determined based on a comparison of the simulation of the biologic synthesis process with a simulation of a variant biologic synthesis process including the variant.

876. The method of claim 875, wherein the variant of the biologic product is determined based on a techno-economic analysis of the variant biologic synthesis process.

877. The method of claim 876, wherein, the techno-economic analysis of the biologic synthesis process includes an analysis of at least one techno-economic feature of the biologic synthesis process, and the techno-economic analysis of the variant biologic synthesis process includes an analysis of the at least one techno-economic feature of the variant biologic synthesis process, and the variant of the biologic product is determined based on a comparison of the at least one techno-economic feature of the biologic synthesis process and the at least one techno-economic feature of the variant biologic synthesis process.

878. The method of claim 873, wherein the biologic synthesis process includes at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

879. The method of claim 873, wherein the biologic product includes at least one of an enzyme protein, a non-enzy me protein, a DNA sequence, an RNA sequence, a plasmid, a metabolite, a biologic strain, a bioreactor process, or a dow nstream purification process.

880. The method of claim 873, wherein the at least two objectives includes at least one of a product expression objective, a product activation objective, a product reaction objective, an enzyme cleaning objective, a product stability objective, a product biocompatibility objective, a process rate objective, a process catalyzation rate objective, a process efficiency objective, a process cost objective, or a process yield objective.

881. The method of claim 873, wherein the biologic product includes a variant of the biologic parent having an edit distance that is within an edit distance threshold of the biologic parent.

882. The method of claim 873, wherein the techno-economic analysis of the biologic synthesis process includes conserving a distance of the variant relative to the biologic parent.

883. The method of claim 882, wherein the distance includes at least one of an edit distance between the biologic parent and each variant, a number of edits between the biologic parent and each variant, a degree of edits between the biologic parent and each variant, a difference between a measurement of an objective of the at least two objectives of each variant relative to a corresponding measurement of the objective of the biologic parent, a structural feature of eachvariant relative to a corresponding structural feature of the biologic parent, or a viability score of each variant relative to a corresponding viability score of the biologic parent.

884. The method of claim 873, wherein the techno-economic analysis of the biologic synthesis process of the biologic parent includes selectively evaluating variants that at least maintain at least one of the at least two objectives relative to the biologic parent.

885. The method of claim 873, wherein the techno-economic analysis of the biologic synthesis process of the biologic parent includes jointly measuring each of the at least two objectives of the variant.

886. The method of claim 885, wherein jointly measuring each of the at least two objectives of the variant includes, determining a first objective of the at least two objectives for the variant according to a first dimension of an evaluation space, determining a second objective of the at least two objectives for the variant according to a second dimension of the evaluation space, and evaluating the variant according to a vector representation in the evaluation space, wherein the vector representation is based on a first objective of the at least two objectives according to the first dimension of the evaluation space and the second objective according to the second dimension of the evaluation space.

887. The method of claim 886, wherein jointly measuring the first objective of the variant and the second objective of the variant includes, generating a weighted evaluation of the first objective of the at least two objectives for the variant according to a first weight associated with the first objective, generating a weighted evaluation of the second objective of the at least two objectives for the variant according to a second weight associated with the second objective, and evaluating the variant according to a combination of the weighted evaluation of the first objective and the weighted evaluation of the second objective.

888. The method of claim 887, wherein the techno-economic analysis of the biologic synthesis process includes evaluating a variant of the biologic parent based on an evaluation threshold of at least one objective of the at least two objectives for the variant.

889. The method of claim 887, wherein the techno-economic analysis of the biologic synthesis process includes at least one of: a measurement of an edit distance between a variant and the biologic parent, or a measurement of an objective of the at least two objectives of the variant and a corresponding measurement of the objective of the biologic parent.

890. The method of claim 887, wherein the techno-economic analysis of the biologic synthesis process of the biologic parent includes, generating a representation of a portion of the variant according to a biologic product language, andevaluating the representation of the portion of the variant according to the biologic product language.

891. The method of claim 890, wherein the biologic product language includes a protein language, and evaluating the representation includes evaluating the representation of the portion of the variant in the protein language according to a protein language model.

892. The method of claim 887, wherein the techno-economic analysis of the biologic synthesis process includes evaluating a set of variants according to a ranking order of the set of variants.

893. The method of claim 892, wherein evaluating the set of variants according to the ranking order of the set of variants includes, for a variant of the set of variants, determining a score based on a comparison between the variant and the biologic parent, and determining the ranking order based on the score of the variant.

894. The method of claim 892, wherein evaluating the set of variants according to the ranking order includes, selecting, from the set of variants, a first set of candidate variants based on the ranking order; evaluating the first set of candidate variants based on each of at least two objectives of variants of the first set of candidate variants; and based on evaluating the first set of candidate variants, selecting a second set of candidate variants for evaluation.

895. The method of claim 894, wherein evaluating the first set of candidate variants includes at least one of: evaluating a simulation of variants of the first set of candidate variants, or evaluating an experimental result of variants of the first set of candidate variants.

896. The method of claim 894, wherein the second set of candidate variants includes at least one of: at least one further variant of at least one variant of the first set of candidate variants, or at least one variant of the set of variants that is not included in the first set of candidate variants.

897. The method of claim 894, wherein the first set of candidate variants includes at least two alternative variants of the biologic parent having an edit location, wherein each of the at least two alternative variants includes a different edit of the edit location.

898. The method of claim 894, wherein the first set of candidate variants includes at least one variant that includes a single edit of the biologic parent, and the second set of candidate variants includes at least one variant that includes at least two edits of the biologic parent.

899. The method of claim 873, wherein selecting the biologic product based on an evaluation of a set of variants of the biologic parent increases a number of determined variants that improve at least one of the at least two objectives relative to the biologic parent.OPTIMIZATION STRATEGIES FOR BOTTLENECK AVOIDANCE900. A method of optimizing a biologic synthesis process, comprising:identifying at least one bottleneck in a biologic synthesis process; selecting, from a set of optimization strategies, an optimization strategy for the biologic synthesis process, wherein the selected optimization strategy is associated with the at least one bottleneck; and selecting an adjusted biologic synthesis process, wherein the adjusted biologic synthesis process is based on applying the selected optimization strategy to the biologic synthesis process, and the adjusted biologic synthesis process reduces the at least one bottleneck of the biologic synthesis process.

901. The method of claim 900, wherein the optimization strategy' is selected by an optimize system that has been trained on at least one data set that indicates relationships between biologic synthesis processes and outcomes.

902. The method of claim 900, wherein, the optimization strategy is selected from an optimization strategy database, and the optimization strategy database indicates, for at least one optimization strategy, at least one of a source of the optimization strategy, a requirement of the optimization strategy, an application of the optimization strategy. an optimization effect of the optimization strategy, or a side-effect of the optimization strategy.

903. The method of claim 902, wherein at least one optimization strategy included in the optimization strategy database is based on at least one of: at least one feature of at least one experiment associated with the optimization strategy, at least one feature of at least one industrial process associated with the optimization strategy, at least one feature of at least one simulation of a biologic synthesis process, wherein the at least one simulation is associated with the optimization strategy, or at least one feature of at least one report included in a natural-language knowledge, wherein the at least one report is associated with the optimization strategy.

904. The method of claim 900, wherein, the optimization strategy is selected by a reinforcement-leaming-based machine learning model, the reinforcement-leaming-based machine learning model has been trained to optimize biologic synthesis processes based on a reinforcement learning policy, and the selected optimization strategy is based on the reinforcement learning policy.

905. The method of claim 900, wherein selecting the adjusted biologic synthesis process includes, performing a simulation of the adjusted biologic synthesis process, andcomparing at least one feature of the simulation of the adjusted biologic synthesis process with a corresponding at least one feature of the biologic synthesis process, wherein the at least one feature is associated with the at least one bottleneck.

906. The method of claim 900, wherein the biologic synthesis process includes at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

907. The method of claim 900, wherein the adjusted biologic synthesis process is based on an adjustment of at least one of a process temperature, a process pressure, a process volume, a process timing, a process order, a biologic product concentration, a biologic product addition, a biologic product substitution, a biologic product elimination, a biologic product expression, a biologic product activation, a biologic product activity, or a biologic product transformation.

908. The method of claim 900, wherein the at least one bottleneck includes at least one of a growth rate bottleneck, a metabolite production rate bottleneck, a byproduct formation rate bottleneck, a protein expression level bottleneck, a process scale bottleneck, a process rate bottleneck, a product expression bottleneck, a product activation bottleneck, a process stability bottleneck, a process efficiency bottleneck, a process cost bottleneck, or a process yield bottleneck.

909. The method of claim 900, wherein selecting the adjusted biologic synthesis process includes at least one of comparing a simulation of the biologic synthesis process with a simulation of the adjusted biologic synthesis process, or comparing an experimental result of the biologic synthesis process with an experimental result of an experiment of the adjusted biologic synthesis process.

910. The method of claim 900, wherein selecting the adjusted biologic synthesis process includes evaluating a set of variants of the biologic synthesis process according to a ranking order of the set of variants.

911. The method of claim 910, wherein evaluating of the set of variants according to the ranking order of the set of variants further comprises: for a respective variant of the set of variants, determining a score based on a comparison between the respective variant and the biologic synthesis process, and determining the ranking order based on the score of the respective variant.

912. The method of claim 911, wherein the comparison includes at least one of a distance between the respective variant and the biologic synthesis process, a measurement of at least one objective of the respective variant and a corresponding measurement of the at least one objective of the biologic synthesis process, or a measurement of a feature of the respective variant and a corresponding measurement of the feature of the biologic synthesis process.

913. The method of claim 910, wherein evaluating the set of variants according to the ranking order further comprises:selecting, from the set of variants, a first set of candidate variants based on the ranking order; evaluating the first set of candidate variants based on at least one objective of respective variants of the first set of candidate variants; and based on evaluating the first set of candidate variants, selecting a second set of candidate variants for evaluation.

914. The method of claim 913, wherein evaluating the first set of candidate variants includes at least one of: evaluating a simulation of respective variants of the first set of candidate variants, or evaluating an experimental result of respective variants of the first set of candidate variants.

915. The method of claim 913, wherein the second set of candidate variants includes at least one of: at least one further variant of at least one variant of the first set of candidate variants, or at least one variant of the set of variants that is not included in the first set of candidate variants.

916. The method of claim 913, wherein the first set of candidate variants includes at least two alternative variants of the biologic synthesis process having a feature, wherein each of the at least two alternative variants includes a different variations of the feature.

917. The method of claim 913, wherein the first set of candidate variants includes at least one variant that includes a single variation of a feature of the biologic synthesis process, and the second set of candidate variants includes at least one variant that includes variations of at least two different features of the biologic synthesis process.

918. The method of claim 917, wherein selecting the adjusted biologic synthesis process based on an evaluation of a set of variants of the biologic synthesis process reduces at least one bottleneck of the biologic synthesis process.

919. The method of claim 910, wherein evaluating the set of variants of the biologic synthesis process further comprises: generating at least one explanation of at least one variant of the biologic synthesis process, wherein the at least one explanation indicates an effect of the at least one variant on the at least one bottleneck of the biologic synthesis process.

920. The method of claim 910, further comprising: identifying at least one additional bottleneck in the adjusted biologic synthesis process; evaluating a set of further variants of the adjusted biologic synthesis process; and selecting a further adjusted biologic synthesis process, wherein the further adjusted biologic synthesis process includes at least one variant of the set of further variants that reduces the at least one additional bottleneck of the adjusted biologic synthesis process.BOTTLENECKS OF SYNTHESIS OBJECTIVES921. A method of optimizing a biologic synthesis process, comprising: selecting at least one objective of the biologic synthesis process;identifying at least one bottleneck in the biologic synthesis process that relates to the at least one objective; and selecting an adjusted biologic synthesis process, wherein the adjusted biologic synthesis process includes at least one variant of a set of variants of the biologic synthesis process, each variant of the set of variants relates to the at least one bottleneck, and each variant of the set of variants reduces the at least one bottleneck of the at least one objective of the biologic synthesis process.

922. The method of claim 921, wherein, the at least one objective is associated with a techno-economic analysis of the biologic synthesis process, the at least one bottleneck in the biologic synthesis process is associated with the techno-economic analysis, and the set of variants is determined based on the techno-economic analysis.

923. The method of claim 921, wherein selecting the adjusted biologic synthesis process includes, performing a simulation of the adjusted biologic synthesis process, and performing a comparison of the biologic synthesis process and the simulation of the adjusted biologic synthesis process, wherein the comparison is based on the at least one bottleneck of the at least one objective.

924. The method of claim 921, wherein selecting the adjusted biologic synthesis process includes, performing a simulation of the adjusted biologic synthesis process, and performing a comparison of the biologic synthesis process and the simulation of the adjusted biologic synthesis process, wherein the comparison includes a comparison of the at least one bottleneck of the at least one objective in the biologic synthesis process and a corresponding bottleneck of the at least one objective in the simulation of the adjusted biologic synthesis process.

925. The method of claim 924, wherein the simulation of the adjusted biologic synthesis process is based on a digital twin of at least one component of the biologic synthesis process.

926. The method of claim 921, wherein the biologic synthesis process includes at least one of a DNA synthesis process, an RNA synthesis process, a protein synthesis process, a metabolite synthesis process, a metabolic process, at least one pathway of a metabolic system, a plate growth process, or a fermentation process.

927. The method of claim 921, wherein the set of variants of the biologic synthesis process includes at least one of a process temperature variant, a process pressure variant, a process volume variant, a process timing variant, a process order variant, a biologic product concentration variant, a biologic product addition variant, a biologic product substitution variant, a biologic product elimination variant, a biologic product expression variant, a biologic product activation variant, a biologic product activity variant, or a biologic product transformation variant.

928. The method of claim 921, wherein the at least one bottleneck includes at least one of a growth rate bottleneck, a metabolite production rate bottleneck, a byproduct formation rate bottleneck, a protein expression level bottleneck, a process scale bottleneck, a process rate bottleneck, a product expression bottleneck, a product activation bottleneck, a process stability bottleneck, a process efficiency bottleneck, a process cost bottleneck, or a process yield bottleneck.

929. The method of claim 921, wherein evaluating the set of variants of the biologic synthesis process includes at least one of: comparing a simulation of the biologic synthesis process with a simulation of each variant of the set of variants of the biologic synthesis process, or comparing an experimental result of the biologic synthesis process with an experimental result of a respective experiment of each variant of the set of variants of the biologic synthesis process.

930. The method of claim 921, wherein evaluating the set of variants of the biologic synthesis process includes determining, within an evaluation space, a location of each variant of the set of variants of the biologic synthesis process.

931. The method of claim 930, wherein the evaluation space includes at least two dimensions that respectively represent a feature of the biologic synthesis process, and the location of a respective variant of the set of variants further comprises a vector within the evaluation space, wherein respective dimensions of each vector correspond to a feature of the respective variant of the biologic synthesis process.

932. The method of claim 931, wherein evaluating a set of variants of the biologic synthesis process further comprises identifying, within the evaluation space, at least one region of variants that reduce at least one bottleneck of the biologic synthesis process.

933. The method of claim 930, further comprising: representing the evaluation space as a heat map, wherein each location within the evaluation space is associated with a temperature that is related to an effect of a variant at the location on the at least one bottleneck of the biologic synthesis process.

934. The method of claim 921, wherein evaluating the set of variants of the biologic synthesis process further comprises: evaluating respective variants of the set of variants according to a ranking order of the set of variants.

935. The method of claim 934, wherein evaluating of the set of variants according to the ranking order of the set of variants further comprises: for a respective variant of the set of variants, determining a score based on a comparison between the respective variant and the biologic synthesis process, and determining the ranking order based on the score of the respective variant.

936. The method of claim 935, wherein the comparison includes at least one of: a distance between the respective variant and the biologic synthesis process, a measurement of at least one objective of the respective variant and a corresponding measurement of the at least one objective of the biologic synthesis process, ora measurement of a feature of the respective variant and a corresponding measurement of the feature of the biologic synthesis process.

937. The method of claim 934, wherein evaluating the set of variants according to the ranking order further comprises: selecting, from the set of variants, a first set of candidate variants based on the ranking order; evaluating the first set of candidate variants based on at least one objective of respective variants of the first set of candidate variants; and based on evaluating the first set of candidate variants, selecting a second set of candidate variants for evaluation.

938. The method of claim 937, wherein evaluating the first set of candidate variants includes at least one of: evaluating a simulation of respective variants of the first set of candidate variants, or evaluating an experimental result of respective variants of the first set of candidate variants.

939. The method of claim 937, wherein the second set of candidate variants includes at least one of: at least one further variant of at least one variant of the first set of candidate variants, or at least one variant of the set of variants that is not included in the first set of candidate variants.

940. The method of claim 937, wherein the first set of candidate variants includes at least two alternative variants of the biologic synthesis process having a feature, wherein each of the at least two alternative variants includes a different variations of the feature.

941. The method of claim 937, wherein the first set of candidate variants includes at least one variant that includes a single variation of a feature of the biologic synthesis process, and the second set of candidate variants includes at least one variant that includes variations of at least two different features of the biologic synthesis process.

942. The method of claim 941, wherein selecting the adjusted biologic synthesis process based on an evaluation of a set of variants of the biologic synthesis process reduces at least one bottleneck of the biologic synthesis process.

943. The method of claim 921, wherein evaluating the set of variants of the biologic synthesis process further comprises: generating at least one explanation of at least one variant of the biologic synthesis process, wherein the at least one explanation indicates an effect of the at least one variant on the at least one bottleneck of the biologic synthesis process.

944. The method of claim 921, further comprising: identifying at least one additional bottleneck in the adjusted biologic synthesis process; evaluating a set of further variants of the adjusted biologic synthesis process; and selecting a further adjusted biologic synthesis process, wherein the further adjusted biologic synthesis process includes at least one variant of the set of further variants that reduces the at least one additional bottleneck of the adjusted biologic synthesis process.GENETIC GENERALIZATION TARGETING BIOREACTOR PERFORMANCE945. A method for predicting performance of a strain of a biologic organism, the method comprising: receiving, by a platform, information about the strain of the biologic organism, wherein the information describes one or more genetic edits associated with the strain; generating, by the platform, a set of embeddings based on the information about the strain of the biologic organism; receiving, by the platform, a set of bioreactor process conditions; and generating, by the platform, a prediction of a performance of the strain of the biologic organism in a bioreactor based on inputting both the set of embeddings and the bioreactor process conditions to a pre-trained model, wherein the pre-trained model is trained using training data for a plurality of strains of the biologic organism, wherein the training data comprises: information about corresponding genetic edits for the plurality of strains of the biologic organism; information about corresponding bioreactor process conditions for the plurality of strains of the biologic organism; and target data indicating corresponding performance for the plurality of strains of the biologic organism.

946. The method of claim 945, wherein the bioreactor process conditions comprise at least one of bioreactor volume, temperature, pH, dissolved oxygen level, feed rate, or agitation speed.

947. The method of claim 945, wherein the prediction of the performance of the strain indicates at least one of a grow th rate, a metabolite production rate, a byproduct fonnation rate, a protein expression level, or a titer.

948. The method of claim 945, wherein generating the set of embeddings comprises inputting the information about the strain of the biologic organism to one or more embeddings models, wherein the one or more embedding models include at least one of a GenePT model, a Proteinfer model, a pFBA-PCA model, or a GO-PCA model.

949. The method of claim 948, wherein the one or more embeddings models comprise two or more embeddings models, the method further comprising aggregating the respective embeddings generated by the two or more embedding models to create the set of genetic embeddings.

950. The method of claim 945, wherein the pre-trained model comprises a first stage that generates a strain embedding characterizing the strain of the biologic organism and a second stage that generates the prediction based on the strain embedding.

951. The method of claim 950, wherein the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model.

952. The method of claim 950, wherein the second stage is a multi-layer perceptron.

953. The method of claim 945, wherein the pre-trained model is an ensemble of multiple pretrained models.

954. The method of claim 945, wherein the set of embeddings encodes the one or more genetic edits.

955. The method of claim 945, wherein the information about the strain comprises information about a base strain of the biologic organism.

956. The method of claim 955, wherein the one or more genetic edits are with respect to the base strain, wherein the information about the one or more genetic edits comprises information indicating one or more gene knockouts, gene overexpressions, or gene underexpressions.

957. A system for predicting performance of a strain of a biologic organism, the system comprising: one or more processors; and memory storing instructions that, when executed by the one or more processors, cause the system to: receive information about the strain of the biologic organism, wherein the information describes one or more genetic edits associated with the strain; generate a set of embeddings based on the information about the strain of the biologic organism; receive a set of bioreactor process conditions: and generate a prediction of a performance of the strain of the biologic organism in a bioreactor based on inputting both the set of embeddings and the bioreactor process conditions to a pre-trained model, wherein the pre-trained model is trained using training data for a plurality of strains of the biologic organism, wherein the training data comprises: information about corresponding genetic edits for the plurality of strains of the biologic organism; information about corresponding bioreactor process conditions for the plurality of strains of the biologic organism; and target data indicating corresponding performance for the plurality of strains of the biologic organism.

958. The system of claim 957, wherein the bioreactor process conditions comprise at least one of bioreactor volume, temperature, pH, dissolved oxygen level, feed rate, or agitation speed.

959. The system of claim 957, wherein the prediction of the performance of the strain indicates at least one of a growth rate, a metabolite production rate, a byproduct formation rate, a protein expression level, or a titer.

960. The system of claim 957, wherein generating the set of embeddings comprises inputting the information about the strain of the biologic organism to two or more embeddings models, wherein the embeddings models include at least one of a GenePT model, a Proteinfer model, a pFBA-PCA model, or a GO-PCA model, and wherein the system aggregates the respective embeddings generated by the two or more embedding models to create the set of genetic embeddings.

961. The system of claim 958, wherein the pre-trained model comprises:a first stage that generates a strain embedding characterizing the strain of the biologic organism, wherein the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model; and a second stage that generates the prediction based on the strain embedding, wherein the second stage is a multi-layer perceptron.

962. The system of claim 958, wherein the pre-trained model is an ensemble of multiple pretrained models.

963. The system of claim 958, wherein the set of embeddings encodes the one or more genetic edits.

964. The system of claim 958, wherein the information about the strain comprises information about a base strain of the biologic organism, wherein the one or more genetic edits are with respect to the base strain, and wherein the information about the one or more genetic edits comprises information indicating one or more gene knockouts, gene overexpressions, or gene underexpressions.TRANSFER LEARNING FOR GENETIC GENERALIZATION965. A method comprising: receiving, by a platform, a first training dataset comprising a plurality of sets of genetic edits corresponding to a first plurality of strains of a biologic organism, wherein the first training dataset further comprises at least one first target, wherein the at least one first target comprises performance data for the plurality of strains of the biologic organism; pre-training, by the platform, a model using the first training dataset, wherein the pretraining comprises training embeddings for the plurality of sets of genetic edits; receiving, by the platform, a second training dataset smaller than the first training dataset, wherein the second training dataset comprises: information about genetic edits for a second plurality of strains, wherein the second plurality of strains are different from the first plurality of strains; and information about at least one second target, wherein the at least one second target is different from the at least one first target; and fine-tuning, by the platform, the pre-trained model using the second training dataset to generate a second model that is trained to predict the at least one second target.

966. The method of claim 965, wherein the at least one second target comprises at least one of a bioreactor growth rate, a metabolite production rate, a byproduct formation rate, or a titer.

967. The method of claim 965, wherein the second plurality of strains are strains of a different biologic organism than the first plurality of strains.

968. The method of claim 965, wherein the second plurality of strains are strains of a same biologic organism as the first plurality of strains.

969. The method of claim 965, wherein the model comprises a first stage that generates a strain embedding and a second stage that generates a prediction based on the strain embedding, wherein the fine-tuning comprises updating parameters of the second stage to predict the at least one second target.

970. The method of claim 969, wherein the fine-tuning comprises replacing at least a portion of the second stage with new layers trained to predict the at least one second target.

971. The method of claim 969, wherein the fine-tuning uses a lower learning rate for the finetuning as compared to the pre-training.

972. The method of claim 969, wherein the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model.

973. The method of claim 969, wherein the second stage is a multi-layer perceptron.

974. The method of claim 965, wherein the embeddings are generated at least in part by processing gene descriptions using a large language model prior to the pre-training.

975. The method of claim 965, wherein the embeddings are trainable parameters during the pre-training such that they are iteratively updated during the pre-training.

976. The method of claim 965, wherein the plurality of sets of genetic edits comprises information indicating that each genetic edit is at least one of a gene knockout, a gene overexpression, or a gene underexpression.

977. A system comprising: one or more processors; and memory storing instructions that, when executed by the processor, cause the system to: receive a first training dataset comprising a plurality of sets of genetic edits corresponding to a first plurality of strains of a biologic organism, wherein the first training dataset further comprises at least one first target, and wherein the at least one first target comprises performance data for the plurality' of strains of the biologic organism; pre-train a model using the first training dataset, wherein the pre-training comprises training embeddings for the plurality' of sets of genetic edits; receive a second training dataset smaller than the first training dataset, wherein the second training dataset comprises: information about genetic edits for a second plurality7of strains, wherein the second plurality of strains is different from the first plurality^ of strains; information about at least one second target, wherein the at least one second target is different from the at least one first target; and fine-tune the pre-trained model using the second training dataset to generate a second model that is trained to predict the at least one second target.

978. The system of claim 977, wherein the at least one second target comprises at least one of a bioreactor grow th rate, a metabolite production rate, a byproduct formation rate, or a titer.

979. The system of claim 977, wherein the model comprises a first stage that generates a strain embedding and a second stage that generates a prediction based on the strain embedding, wherein the fine-tuning comprises updating parameters of the second stage to predict the at least one second target.

980. The system of claim 979, wherein the fine-tuning comprises replacing at least a portion of the second stage with new layers trained to predict the at least one second target.

981. The system of claim 979. wherein the fine-tuning uses a lower learning rate for the finetuning as compared to the pre-training.

982. The system of claim 979, wherein the first stage is one or more of a long-short term memory (LSTM) model, a transformer model, or a convolutional neural network (CNN) model, wherein the second stage is a multi-layer perceptron.

983. The system of claim 979, wherein: the embeddings are generated at least in part by processing gene descriptions using a large language model prior to the pre-training; and the embeddings are trainable parameters during the pre-training such that they are iteratively updated during the pre-training.

984. The system of claim 977, wherein the plurality of sets of genetic edits comprises information indicating that each genetic edit is at least one of a gene knockout, a gene overexpression, or a gene underexpression.PROCESS CONTROL BASED ON GENETIC GENERALIZATION PREDICTIONS985. A method comprising: receiving, by a platform, information about a strain of a biologic organism, wherein the information describes one or more genetic edits associated with the strain; generating, by the platform, a set of embeddings based on the information about the strain of the biologic organism; receiving, by the platform, a set of bioreactor process conditions for a bioreactor containing the strain; generating, by the platform, at least one prediction of performance of the strain using a pre-trained model that processes both the set of embeddings and the set of bioreactor process conditions, wherein the pre-trained model is trained using training data comprising: information about genetic edits for a plurality of strains; information about corresponding bioreactor process conditions for the plurality of strains; and target data indicating corresponding performance of the plurality of strains with respect to the corresponding bioreactor process conditions; determining, by the platform, adjusted bioreactor process conditions based on the at least one prediction of performance; and automatically adjusting controls of the bioreactor based on the adjusted bioreactor process conditions.

986. The method of claim 985, wherein automatically adjusting controls comprises real-time adjustment of at least one of feed rates, pH levels, temperature, or dissolved oxygen levels of the bioreactor.

987. The method of claim 985, wherein determining the adjusted bioreactor process conditions comprises:generating multiple predictions of performance for different combinations of bioreactor ...

Images